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1.1 Background information 
Based on epidemiological studies protective effects of fruits and vegetables against 
degenerative conditions including cancer [1], cardiovascular diseases [2], obesity and diabetes 
[3, 4], as well as neurodegenerative disorders [5, 6] have been suggested. Among many 
dietary phytochemicals, phenolic compounds especially flavonoids have perhaps attracted the 
most attention and are believed to be responsible, at least partly, for these protective health 
effects. This truly sparked the interest in the beneficial health effects of flavonoids and as a 
consequence numerous studies have been carried out in the past decades to determine the 
beneficial health effects of flavonoids [7]. 
Possible modes of action underlying the beneficial health effects of flavonoids, 
including their activity as ligands for various receptors, kinases, enzymes, and/or transport 
proteins, have been often studied using in vitro test system [7-9]. Although such in vitro 
results can be informative on the possible mechanisms involved in health effects of 
flavonoids, these results cannot be directly applied to humans. This is because in vitro studies 
have mostly been performed with flavonoid aglycones at high concentrations far beyond the 
plasma concentrations that can be achieved upon dietary or even supplementary intake in 
humans [8]. Pharmacokinetic studies have shown that flavonoids are extensively metabolized 
and thus mainly available in the systemic circulation in their conjugated forms [10]. The 
review article of Beekmann et al. [9] indicated that conjugation can affect biological activities 
as compared to the aglycone depending on the type and position of the conjugation. 
Altogether, the in vivo effects of flavonoids will ultimately depend on the systemic 
bioavailability of the flavonoid aglycones and their metabolites. As a result absorption, 
distribution, metabolism, and excretion (ADME) represent important factors determining the 
biological activity of flavonoids in vivo [11]. The aim of the present PhD project was to gain 
quantitative insight into the dose-dependent plasma concentrations of flavonoid aglycones and 
their metabolites using a physiologically based kinetic (PBK) modeling approach, and the 
flavonoids quercetin, genistein and hesperitin as model compounds.  
 
1.2 Flavonoids  
Flavonoids are a diverse group of polyphenolic compounds vastly distributed in the 
plant kingdom, with more than 6000 flavonoids identified so far [12]. They are secondary 
metabolites of plants and generally protect the plant against a variety of stress factors [13]. 
The basic chemical structure of flavonoids consists of 15 carbons, with two aromatic rings (A 
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and B) connected by a three carbon bridge (ring C) as shown in Figure 1.1 [12]. Depending on 
the degree of oxidation of the heterocyclic ring C, flavonoids can be classified into six major 
subclasses including flavonols, flavanones, flavan-3-ols, flavones, anthocyanidins, and 
isoflavones [14]. Flavonoids are commonly present in edible fruits and vegetables, but the 
type and amount of flavonoids present vary with the different dietary sources [12, 14].  
 
Figure 1.1 Basic chemical structure of flavonoids [12]. 
 
1.2.1 Quercetin 
 Quercetin (3,5,7,3´,4´-pentahydroxyflavone) belongs to the flavonol subclass widely 
distributed in fruits and vegetables. It is one of the most prevalent flavonoids in human diets 
and also one of the most widely studied flavonoids [15]. The major dietary source of 
quercetin is onion followed by lettuce, red wine, and apple [16]. Dietary intake of quercetin is 
estimated to be 15-40 mg/day in Western countries [17]. In some countries, quercetin is 
widely available as food supplement with recommended daily intakes of 250-1500 mg 
quercetin/day [17]. Bioavailability of quercetin aglycone has been reported to be very low due 
to extensive metabolism, as no quercetin aglycone or only a trace amount of the aglycone has 
been detected in animal [15, 18, 19] or in human plasma [20-22]. Quercetin naturally occurs 
as β-glycosides, with the type of sugar moiety varying depending on the dietary source. In 
onions, for example, quercetin is mainly present in the form of glucosides, whereas in apples 
it is mainly present as arabinoside, galactoside, glucoside, and rhamnoside [23]. The sugar 
moiety is key in determining the site of absorption [24]. Only glucosides are efficiently 
hydrolyzed prior to absorption in the small intestine by lactase phlorizin hydrolase (LPH), a 
β-glucosidase on the outside of the brush border membrane of the small intestine [24]. Other 
glycosides that are not substrates for LPH will be moved toward the colon where they are 
subjected to colonic metabolism leading to removal of the sugar moiety before quercetin is 
taken up in the colonic enterocytes [24]. The aglycone can be directly taken up in the small 
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intestine by passive diffusion [24]. The absorbed quercetin is metabolized mainly by uridine 
5′-diphospho-glucuronosyl transferases (UGTs), sulfotransferases (SULTs), and catechol O-
methyltransferases (COMTs) forming several mono-conjugates at the 3-, 7-, 3´-, and/or 4´-
position as depicted in Figure 1.2 [25, 26]. Further conjugation of mono-conjugates is likely 
to happen at the available OH-positions and numerous different glucuronidated, sulfated, 
and/or methylated di- or tri-conjugates have been identified in plasma [18, 23, 27-30]. The 
major circulating metabolites of quercetin have been reported to be di- and tri-conjugates 
containing glucuronide, sulfate, and/or methyl moieties in rats [18, 27, 28] and mono-
conjugates containing a glucuronide or sulfate moiety in humans [23, 29, 30], indicating 
species differences in the metabolism of quercetin. Quercetin conjugates are excreted from the 
systemic circulation via intestinal excretion (upon efflux transport back to the intestinal 
lumen), and biliary and urinary excretion [19, 31]. Both in rats and humans, quercetin is also 
excreted as CO2 accounting for 30-60% of intravenously administered quercetin [32, 33].  
 
Figure 1.2 Metabolic conversion of quercetin to different mono-conjugates [25, 26]. 
 
1.2.2 Genistein 
 Genistein (4´, 5, 7-trihydroxyisoflavone) belongs to the isoflavone subclass and is 
predominantly present in soy and soy-based products [34]. In soy, genistein mainly exists in a 
glycosylated form, genistin (genistein-7-O-glucoside). Dietary intake of genistein/isoflavones 
is estimated to be low in Western countries amounting to <1 mg/day [35], whereas in Asian 
countries genistein/isoflavones are regularly consumed at high oral doses amounting to 15-50 
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mg/day [36]. Genistein is also available as food supplement either as pure genistein or in a 
mixture with other isoflavones at levels that would result in an estimated daily intake of 30-
900 mg/day [35]. Bioavailability of genistein aglycone has been recently reviewed and this 
overview showed low bioavailability in animals (6.8-23.4% at 4-20 mg genistein/kg bw) and 
in humans (though for humans the absolute value is not available), mainly due to extensive 
metabolism of genistein in vivo [34]. Figure 1.3 depicts the proposed metabolic pathways of 
genistin in vivo [37-39]. Upon oral ingestion, the glycosylated genistin is hydrolyzed to the 
aglycone genistein by LPH in the small intestine [40] and/or by gut microflora in the colon 
when LPH is not sufficiently efficient to completely cleave the sugar moiety [41]. The 
absorbed genistein undergoes metabolism by UGTs and SULTs forming different mono-
conjugates at the 4´- and/or 7-position [42]. The mono-conjugates can be conjugated to a 
further extent at the available free 4´ or 7 OH-position resulting in formation of different di-
conjugates [37-39]. Gu et al. reported that 78.4% of the total genistein in human plasma 
consisted of glucuronidated conjugates, 20.4% being sulfated conjugates, and 1.2% being 
present as the aglycone [43]. In rat plasma genistein was reported to be present mainly as 
glucuronidated conjugates (50.4%) and sulfated conjugates (45.9%) with 3.6% being present 
as the aglycone [43]. Thus, there appear to be some species differences in metabolism of 
genistein between human and rat [43]. Genistein and its metabolites are distributed in tissues 
and plasma via the systemic circulation. Bolca et al. report that genistein aglycone was 
present at relatively low concentration in breast tissue (tissue (12 ± 2 pmol/g) as compared to 
plasma (67 ± 19 nmol/l) and the aglycone only accounted for 2% of total genistein (aglycone 
and metabolites) in women receiving 50.94 mg genistein daily for 5 days [44]. Genistein is 
excreted mainly as conjugates via intestinal excretion (upon efflux back to the intestinal 
lumen), and biliary and urinary excretions [34]. The cumulative urinary excretion of genistein 
metabolites is reported to vary from 8-30% of the dose in humans [34]. The major excreted 
metabolites are reported to be glucuronides mainly genistein-7-O-glucuronide in both rats and 
in humans [34, 38, 39]. 
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Figure 1.3 Proposed metabolic pathways of genistin in vivo [37-39]. 
 
1.2.3 Hesperetin 
 Hesperetin (3´,5,7-trihydroxy-4´-methoxyflavanone) is a flavanone widely distributed 
in citrus fruits and naturally existing as hesperidin (hesperetin-7-O-rutinoside) [45]. Dietary 
intake of hesperetin is estimated to be 1.41-61.11 mg/day in Western countries [16]. When 
hesperetin is consumed as its glycoside, hesperidin, it is absorbed only in the distal part of the 
intestine after hydrolysis by colonic microflora [46]. The release of hesperetin aglycone is 
reported to be the rate-limiting step for the absorption [47]. In contrast, the hesperetin 
aglycone can be directly absorbed in the upper intestine by passive diffusion [46]. The 
absorbed hesperetin is metabolized by UGTs and SULTs at the 3´- and 7-position in the colon, 
small intestine, and liver forming different mono-conjugates as shown in Figure 1.4 [48-50]. 
Mono-conjugates are further metabolized by UGTs and SULTs at the available free OH-
positions forming different di-conjugates. Bioavailability of hesperetin aglycone is low in 
humans as hesperetin is mainly present as monoglucuronides in human plasma [46-49]. The 
total urinary excretion of conjugated hesperetin in human varied from 3.9-6.7% of the dose 
after consumption of a diet containing hesperidin [47-49, 51]. 
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Figure 1.4 Proposed metabolic pathways of hesperidin in vivo [48-50].  
 
1.3 PBK models  
In vivo data reveal that flavonoids are hardly available as aglycone, but mainly present 
as conjugates [10]. These conjugates might contribute, at least partly, to the observed 
beneficial health effects of flavonoids in vivo. The possible effects of conjugation of 
flavonoids on the biological activity have been recently reviewed by Beekmanm et al. [9]. 
The results indicate that depending on the type and position of the conjugation as well as the 
endpoint studied, conjugates are less active or equally active as the aglycone, whereas in some 
cases the conjugates are more active than the aglycone or even showed an inverse activity [9]. 
Altogether, biological activity of flavonoids in vivo will ultimately depend on the systemic 
bioavailability of the flavonoid aglycones and their metabolites. Therefore, it is of importance 
to gain insight in the ADME of flavonoids, resulting in the better understanding of flavonoid 
in vivo effects. 
PBK modeling describes the ADME of chemicals with a set of mathematical 
equations and allows simulation of plasma and tissue concentrations at low- and high-dose 
levels as well as evaluation of inter- and intraspecies differences [52-54]. Furthermore, the 
effect of kinetic interactions between different compounds, such as competition for 
Chapter 1 
 14 
metabolizing enzymes, can be modeled based on in vitro derived kinetic constants for 
inhibition [55]. And by combining the PBK model with in vitro data, in a so-called reverse-
dosimetry approach, in vivo dose-response curves can be predicted [56-58]. Overall, PBK 
modeling provides a powerful tool to explore the in vivo bioavailability as well as the ADME 
of a chemical.  
A PBK model can be developed by integrating three type of parameters including 1) 
physiological and anatomical parameters (e.g. cardiac output, tissue volumes and tissue blood 
flows), 2) physio-chemical parameters (e.g. tissue:blood partition coefficients), and 3) kinetic 
constants for metabolic conversions [52]. The physiological and anatomical parameters can be 
obtained from literature [59]. Tissue:blood partition coefficients might be obtained 
experimentally in vitro using solid phase microextraction based approach [57]. Alternatively, 
tissue:blood partition coefficients can also be obtained using in silico methods based on 
octanol-water partition coefficient [60]. Kinetic parameters for ADME can be obtained using 
1) experimental in vitro models using primary cell cultures, cells from cell lines in culture, 
subcellular fractions, tissue slices, or relevant recombinants enzymes of organs [61, 62], 2) 
available in silico methods [63-65], or 3) by fitting the model to available in vivo data [66]. 
By numerically integrating all mathematical equations for the ADME in computer software 
packages, the model can be simulated. Commonly used software is for example Berkeley 
Madonna (Macey and Oster, UC Berkeley, CA, USA), acslXtreme (AEgis Technologies 
Group), and MATLAB (The MathWorks) [52]. Once the model is developed, it is of 
importance to evaluate the performance of the newly developed model against in vivo data, 
since this supports the validity of the model and thus its predictions.  
 
1.4 Objectives and outline of the thesis 
In vivo effects of flavonoids will ultimately depend on the availability of the flavonoid 
aglycones and their metabolites in the systemic circulation. The type and position of the 
conjugation of the circulating metabolites is also important to better understand in vivo effects 
of flavonoids [9]. The aim of the present PhD project was to gain quantitative insight in dose-
dependent plasma concentrations of flavonoid aglycones and their metabolites using a PBK 
modeling approach. The developed PBK models can be used to guide future experimental in 
vitro and in vivo studies as well as to facilitate the translation of in vitro results to the in vivo 
situation. Furthermore, the developed models have a great potential to be used as a platform 
to build PBK models for other flavonoids as we still lack in vivo kinetic data for many 
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flavonoids. The present PhD project was focused on the flavonoids quercetin, genistein and 
hesperetin as model compounds.  
 In Chapter 1 of this thesis, an introduction to the fate of flavonoids in the body 
(ADME), focusing on quercetin, gensitein, and hesperetin, a short introduction to PBK 
modeling, and the aim and the outline of the present thesis are given. In Chapter 2, a PBK 
model for quercetin in rats was developed enabling prediction of plasma concentrations of 
quercetin aglycone and the tentative identification of the major circulating metabolites at 
different oral doses. The PBK model was built by integrating kinetic constants for metabolic 
conversions obtained from in vitro incubations with relevant rat tissue fractions and by fitting 
kinetic parameters to literature available data in rats. The PBK model developed in rats was 
used as a platform to build a PBK model for quercetin in humans as described in Chapter 3, 
facilitating interspecies extrapolation. In the human population, the activity of enzymes 
involved in the metabolism of quercetin can vary due to genotype- and lifestyle-based factors, 
which could influence the bioavailability of quercetin aglycone and its metabolites in the 
systemic circulation. Therefore, in Chapter 3 also individual PBK models were developed by 
incorporating kinetic constants for metabolic conversions obtained using individual human 
samples. For many flavonoids, unlike quercetin, in vivo kinetic data are still lacking, and 
therefore the developed quercetin models can form a basis for the development of similar 
models for other relevant dietary flavonoids such as genistein (soy-based isoflavone) and 
hesperetin (citrus-based flavanone). In Chapter 4, a PBK model for genistein in humans was 
developed based on the methods that were developed for simulating quercetin kinetics. Due to 
the weak estrogenicity of genistein, there is an increasing use of genistein for example in 
hormone replacement therapy in postmenopausal women. To assess whether at the current 
intake levels estrogenic activity of genistein can actually be achieved in humans, a reverse-
dosimetry approach was applied combining in vitro genistein estrogenicity data with the 
developed PBK model for genistein to convert in vitro effect concentrations to in vivo 
effective dose levels, enabling prediction of in vivo estrogenic dose-response curves in 
humans. In Chapter 5, the PBK models for quercetin were further used as a platform to build 
a PBK model for hesperetin in humans to predict dose-dependent plasma concentrations of 
hesperetin aglycone and its metabolites. Also this PBK model was used to convert reported 
effect concentrations from in vitro bioassays to corresponding in vivo dose levels, in order to 
provide insight in whether the observed in vitro effects may be relevant under realistic dietary 
or supplementary intake. Finally, Chapter 6 presents main finding obtained in this thesis and 
provides a discussion on how these results can contribute to future research on flavonoids. 
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Abstract  
Biological activities of flavonoids in vivo are ultimately dependent on the systemic 
bioavailability of the aglycones as well as their metabolites. In the present study, a 
physiologically based kinetic (PBK) model was developed to predict plasma concentrations of 
the flavonoid quercetin and its metabolites and to tentatively identify the regiospecificity of 
the major circulating metabolites. The model was developed based on in vitro metabolic 
parameters and by fitting kinetic parameters to literature available in vivo data. Both exposure 
to quercetin aglycone and to quercetin-4′-O-glucoside, for which in vivo data were available, 
were simulated. The predicted plasma concentrations of different metabolites adequately 
matched literature reported plasma concentrations of these metabolites in rats exposed to 4′-
O-glucoside. The bioavailability of aglycone was predicted to be very low ranging from 
0.004% to 0.1% at different oral doses of quercetin or quercetin-4′-O-glucoside. 
Glucuronidation was a crucial pathway that limited the bioavailability of the aglycone, with 
95 to 99% of the dose being converted to monoglucuronides within 1.5 h to 2.5 h at different 
dose levels ranging from 0.1 to 50 mg/kg bw quercetin or quercetin-4′-O-glucoside. The fast 
metabolic conversion to monoglucuronides allowed these metabolites to further conjugate to 
di- and tri-conjugates. The regiospecificity of major circulating metabolites was observed to 
be dose-dependent. As we still lack in vivo kinetic data for many flavonoids, the developed 
model has a great potential to be used as a platform to build PBK models for other flavonoids 
as well as to predict the kinetics of flavonoids in humans. 
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2.1 Introduction 
Flavonoids are important bioactive compounds widely distributed in plant based foods 
and often suggested to be of interest for their biological effects against several chronic and 
degenerative diseases, including cancer [1], cardiovascular diseases [2, 3], obesity and 
diabetes [4, 5], as well as neurodegenerative disorders [6, 7]. To elucidate the modes of action 
underlying the beneficial health effects, flavonoids are widely studied in vitro for their 
antioxidant activity as well as their activity as ligands for various receptors, kinases, enzymes, 
and/or transport proteins [8-11]. However, a key limitation in interpretation of these results is 
that in vitro data are often performed with the aglycone as the test compound [12]. In vivo 
effects will ultimately depend on the systemic bioavailability of the aglycone as well as its 
metabolites, though little is known about the contribution of circulating metabolites to the 
health effects or the precise nature of circulating metabolites. For a better interpretation of in 
vitro results and to better guide the experimental design of in vitro experiments with 
flavonoids, a clearer insight is needed on how flavonoids are absorbed, distributed, 
metabolized and excreted, especially to obtain an indication of the physiologically relevant 
concentrations of circulating metabolites in plasma and the precise nature of these 
metabolites.  
The objective of the present study was to define a physiologically based kinetic (PBK) 
model that can predict plasma concentrations of the flavonoid quercetin and its metabolites 
and to tentatively identify the regiospecificity of the major circulating metabolites. Among 
many flavonoids, the flavonol quercetin is relatively abundant in our diet and the most 
frequently studied [13]. In Western countries, the total dietary intake of quercetin is estimated 
to be 15-40 mg corresponding to 0.2-0.6 mg/kg body weight (bw) for a 70 kg person [3]. In 
some countries, quercetin is also available as a dietary supplement with daily doses of 250-
1500 mg quercetin corresponding to 3.6-21 mg quercetin/kg bw for a 70 kg person [3]. 
Naturally, quercetin occurs almost exclusively bound to one or more sugar molecules, mainly 
as β-glycosides in a wide variety of fruits and vegetables especially onions [3]. Quercetin 
glucosides such as 3,4′-O-diglucoside, 4′-O-glucoside, and 3-O-glucoside are the most 
abundant in onions [14]. Most industrial and domestic food processing procedures are not 
able to cleave the glycosidic linkage, except for fermentation [15] which implies that 
exposure via the diet is mostly to quercetin glucosides.  
The glucoside forms of the quercetin are generally too polar to cross cellular 
membranes by diffusion, and this hampers their cellular uptake and bioavailability [16, 17]. 
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However, quercetin glucosides can be taken up in the intestine after being hydrolyzed into 
quercetin aglycone by luminal lactase phlorizin hydrolase or by intestinal microflora [15, 18]. 
Upon absorption quercetin is metabolized by UDP-glucuronosyl transferases, 
sulfotransferases, and/or catechol O-methyltransferases in the small intestine and in the liver, 
forming different glucuronidated, sulfated and O-methylated quercetin mono-conjugates, 
respectively (Figure 2.1) [13, 19, 20]. Numerous different methylated, glucuronidated, and/or 
sulfated quercetin, di- and tri-conjugates have been identified in plasma in vivo as well, 
suggesting further metabolism of mono-conjugated metabolites in rats as well as in humans 
[21-25].  
 
 
Figure 2.1 Conversion of quercetin to different mono-conjugates [19, 20]. 
 
To provide a better indication of the in vivo bioavailability of quercetin and the 
relative importance and structure of different circulating metabolites in plasma, we have 
developed a PBK model for quercetin in rats. To this end the kinetics for the formation of 
different quercetin metabolites where studied in vitro. Both a direct exposure to quercetin 
aglycone and to quercetin as its 4′-O-glucoside were simulated and evaluated by comparing 
the predicted total plasma concentrations of different metabolites obtained against available 
literature data obtained with rats exposed to quercetin-4′-O-glucoside [22]. The experiments 
and model of the present paper can set an example of how in vitro data can be integrated to 
predict in vivo plasma concentrations of flavonoids and their conjugated metabolites.  
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2.2 Material and methods 
2.2.1. Materials 
Pooled male small intestine and liver S9 fractions from Sprague-Dawley rats were 
purchased from Xenotech (Lenexa, USA). Quercetin, L-ascorbic acid, uridine 5′-
diphosphoglucuronic acid (UDPGA, purity 98%), S-(5′-adenosyl)-L-methionine (SAM, purity 
80%), 3′-phosphoadenosine 5′-phosphosulfate (PAPS, purity 65%), tris (hydroxymethyl)-
aminomethane, alamethicin (from Trichoderma viride), and β-glucuronidase/sulfatase (from 
Helix pomatia) were purchased from Sigma-Aldrich (Steinheim, Germany). Potassium 
dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, acetic acid (glacial), 
hydrochloric acid (HCl, fuming 37%), ammonium acetate, magnesium chloride (MgCl2), 
sodium acetate trihydrate and trifluoroacetic acid (TFA, for spectroscopy) were purchased 
from VWR International (Darmstadt, Germany). Dimethyl sulfoxide (DMSO) was purchased 
from Acros Organic (New Jersey, USA). Acetonitrile (ULC/MS) was purchased from 
Biosolve (Valkenswaard, The Netherlands). Quercetin-3-O-glucuronide, isorhamnetin (3′-O-
methylquercetin), and tamarixetin (4′-O-methylquercetin) were purchased from Extrasynthese 
(Genay Cedex, France). 
 
2.2.2 Glucuronidation of quercetin 
The kinetic constants for glucuronidation of quercetin were determined by performing 
incubations with pooled S9 fractions from male rat small intestine and liver (Sprague-
Dawley). The incubation mixtures had a final volume of 100 µl, containing (final 
concentration) 0.1 M Tris-HCl, pH 7.4, 10 mM MgCl2, 1 mM ascorbic acid to stabilize 
quercetin [20], 0.02 mg/ml S9 protein, and quercetin added from a 200 times concentrated 
stock solution in DMSO. The concentration of DMSO was kept at 0.5%, which has 
previously shown to not have any effect on the enzyme activities [26]. Quercetin was stable 
for 2 h upon the addition of ascorbic acid at 37ºC (90-100% of the dose remains after 2 h). 
The incubation mixtures were pre-treated on ice with 0.025 mg/ml alamethicin added from a 
200 times concentrated stock solution in methanol for 15 min to overcome enzyme latency 
and obtain maximal glucuronidation activity [27]. The reactions were initiated by adding the 
cofactor UDPGA (4 mM, final concentration) after preincubating at 37ºC for 1 min. The 
kinetic constants for glucuronidation of quercetin were determined at substrate concentrations 
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that ranged from 0.2 to 20 µM quercetin. The reactions were terminated after 5 min by adding 
25 µl ice-cold acetonitrile:acetic acid (94:6) (v/v) to 100 µl incubation mixture. Under these 
conditions, the formation of quercetin monoglucuronide conjugates was linear in time and 
with protein concentration (data not shown). Three replicates of each experiment were 
performed. Blank incubations were carried out without the cofactor. Identification of different 
monoglucuronides was done following UPLC analysis by comparing the UV-spectra and the 
order of elution of each metabolite with the data reported in the study of Boersma et al.[19]. 
The nature of these metabolites was indirectly confirmed by treating samples with β-
glucuronidase. For this reaction, 50 µl of the non-terminated mixtures where added to 50 µl of 
0.1 M sodium acetate, pH 5 containing 1 mM ascorbic acid and β-glucuronidase 0.8 units/ml. 
Incubation was carried out for 1 h at 37ºC and terminated by addition of 25 µl ice-cold 
acetonitrile:acetic acid (94:6) (v/v). Samples were immediately analyzed by UPLC (Ultra 
Performance Liquid Chromatography) as described in section 2.2.5. 
 
2.2.3 Sulfation of quercetin 
The kinetic constants for sulfation of quercetin were determined by performing 
incubations with pooled S9 fractions from male rat small intestine and liver (Sprague-
Dawley). The incubation mixtures had a final volume of 100 µl, containing (final 
concentration) 0.1 M potassium phosphate, pH 7.4, 1 mM ascorbic acid, S9 fractions, and 
quercetin added from a 200 times concentrated stock solution in DMSO. The final protein 
content was 0.5 or 0.1 mg/ml for the incubations with small intestine or liver S9 fractions, 
respectively. Samples were preincubated at 37ºC for 1 min prior to the addition of the 
cofactor PAPS (0.1 mM, final concentration) to initiate the reaction. The kinetic constants for 
formation of the sulfate conjugates of quercetin were determined based on incubations 
performed at substrate concentrations ranging from 0.1 to 4 µM quercetin. The reactions were 
terminated after 12 min by the addition of 25 µl ice-cold acetonitrile:acetic acid (94:6) (v/v). 
Under these conditions, the formation of sulfate conjugates of quercetin was linear in time 
and with protein concentration (data not shown). Three replicates of each experiment were 
performed. Blank incubations were carried out without the cofactor PAPS. Identification of 
quercetin sulfate conjugates was carried out following UPLC analysis by comparing the UV-
spectra and the elution order of each metabolite with the study of van der Woude et al. [20]. 
Formation of the sulfate conjugates of quercetin was indirectly confirmed by treating the 
sample with sulfatase. To this end, 50 µl of a non-terminated mixture was added to 50 µl of 
0.2 M potassium phosphate, pH 6.2 containing 1 mM ascorbic acid and sulfatase 100 
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units/ml. These samples were incubated for 1 h at 37ºC and the reactions were terminated by 
addition of 25 µl ice-cold acetonitrile:acetic acid (94:6) (v/v). Samples were immediately 
analyzed by UPLC as described in section 2.2.5. 
2.2.4 Methylation of quercetin 
To obtain the kinetic constants for methylation of quercetin, in vitro incubations were 
performed containing (final concentrations) 0.1 M potassium phosphate, pH 7.4, 1 mM 
ascorbic acid, 1 mg/ml small intestine or liver S9 fractions (male Sprague-Dawley rat), and 
quercetin added from a 200 times concentrated stock solution in DMSO (100 µl final 
volume). The reactions were initiated by the addition of the cofactor SAM (2 mM, final 
concentration) after 1 min preincubation at 37ºC. Upon incubating for 5 min, 25 µl ice-cold 
acetonitrile:acetic acid (94:6) (v/v) were added to terminate the reaction. The kinetic constants 
were determined using substrate concentrations ranging from 10 to 80 µM quercetin. Under 
these conditions, methylation of quercetin was linear in time and with protein concentration 
(data not shown). Three replicates of each experiment were performed. Blank incubations 
were carried out without the cofactor. The methyl conjugates of quercetin were identified 
following UPLC analysis by comparing the UV-spectra and the retention time to the 
commercially available standard compounds isorhamnetin (3′-O-methylquercetin) and 
tamarixetin (4′-O-methylquercetin). Samples were immediately analyzed by UPLC as 
described in section 2.2.5. 
 
2.2.5 UPLC analysis 
The amount of glucuronide, sulfate and methyl conjugates formed in the different 
incubations was quantified using UPLC-DAD analysis. The UPLC system consisted of a 
Waters (Milford, MA) Acquity binary solvent manager, sample manager, and photodiode 
array detector, equipped with a Waters Acquity UPLC BEH RP 18 column (1.7 μm, 2.1 x 50 
mm). Before analysis, all samples were centrifuged at 18 600 xg for 5 min at 5ºC to 
precipitate proteins using a VWR microcentrifuge (Model CT15RE, Amsterdam, The 
Netherlands).  Aliquots of 3.5 µl of the supernatant obtained from the methylation incubations 
or aliquots of 10 µl of the supernatant obtained from the glucuronidation or sulfation 
incubations were immediately analyzed. The gradient consisted of acetonitrile and nanopure 
water containing 0.1% TFA and a flow rate of 0.6 ml/min was used. A gradient was applied 
from 20% acetonitrile to 25% acetonitrile over 1.8 min, to 35% over 0.5 min, keeping the 
percentage of acetonitrile at 35% for 0.5 min, followed by an increase to 80% over 0.2 min. 
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This percentage was maintained for 1 min before decreasing to 0% over 0.2 min, keeping the 
percentage of acetonitrile at 0% for 1.3 min, followed by increasing the percentage of 
acetonitrile to reach initial conditions and keeping it at these conditions for 1.1 min.  
Another UPLC method was employed to obtain a complete separation of quercetin-7-
O-glucuronide and quercetin-3-O-glucuronide. This method was less sensitive than the 
method described above, therefore it was only used to estimate the ratio between these two 
metabolites. The eluents consisted of acetonitrile and 2.5 mM ammonium acetate in nanopure 
water. At a flow rate of 0.6 ml/min, a gradient was applied from 10% acetonitrile to 25% 
acetonitrile over 1.8 min, to 90% over 0.7 min, keeping it at this percentage for 1.3 min before 
returning to the starting condition over 0.2 min.  
Quercetin metabolites were quantified by integrating the peak areas at 370 nm. 
Concentrations of quercetin metabolites formed in incubations were quantified using the 
average of three calibration curves obtained with the commercially available quercetin-3-O-
glucuronide, isorhamnetin (3′-O-methylquercetin), and tamarixetin (4′-O-methylquercetin). 
 
2.2.6 Kinetic analysis 
Kinetic parameters (i.e. apparent maximum velocity (Vmax(app)) and apparent 
Michaelis-Menten constant (Km(app))) for glucuronidation, sulfation, and methylation of 
quercetin were determined by fitting the data to the standard Michaelis-Menten equation:  
v = Vmax*[S]/(Km+[S])        (1) 
in which [S] represents the substrate concentration. Fitting the data to the Michaelis-Menten 
equation was performed using GraphPad Prism, version 5.04 (GraphPad Software, San Diego, 
California, USA). The values of Vmax and Km were expressed in nmol/min/mg S9 protein and 
µM, respectively.  
 
2.2.7 PBK model 
All kinetic parameters obtained were integrated in a PBK model describing the 
absorption, distribution, metabolism, and excretion (ADME) of quercetin and its metabolites 
in rats. The model was defined to include separate compartments for blood, liver, kidney, 
small intestine, lumen, rapidly perfused tissues (e.g. heart, lung, brain), and slowly perfused 
tissues (e.g. skin, muscle, bone) as shown in Figure 2.2A. Orally ingested quercetin-4′-O-
glucoside was hydrolyzed to quercetin aglycone in the intestinal lumen with a clearance of 
0.03 l/h. This value was calculated according to the method described by Mihara et al. [28] by 
using the data obtain from an in situ perfusion of quercetin-4′-O-glucoside in rat small 
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intestine at steady-state concentrations [29]. In short, the luminal clearance of quercetin-4′-O-
glucoside was calculated as follows:  
CLLu = (Qp*(Cin – Cout))/ Cin        (2)  
in which, Qp is the perfusion flow rate (1 ml/min), Cin represents the concentration of 
quercetin-4′-O-glucoside before perfusion of 50 µM, and Cout is the concentration of 
quercetin-4′-O-glucoside after passing through the intestinal loop of 23.5 µM.  
 
Figure 2.2 Schematic diagram of the PBK model for mono-conjugates (A), di-conjugates (B), and tri-
conjugates (C) of quercetin. 
 
 The uptake of quercetin to the small intestine compartment was described by first-
order kinetics with an absorption rate constant of 5.32 h-1 as reported by Chen et al. [30]. As a 
first step the in vitro kinetic data were integrated in the PBK model to simulate systemic 
bioavailability of quercetin aglycone and the percentage of formation of different mono-
conjugates of quercetin. Incubations with small intestine S9 fractions and relevant cofactors 
resulted in the formation of four mono-conjugates of quercetin: quercetin-7-O-glucuronide, 
quercetin-3-O-glucuronide, quercetin-3′-O-glucuronide, and quercetin-3′-O-sulfate (see 
section 2.3.1-2.3.3), which are thus described for this organ. Seven mono-conjugates of 
quercetin were observed in the incubations with liver S9 fractions and relevant cofactors: 
quercetin-7-O-glucuronide, quercetin-3′-O-glucuronide, quercetin-4′-O-glucuronide, 
quercetin-7-O-sulfate, quercetin-3′-O-sulfate, 3′-O-methylquercetin, and 4′-O-
methylquercetin (see section 2.3.1-2.3.3) and thus described for this compartment. The kinetic 
constants for the formation of these metabolites were determined in vitro in the present study 
(see section 2.3.4). The apparent in vitro Vmax values for glucuronidation, sulfation, and 
methylation were scaled to in vivo Vmax values using a S9 protein yield of 11.4 mg/g small 
intestine [31] or 143 mg/g liver [32] as a scaling factor. With the obtained model, the systemic 
bioavailability (BIO) of quercetin aglycone was determined based on the following equation:  
 BIO(%) = Dose (i.v.)/Dose (oral)*AUC (oral)/AUC (i.v.)*100    (3) 
Chapter 2 
 30 
in this equation, AUC0-24 h (oral dose) is the area under the concentration-time curve of the 
blood compartment after an oral dose of quercetin and AUC0-24 h (i.v. dose) is the area under 
the concentration-time curve of the blood compartment after an intravenous dose of quercetin. 
In the model, intravenous dose was applied in the blood compartment over a time period of 10 
sec.  
 In a second step the model was adjusted to also include a description of di- and tri-
conjugations and excretion of the different metabolites via bile, urine, and intestinal efflux 
transport. From the first model, quercetin was predicted to mainly converted to quercetin 
monoglucuronides (QG) (see section 2.3.5) and thus in a second step further refinement of the 
model for further conjugation of the monoglucuronides to di- and tri-conjugates was 
simulated. All monoglucuronides were assumed to be subject to further glucuronidation (at 
the 3-, 7-, 4′- or 3′- position), sulfation (at the 7- or 3′- position) and/or methylation (at the 4′- 
or 3′- position) when these positions were still available. The regioselectivity for further 
conjugation was considered to be the same as observed with the formation of mono-
conjugates. The 5-position is not a site for conjugation of quercetin [33]. Conjugation was 
assumed to only occur at different positions on the flavonol ring and not on a functional group 
that already contains a conjugate [22, 34]. Based on this approach, the formation of different 
combinations of quercetin diglucuronides (QdiG), quercetin glucuronide sulfate conjugates 
(QGS), and quercetin glucuronide methyl conjugates (QGM) were described in the model. 
The di-conjugates were assumed to be subject to further conjugation forming two major types 
of tri-conjugates, including quercetin diglucuronide methyl conjugates(QdiGM) and quercetin 
glucuronide sulfate methyl conjugates(QGSM) as these metabolites have been reported in 
vivo [21]. QGSM conjugates can be formed from either sulfation of QGM or methylation of 
QGS, and QdiGM can be formed from glucuronidation of QGM or methylation of QdiG. 
Other theoretically possible tri-conjugates, such as for example quercetin diglucuronide 
sulfates, were not included in the model because these have not been observed in plasma of 
rats in vivo and are therefore considered unlikely to be formed. Taking the regiospecifity of 
possible conjugations into account, a total of 34 different mono-, di-, and tri-conjugates were 
included in the model.  
Metabolism, distribution and excretion of the different mono-, di- and tri-conjugates 
were described in separate submodels for each metabolite. Each of these submodels consisted 
of different compartments for blood, liver, kidney, small intestine, rapidly perfused tissues 
(e.g. heart, lung, brain), and slowly perfused tissues (e.g. skin, muscle, bone) as shown in 
Figure 2.2B and Figure 2.2C describing for di- and tri-conjugates. Excretion was considered 
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to occur in the liver via bile, in the kidney via urine, or in the in the small intestine by active 
transporters (i.e. P-glycoprotein, breast cancer resistance protein and multidrug resistance 
proteins) [35, 36]. The quercetin aglycone was not modeled to be excreted since the aglycone 
has not been detected in urine and bile in rats following oral uptake of quercetin [30] or in 
lumen of in situ perfusion of rat small intestine with quercetin [37]. The excretion parameters 
were considered to be the same for all metabolites and were obtained by fitting the plasma 
AUC0-5h of the total metabolites to literature derived AUC0-5h levels of all metabolites in 
plasma of rats exposed to 7.6 mg/kg bw [2-14C]quercetin-4′-O-glucoside [21]. Conversion of 
the blood concentrations of the different metabolites to plasma concentrations was done by 
dividing the blood concentrations by a blood/plasma ratio (R). For all metabolites a R value of 
0.55 (1-hematocrit) was assumed, since most metabolites of quercetin are acidic molecules 
(see pKa values Table 2.2) [38]. Based on this approach, the biliary and the urinary excretion 
rate constants were estimated to be 16 and 6.5 h-1, and the intestinal efflux clearance of the 
metabolites to the lumen was estimated to be 0.17 l/h. Finally, enterohepatic circulation of 
quercetin and its metabolites has not been included in the model as Chen et al. reported the 
absence of significant enterohepatic circulation of quercetin and its metabolites in rats [30].   
The kinetic constants for formation of the 30 different di- and tri-conjugates were 
estimated by fitting the predicted plasma AUC0-5h of QG, QdiG, QGS, QGM, QdiGM, and 
QGSM to literature derived AUC0-5h levels of these metabolites [21]. Further conjugation of 
monoglucuronides was simulated under the assumption that the catalytic efficiency for further 
conjugation was lower than observed for the formation of the different mono-conjugates, due 
to both an increase in Km and a decrease in Vmax. This assumption was validated with an in 
vitro experiment in which quercetin-3-O-glucuronide was used as a substrate. Although the 
exact kinetic constants for further conjugation of quercetin-3-O-glucuronide could not be 
determined due to low catalytic efficiencies of the different reactions, both the affinity and 
capacity of the reactions seemed to decrease (data not shown). The factors by which the Km 
and the Vmax values for di- and tri-conjugates with glucuronide, sulfate, or methyl moiety 
were affected, as determined by fitting to the experimental data, are shown in Table 2.1. 
The physiological parameters and the tissue:blood partition coefficients used in the 
model are given in Table 2.1 and Table 2.2, respectively. The physiological parameters were 
obtained from Brown et al. [39]. The tissue:blood partition coefficients of quercetin and its 
metabolites were estimated from log Kow according to a method of DeJongh et al. [40]. Log 
Kow values were estimated from LogP value obtained from Scifider (american Chemical 
Society, USA) for quercetin and its mono-conjugates or CLogP values obtained from 
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ChemBio3D Ultra 2010 (CambridgeSoft, USA) for di- and tri-conjugates (Table 2.2). The 
derived partition coefficients are around one, which can be expected based on the low 
lipophilicity of quercetin and its metabolites [41]. Only the partition coefficients of 3′-O-
methylquercetin and 4′-O-methylquercetin are slightly higher due to a higher lipophilicity of 
these metabolites [42]. Mass balance and model equations were coded and numerically 
integrated in Berkeley Madonna 8.3.18 (Macey and Oster, UC Berkeley, CA) using the 
Rosenbrock′s algorithm for stiff system. The parameters for excretion of metabolites and 
factors by which Km and Vmax for formation of di-and tri-conjugates were affected, were 
obtained by using the multiple-curve fitting function in Berkeley Madonna, which minimizes 
the root mean square deviation between the reported in vivo data points and the model output. 
When using this function, increasing in the number of parameters to be fitted also increase the 
risk that the program will find a local minimum of residual instead of the global minimum 
[43]. To prevent this to happen, several different starting values were set. Furthermore, by 
limiting the values of the parameters to physiologically plausible values, the estimation of 
unrealistic parameters can be prevented [43]. With the model obtained, predictions were made 
on circulating metabolites in plasma specifying the conjugation position. The model equations 
for quercetin and its metabolites are described as follows: 
 
Amount of quercetin in tissues and blood 
Small intestine: dAIQ/dt =  Ka*ALuQ + QI*(CBQ - CIQ/PIQ)  
- Vmax,I_Mmono*CIQ/PIQ/(Km,I_Mmono + CIQ/PIQ)  (4) 
CIQ = AIQ/VI        (5) 
Liver:  dALQ/dt =  QI* CIQ/PIQ + QL*(CBQ - CLQ/PLQ) 
- Vmax,L_Mmono*CLQ/PLQ/(Km,L_M mono + CLQ/PLQ)  (6)  
  CLQ = ALQ/VL       (7) 
Kidney: dAKQ/dt =  QK*(CBQ - CKQ/PKQ)      (8) 
   CKQ = AKQ/VK       (9) 
Blood:  dABQ/dt =  (QI+QL) * CLQ/PLQ + QK* CKQ/PKQ  + QR* CRQ/PRQ   
+ QS* CSQ/PSQ - QC*CBQ     (10) 
   CBQ = ABQ/VB       (11) 
where CTiQ (in µmol/l) is the concentration of quercetin in tissue (Ti = Lu (lumen), I (small 
intestine), L (liver), or K (kidney), R (rapidly perfused tissues), or S (slowly perfused tissues), 
ATiQ (in µmol) is the amount of quercetin in a tissue, ABQ (in µmol) and CBQ (in µmol/l) are 
the amount and the concentration of quercetin in blood, QTi (in l/h) is the blood flow to a 
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tissue, and PTiQ is the tissue:blood partition coefficient of quercetin. Mmono refers to either 
of the specified mono-conjugates as described in Table 2.3 and Figure 2.2.  
 
Amount of quercetin mono-conjugate in tissues and blood  
Small intestine: dAIMmono/dt = QI*(CBMmono – CIMmono/PIMmono) 
+ Vmax,I_Mmono*CIQ/PIQ/(Km,I_Mmono  + CIQ/PIQ)  
-Vmax,I_Mdi*CIMmono/PIMmono/(Km,I_Mdi + CIMmono/PIMmono)  
- CLIef*(CIMmono/PIMmono)     (12) 
  CIMmono = AIMmono/VI       (13) 
Liver:  dALMmono/dt = QI* CIMmono/PIMmono + QL*CBMmono 
- (QI+QL)* CLMmono/PLMmono  
+ Vmax,L_Mmono*CLQ/PLQ/(Km,L_M mono + CLQ/PLQ)  
- Vmax,L_Mdi*CLMmono/PLMmono/(Km,L_M di + CLMmono/PLMmono)  
- Kbile*ALMmono      (14) 
  CLMmono = ALMmono/VL      (15) 
Kidney: dAKMmono/dt = QK*(CBMmono - CKMmono/PKMmono)  
- Kurine*AKMmono      (16) 
   CKMmono = AKMmono/VK      (17) 
Blood:  dABMmono/dt = (QI+QL)* CLMmono/PLMmono  +  QK* CKMmono/PKMmono  
+ QR* CRMmono/PRMmono + QS* CSMmono/PSMmono  
- QC*CBMmono      (15) 
   CBMmono = ABMmono/VB      (18) 
   CPMmono = CBMmono/R       (19) 
where, CTiMmono (in µmol/l) is the concentration of mono-conjugate metabolite in tissue (Ti = 
I (small intestine), L (liver), K (kidney), R (rapidly perfused tissues), or S (slowly perfused 
tissues), ATiMmono (in µmol) is the amount of mono-conjugate metabolite in a tissue, ABMmono 
(in µmol) and CBMmono (in µmol/l) are the amount and the concentration of mono-conjugate 
metabolite in blood, QTi (in l/h) is the blood flow to a tissue, PTiMmono is the tissue:blood 
partition coefficient of mono-conjugate, and CPMmono (in µmol/l) are the concentration of 
mono-conjugate metabolite in plasma. R is the blood/plasma ratio. Mmono and Mdi refer to 
either of the specified mono-conjugates or di-conjugates as described in Table 2.3 and Figure 
2.2. 
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Amount of quercetin di- and tri-conjugate in tissues and blood 
The amount of quercetin di-and tri-conjugates in tissues and blood were described in 
the model using the same equations as described for mono-conjugates (equation 12-19). The 
equations used to describe the formation of di-and tri-conjugates of quercetin in the small 
intestine and liver included the factors by which the Km and the Vmax values for di- and tri-
conjugates with glucuronide, sulfate, or methyl moiety were affected, and are described as 
follows: 
sulfation of QG   = Vmax,Ti_Mmono/a* CTiMmono/PTiMmono 
    /(Km,Ti_Mmono*d + CTiMmono/PTiMmono)  (20) 
sulfation of QGM  = Vmax,Ti_Mmono/a* CTiMdi/PTiMdi 
   /(Km,Ti_Mmono*d + CTiMdi/PTiMdi)   (21) 
methylation of QG   = Vmax,Ti_Mmono/b* CTiMmono/PTiMmono 
   /(Km,Ti_Mmono*e + CTiMmono/PTiMmono)  (22) 
 methylation of QGS   = Vmax,Ti_Mmono/b* CTiMdi/PTiMdi 
  /(Km,Ti_Mmono*e+ CTiMdi/PTMdi)   (23) 
methylation of QdiG   = Vmax,Ti_Mmono/b3* CTiMdi/PTiMdi 
  /(Km,Ti_Mmono*e3+ CTiMdi/PTMdi)   (24) 
glucuronidation of QG = Vmax,Ti_Mmono/c* CTiMmono/PTiMmono 
  /(Km,Ti_Mmono*f + CTiMmono/PIMmono)   (25) 
 glucuronidation of QGM  = Vmax,Ti_Mmono/c* CTiMdi/PTiMdi 
  /(Km,Ti_Mmono*f+ CTiMdi/PIMdi)   (26) 
Where CTi (in µmol) and PTi is the concentration and the tissue:blood partition coefficient of 
mono-conjugate (Mmono), di-conjugate (Mdi), or tri-conjugate (Mtri) in tissue. The reduction 
factors for the Vmax values and the induction factors for Km valuesfor formation of di- and tri-
conjugates, as obtained by fitting the plasma AUC0-5h of the total metabolites to literature 
derived AUC0-5h levels of all metabolites, are presented in Table 2.1.  
 
2.8 Sensitivity analysis 
A sensitivity analysis was performed to assess which model parameters contribute 
substantially to a specific model output. Normalized sensitivity coefficients (SCs) were 
calculated for the model parameters according to the method described by Evens and 
Andersen [44] as follows:  
SC = (C′-C)/(P′-P)*(P/C)        (27)  
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in this equation, C is the initial value of the model output, C′ is the modified value of the 
model output resulting from an increase in parameter value, P is the initial parameter value, 
and P′ is the modified parameter value assuming a 5% increase in its value.  
 Sensitivity analyses were carried out for the plasma AUC0-5h of mono-, di- and tri- 
conjugates of quercetin at dose of 7.6 mg/kg bw quercetin-4′-O-glucoside; representing the 
dose that was applied in the literature reported in vivo study that was used in the present study 
for parameterization of the model.  
 
Table 2.1 Physiological parameters used in the PBK model for quercetin in rats 
Parameters Symbol Value 
  Literature Fitted in vivo 
Body weight (kg) [39]                  BW 0.25  
Tissue volumes (% body weight) [39]         
     lumen VLu 0.5  
     small intestine VI 1.4  
     liver  VL 3.4  
     kidney  VK 0.7  
     rapidly perfused tissues VR 3.2  
     slowly perfused tissues  VS 74.6  
   blood VB 7.4  
Cardiac output (l/h) [39] QC 5.4  
Blood flow to tissue (% cardiac output) [39]    
     small intestine QI 15.1  
     liver (exclude portal vein) QL 9.9  
     kidney  QK 14.1  
     rapidly perfused tissues QR 36.9  
     slowly perfused tissues  QS 24  
Absorption rate constant of quercetin (h-1) [30] Ka 5.32  
Biliary excretion rate constant (h-1) Kbile  16 
Urinary excretion rate constant (h-1) Kurine  6.5 
Intestinal efflux clearance (l/h)   CLIef  0.17 
Luminal clearance of quercetin-4′-O-glucoside (l/h) [29] CLLu 0.03  
Reduction factor for Vmax    
     sulfation of QG or QGM a  1.5 
     methylation of QG or QGS b  1 
     glucuronidation of QG or QGM c  12 
     methylation of  QdiG b3  31 
Induction factor for Km    
     sulfation of QG or QGM d  2.2 
     methylation of QG or QGS e  1 
     glucuronidation of QG or QGM f  13 
     methylation of QdiG e3  87 
 
 
Chapter 2 
 36 
Table 2.2 Physico-chemical parameters for quercetin and its metabolites1  
Compound LogP2 pKa Small 
intestine 
Liver Kidney Rapidly 
perfused 
tissue 
Slowly 
perfused 
tissue 
quercetin 2.0 6.3 1.3 1.3 1.5 1.5 0.6 
quercetin-7-O-glucuronide -0.5 2.7 0.8 0.8 0.8 0.8 0.4 
quercetin-3-O-glucuronide 0.6 2.8 0.9 0.9 0.9 0.9 0.5 
quercetin-3′-O-glucuronide -0.003 2.8 0.8 0.8 0.8 0.8 0.4 
quercetin-4′-O-glucuronide -0.1 2.8 0.8 0.8 0.8 0.8 0.4 
quercetin-7-O-sulfate 1.2 -4.9 1.0 1.0 1.0 1.0 0.5 
quercetin-3′-O-sulfate 1.2 -4.4 1.0 1.0 1.0 1.0 0.5 
3′-O-methylquercetin 2.8 6.3 2.0 2.0 2.6 2.6 0.7 
4′-O-methylquercetin 2.7 6.3 1.8 1.8 2.4 2.4 0.7 
quercetin diglucuronides -2.7  0.7 0.7 0.8 0.8 0.4 
quercetin glucuronide sulfate 
conjugates 
-2.2 - 0.7 0.7 0.8 0.8 0.4 
quercetin glucuronide methyl 
conjugates 
-0.2 - 0.8 0.8 0.8 0.8 0.4 
quercetin diglucuronide methyl 
conjugates 
-2.3 - 0.7 0.7 0.8 0.8 0.4 
quercetin glucuronide sulfate 
methyl conjugates 
-1.8 - 0.8 0.8 0.8 0.8 0.4 
1Tissue:blood partition coefficients were calculated based on a method of Dejongh et al. [40]. 
2 For quercetin and its mono-conjugates, LogP values were obtained from Scifinder (American Chemical Society, USA), 
while CLogP values for di- and tri-conjugates were calculated with ChemBio3D Ultra 2010 (Cambridgesoft, USA). 
 
2.3 Results 
2.3.1 Glucuronidation of quercetin  
 UPLC analysis of incubations with rat small intestine and liver S9 fractions in the 
presence of quercetin and UDPGA reveals the formation of different metabolites with 
retention times of 0.52, 0.82 and 0.95 min. Treatment of the samples with β-glucuronidase 
resulted in complete disappearance of these peaks and a concomitant equivalent increase in 
the peak area of quercetin (data not shown). The chromatographic profile was comparable to 
that reported in the literature for the same reaction, enabling assignment of the peaks in our 
chromatograms according to the identifications reported by Boersma et al. [19]. This 
assignment was supported by an additional analysis of collected metabolites from the UPLC 
by HPLC using the same method as described by Boersma et al. [19] (data not shown). Based 
on this comparison, the metabolites with a retention time of 0.82 and 0.95 min were ascribed 
to quercetin-4′-O-glucuronide and quercetin-3′-O-glucuronide, whereas the peak with a 
retention time of 0.52 min was considered to contain a mixture of quercetin-3- and -7-O-
glucuronide. To determine the relative quantity of each of these metabolites in this peak, the 
samples were further analyzed with a different UPLC method that allowed separation of the 
two peaks (see Section 2.2.5). These analyses revealed that for incubations with rat intestine 
S9 the peak at 0.52 min contained 20 % quercetin-3-O-glucuronide and 80 % quercetin-7-O-
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glucuronide. This ratio was consistent at different concentrations. In incubations with rat liver 
S9 fractions, the peak at 0.52 min, was identified to only contain quercetin-7-O-glucuronide. 
Figure 2.3 shows the rate formation of the different quercetin monoglucuronides obtained 
with the incubations with male rat liver (A) or small intestine S9 fractions (B) with increasing 
in concentrations of quercetin. 
 
 
Figure 2.3 Quercetin concentration dependent formation of different glucuronide conjugates by male 
rat liver S9 (A) or small intestinal S9 (B), different sulfate conjugates by male rat liver S9 (C) or 
intestinal S9 (D), and different methyl conjugates by male rat liver S9 (E); quercetin (Q), glucuronide 
(G), sulfate (S), and methylate (M). 
 
2.3.2 Sulfation of quercetin 
  UPLC chromatogram of incubations with rat small intestine S9 fractions in the 
presence of quercetin and PAPS as cofactor reveals the formation of one metabolite with a 
retention time of 1.09 min, while incubations with rat liver S9 fractions result in two 
metabolites with retention times of 0.71 and 1.09 min. Treatment of the samples with 
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sulfatase result in complete elimination of these metabolites and a concomitant equivalent 
increase in the amount of quercetin (data not shown). The chromatographic profile was 
comparable to that reported in the literature for the same reaction by van der Woude et al. 
[20]. The chromatographic profile of sulfate conjugates of quercetin obtained from the UPLC 
analysis was comparable to what has previously been reported by van der Woude et al. [20] 
enabling assignment of the peaks in our chromatograms according to the identifications 
reported by van der Woude et al. [20]. This assignment was supported by an additional 
analysis of collected metabolites from the UPLC by HPLC using the same method as 
described by van der Woude et al. [20] (data not shown). The peaks at 0.71 and 1.09 min 
could thus be ascribed to quercetin-7-O-sulfate and quercetin-3′-O-sulfate, respectively. The 
quercetin concentration dependent rate of formation of these metabolites in incubations with 
rat liver or small intestine S9 fractions is shown in Figure 2.3C and Figure 2.3D.  
 
2.3.3 Methylation of quercetin  
 UPLC chromatogram of incubations with rat small intestine or liver S9 fractions in 
the presence of SAM as cofactor reveals that there was no methylation of quercetin by small 
intestine S9 fractions, whereas two metabolites were formed in incubations with liver S9 
fractions with a retention time of 2.49 and 2.52 min. The metabolite with a retention time of 
2.49 min coeluted with commercially available 3′-O-methylquercetin and was thus identified 
as 3′-O-methylquercetin. The one with a retention of 2.52 min was found to coelute with 
commercially available 4′-O-methylquercetin and was therefore identified as 4′-O-
methylquercetin. The quercetin concentration dependent rate of formation of the 
methylquercetin conjugates by rat liver S9 fractions is depicted in Figure 2.3E. 
 
2.3.4 Kinetic constants for formation of different quercetin mono-conjugates  
 The kinetic constants for formation of mono-conjugates of quercetin with a 
glucuronide, sulfate, or methyl moiety were obtained by fitting the data to a standard 
Michaelis-Menten equation (Table 2.3). The in vitro Vmax values obtained with S9 from 
different organs were scaled to in vivo Vmax values using scaling factors (see section 2.2.7). 
The in vivo catalytic efficiencies for formation of the different mono-conjugates of quercetin 
reveal that liver is the major site for metabolism of quercetin as the catalytic efficiencies for 
all reactions in this tissue are higher than the catalytic efficiencies for all reactions in small 
intestine. Glucuronidation is the most efficient pathway and quercetin-4′-O-glucuronide is the 
A PBK model for quercetin in rats 
 39 
major mono-conjugate formed. The high catalytic efficiency for formation of quercetin-4′-O-
glucuronide is mainly due to a relatively low Km value for this reaction.  
 
Table 2.3 Kinetic parameters for conjuguation of quercetin in incubations with small intestine and 
liver S9 fractions from male Sprague-Dawley rats 
Organ Metabolite 
Km(app) 
(µM) 
Vmax(app) 
(nmol/min/mg
/S9 protein) 
In vitro catalytic 
efficiency 
(µl/min/mg S9 
protein) 
Scaled 
Vmax, in 
vivo 
(µmol/h)1 
In vivo 
catalytic 
efficiency 
(l/h) 
 
Small 
intestine 
quercetin-7-O-glucuronide 0.3 1.9 6.3 4.5 15 
quercetin-3-O-glucuronide 0.3 0.5 1.7 1.2 4.0 
quercetin-3′-O-glucuronide 1.1 0.9 0.8 2.2 2.0 
quercetin-3′-O-sulfate 0.1 0.01 0.1 0.03 0.3 
 
Liver 
quercetin-7-O-glucuronide 8.1 6.1 0.8 445 55 
quercetin-3′-O-glucuronide 1.1 1.5 1.4 109 99 
quercetin-4′-O-glucuronide 0.1 0.7 7.0 51 511 
quercetin-7-O-sulfate 0.5 0.04 0.1 2.9 5.8 
quercetin-3′-O-sulfate 0.3 0.1 0.3 7.3 24 
3′-O-methylquercetin 24 0.5 0.02 36 1.5 
4′-O-methylquercetin 24 0.2 0.01 15 0.6 
1 Small intestine: Vmax(app)/(1000 nmol/umol) * (60 min/hr) * (11.4 mg S9/g intestine)*(14 g intestine/kg bw)*(0.25 kg 
bw), Liver: Vmax(app)/(1000 nmol/umol) * (60 min/hr)*(143 mg S9/g liver)*(34 g liver/kg bw)*(0.25 kg bw). 
 
2.3.5 Integrating the kinetic data to predict the bioavailability of quercetin aglycone and 
formation of mono-conjugate metabolites 
As a first step the kinetic constants obtained were integrated in a PBK model to predict 
systemic bioavailability of quercetin in rats upon exposure to quercetin in its aglycone form or 
to quercetin-4′-O-glucoside and to provide an indication of the percentage of the different 
mono-conjugates of quercetin that are formed. The model predicted that the bioavailability of 
quercetin when dosed as aglycone is very low, amounting to 0.004% at a dose relevant to 
dietary intake (0.4 mg/kg bw quercetin aglycone) and 0.1% at a dose level representing 
supplementary intake (12 mg/kg bw quercetin aglycone). Quercetin-4′-O-glucoside was 
predicted to have the same level of bioavailability at low dose, but 3.3-fold lower at high 
dose, amounting to 0.004 or 0.03% when providing the same level of quercetin equivalents by 
dosing of 0.6 mg/kg bw or 19 mg/kg bw quercetin-4′-O-glucoside.   
When dosed as aglycone, quercetin was completely metabolized within 1.5 h and was 
almost exclusively converted to monoglucuronides accounting to 99 to 95% of the dose at a 
dose ranging from 0.1 to 50 mg/kg bw. Sulfation and methylation only represented minor 
metabolic pathways with 0.9 to 4.5% of the dose being converted via sulfation and 0.01 to 
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0.8% of the dose being converted via methylation at different oral doses of quercetin. When 
quercetin was dosed as 4′-O-glucoside complete metabolism was observed within 2.5 h and 
99 to 97% of the dose was converted to monoglucuronides at a dose ranging from 0.1 to 50 
mg/kg bw. Figure 2.4 presents a plot of the percentage of the dose that is converted into the 
different monoglucuronides at different oral dose levels of quercetin aglycone (Figure 2.4A) 
or quercetin-4′-O-glucoside (Figure 2.4B). At low dose level of quercetin (0.4 mg/kg bw 
quercetin aglycone), 68% of the dose is predicted to be converted to quercetin-7-O-
glucuronide, 18% to quercetin-3-O-glucuronide, 10% to quercetin-3′-O-glucuronide, and 
3.1% quercetin-4′-O-glucuronide. Formation of 7- and 3-O-glucuronidated metabolites thus 
represent the primary metabolic reactions at low doses. However, as the dose increases the 
relative contribution of these metabolites decreases, which is accompanied by a relative 
increase in formation of 3′-and 4′-O-glucuronide. At a dose of 12 mg/kg bw approximately 
39% of the dose is predicted to be converted to quercetin-4′-O-glucuronide, 31% to quercetin-
7-O-glucuronide, 20% to quercetin-3′-O-glucuronide, and 6.6% to quercetin-3-O-glucuronide. 
For quercetin-4′-O-glucoside, this shift in metabolism occurred at higher dose levels. These 
results suggest that regiospecificity of metabolites will depend on the dose of quercetin and 
whether it is absorbed as a glucoside or not.   
                
Figure 2.4 PBK model based prediction on dose-dependent formation of quercetin-7-O-glucuronide 
(Q7G), quercetin-3-O-glucuronide (Q3G), quercetin-3′-O-glucuronide (Q3′G), and quercetin-4′-O-
glucuronide (Q4′G) in rat orally exposed to quercetin (A) or quercetin-4′-O-glucoside (B). Data are 
expressed as percentage of the dose. 
 
2.3.6 Adjustment of the model to predict plasma concentrations of mono-, di- and tri-
conjugates 
Given that 95 to 99 % of quercetin and quercetin-4′-O-glucoside is converted to 
different monoglucuronides after 1.5 h to 2.5 h and the fact di- and tri-conjugates have been 
observed in the plasma of rats in vivo [21, 22], we considered that all monoglucuronides that 
A PBK model for quercetin in rats 
 41 
are formed are subjected to further conjugation. In a second step, we have therefore included 
the further conjugation of quercetin monoglucuronides into di- and tri-conjugates in the model 
as well as urinary, biliary, and intestinal excretion of the different metabolites. This enabled 
prediction of the plasma concentrations of the various mono-, di- and tri-conjugates. The 
kinetic constants for further conjugation and urinary, biliary, and intestinal excretion were 
obtained by fitting the predicted plasma AUC0-5h of different metabolites to the AUC0-5h 
values that were derived from in vivo reported plasma concentrations of the same metabolites 
in rats exposed to 7.6 mg/kg bw [2-14C]quercetin-4′-O-glucoside as described by Graf et al. 
[21]. Figure 2.5A shows the best fit that was obtained, which allowed to predict the AUC0-5h 
of these metabolites in plasma within 0.9 to 3.9-fold from the reported levels [21]. In addition, 
the model obtained allowed to adequately predict results from a second study in which rats 
were exposed to 7.6 mg/kg bw [2-14C]quercetin-4′-O-glucoside as reported by Mullen et al. 
[22] (Figure 2.5B). Plasma concentrations of different metabolites at 1 h after exposure were 
observed to be within 19 to 3-fold of the observed plasma concentrations.  
 
Figure 2.5 Comparison of the predicted 
plasma AUC0-5h levels of quercetin 
metabolites (black bar) to literature derived 
AUC0-5h  levels of these metabolites by Graf 
et al. [21] (white bar) (A) and comparison 
of the predicted amount of quercetin 
metabolites in plasma at 1 h (black bar) to 
the reported in vivo levels of these 
metabolites by Mullen et al. [22] (white bar) 
of rat exposed to 7.6 mg/kg bw quercetin-4′-
O-glucoside; quercetin monoglucuronides 
(QG), quercetin diglucuronides (QdiG), 
quercetin glucuronide methyl conjugates (QGM), quercetin glucuronide sulfate conjugates (QGS), 
quercetin diglucuronide methyl conjugates (QdiGM), and quercetin glucuronide sulfate methyl 
conjugates (QGSM) (B). 
 
 Apart from simulating total concentrations of the different major circulating 
metabolites the model also allowed to tentatively predict the regiospecificity of the 
conjugation for the most important circulating metabolites. The regiospecificity of the ten 
metabolites with the highest AUC0-5h at a dose level ranging from 0.1 to 50 mg/kg bw 
quercetin and quercetin-4′-O-glucoside is shown in Figure 2.6A and Figure 2.6B. Together 
these metabolites contributed to approximately 71 to 86% of the total plasma AUC0-5h. At a 
low dose of quercetin (0.4 mg/kg bw), Q7G3′S4′M is predicted to be the major circulating 
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metabolites, followed by Q74′diG′, and Q7G3′S accounting to 27, 16, and 10% total plasma 
AUC0-5h. However, as the dose increase the relative contribution of these metabolites 
decreases, which is accompanied by a relative increase in plasma concentrations of Q3′4′diG, 
Q4′G3′S, Q74′diG3′M, and Q4′G7S3′M. For quercetin-4′-O-glucoside, the predicted 
regiospecificity of the major circulating metabolites is similar to what is predicted for 
quercetin, but the shift in the metabolism happened at higher dose levels.  
 
Figure 2.6 PBK model predicted dose-dependent regiospecificity of the major circulating metabolites 
of quercetin in plasma of rat orally exposed to quercetin (A) or quercetin-4′-O-glucoside (B); quercetin 
(Q), glucuronide (G), sulfate (S), methylate (M). Data were expressed as percentage of the total 
plasma AUC0-5h. 
 
2.3.7 Sensitivity analysis  
A sensitivity analysis was performed to assess the key parameters that influence the 
predicted plasma AUC0-5h of quercetin metabolites at a dose of 7.6 mg/kg bw quercetin-4′-O-
glucoside. Only parameters that had a normalized sensitivity coefficient higher than 0.1 (in 
absolute value) are shown in Figure 2.7. The results obtained reveal that the AUC0-5h levels of 
quercetin metabolites in plasma are mainly influenced by the kinetic constants for formation 
of quercetin-4′-O-glucuronide and querctin-3′-O-sulfate in the liver as well as factors by 
which the kinetic constants for formation of di- and tri-conjugates were estimated to be 
reduced (Table 2.1). The plasma AUC0-5h levels of methyl containing metabolites are also 
affected by the kinetic constants for formation of 3′- and 4′-O-methylquercetin in the liver. 
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The kinetic constants for formation of 4′-O-methylquercetin are found to greatly affect the 
plasma AUC0-5h levels of QGS. Parameters determining the excretion of quercetin metabolites 
especially the biliary excretion rate constant and the intestinal efflux clearance as well as the 
parameter determining plasma concentration (R value) are found to predominantly influence 
the plasma AUC0-5h levels of quercetin di- and tri-conjugates. Other parameters including 
physiological parameters especially the body weight and the tissue volumes (i.e. small 
intestine and liver), and the scaling factor for liver S9 concentration are found to have an 
impact on the plasma AUC0-5h levels of all quercetin metabolites. To a minor extent, the 
plasma AUC0-5h levels of quercetin metabolites are influenced by the blood flow to tissue (i.e. 
small intestine and liver). Partition coefficient parameters do not significantly affect the 
plasma AUC0-5h levels of the different quercetin metabolites.  
 
2.4 Discussion  
In vitro tests to elucidate the mechanisms of action are often performed with flavonoid 
aglycones. Questions remain as in what form the flavonoids are ultimately present in the in 
vivo systemic circulation. PBK models can be used to answer this question since these models 
allows to predict time-dependent concentrations of compounds as well as their metabolites in 
plasma or in tissues. Therefore, in the present study PBK models were developed using 
quercetin and its glucoside (quercetin-4′-O-glucoside) as model compound to predict plasma 
concentrations of quercetin and its metabolites.  
Bioavailability of quercetin as aglycone was estimated to range between 0.004% to 
0.1% at dose levels of 0.4 mg/kg bw and 12 mg/kg bw quercetin or quercetin equivalent when 
dosing as 4′-O-glucoside (0.6 and 19 mg/kg bw). In most in vivo studies no quercetin 
aglycone or only a trace amount of the aglycone have been detected in plasma of rats upon 
oral exposure to quercetin or quercetin-4′-O-glucoside [13, 21, 45], supporting the low 
bioavailability of quercetin. One study did report quercetin concentrations in plasma and 
estimated an oral bioavailability of quercetin in rats of 5.3% at an oral dose of 10 mg/kg bw 
quercetin [30]. This value is somewhat higher than the predicted level with the PBK model, 
but confirms that the plasma concentrations of quercetin aglycone will be limited.  
 Glucuronidation was found to be the major pathway responsible for the low 
bioavailability of quercetin aglycone, since as much as 95 to 99% of the dose was predicted to 
be converted to monoglucuronides within 1.5 h to 2.5 h at different oral doses of quercetin or 
quercetin-4′-O-glucoside (Figure 2.4). This is in line with the study of Mullen et al. as 73.8% 
of quercetin was metabolized within 1 hour at a dose of 7.6 mg/kg bw [2-14C]quercetin-4′-O-
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glucoside, primarily resulting in metabolites that contain a glucuronide [22]. An additional 
level of evaluation of the model performance may be obtained by comparison of the 
 
Figure 2.7 Sensitivity analysis of the predicted plasma AUC0-5h of quercetin monoglucuronides (QG), 
quercetin diglucuronides (QdiG), quercetin glucuronide methyl conjugates (QGM), quercetin 
glucuronide sulfate conjugates (QGS), quercetin diglucuronide methyl conjugates (QdiGM), and 
quercetin glucuronide sulfate methyl conjugates (QGSM) in rat exposed to 7.6 mg/kg bw quercetin-4′-
O-glucoside. The parameters are stand for:  bw = body weight, VTi = tissue volume (Ti = I (small 
intestine), L (liver)), QC = cardiac output, QI = blood flow to small intestine, Kbile = biliary excretion 
rate constant, R = blood/plasma ratio, CLIef = intestinal efflux clearance, S9PI = small intestinal S9 
protein content, S9PL = liver S9 protein content, Vmax and Km =  the maximum rate of formation and 
the Michaelis-Menten constant for formation of metabolite (G (glucuronide), S (sulfate), M 
(methylate), reduction factor of Vmax for sulfate-conjugate of QG or QGM (a), methylate-conjugate of 
QG or QGS (b), glucuronide-conjugate of QG or QGM (c), and induction factor of Km for sulfate-
conjugate of QG or QGM (d), methylate-conjugate of QG or QGS (e), glucuronide-conjugate of QG 
or QGM (f). 
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predicted excretion of quercetin metabolites via bile, urine and intestinal efflux transport to in 
vivo reported levels of excretion through these routes. The excretion parameters for the model 
 defined were obtained by fitting the predicted AUC0-5h of the total quercetin metabolites in 
plasma to the reported levels in vivo. Based on this approach, the model predicted that the 
amount of quercetin metabolites excreted to bile after 24 h corresponds to 35% of the dose at 
a dose of 10 mg/kg bw quercetin, which is the same as the reported level in rats of 35% of the 
dose at the same dose level [30]. The predicted urinary excretion of quercetin metabolites 
after 24 h, corresponding to 3% of the dose at a dose of 49 mg/kg bw quercetin-4′-O-
glucoside, is only 4-fold lower than the level reported in rats exposed to an equivalent dose 
quercetin-3-O-glucoside which amounted to 12% of the dose [46]. The predicted intestinal 
efflux of quercetin metabolites after 24 h, amounting to 63% of the dose at a dose of 0.9 
mg/kg bw quercetin, is only 1.2-fold higher than the level of 52% of the dose reported for rats 
exposed to the same dose [37]. Altogether, the model adequately predicted biliary and urinary 
excretion as well as intestinal efflux of quercetin metabolites, indicating that the highest level 
of excretion occurs via intestinal efflux transporters. 
   Due to the fast level of formation of monoglucuronides, these metabolites can be 
subjected to further metabolism resulting in the formation of di- and tri-conjugates of 
quercetin. The kinetic parameters for all possible di- and tri-conjugates were obtained by 
fitting these parameters to match in vivo reported plasma concentrations of the different 
mono-, di-, and tri-conjugates. The results revealed that especially further glucuronidation of 
quercetin monoglucuronides occurs with a lower catalytic efficiency than glucuronidation of 
the quercetin itself. This is likely due to an increase in the molecular size of the substrates 
which could affect their binding to the conjugating enzymes as reported by Takenaga et al. 
who stated that for indolocarbazole analogs a molecular size smaller than 14.5 Å might be 
required for a compound to be a substrate for O-glucuronidation [47]. Manevski et al. also 
reported an effect of the size of substrate on the binding to UGT1A6 with the relatively 
bulkier size chain of psilocin preventing its binding to the active site of UGT1A6, whereas the 
somewhat smaller size chain of serotonin allows binding [48]. In addition to further 
glucuronidation, also methylation of quercetin diglucuronides was also predicted to occur 
with a much lower catalytic efficiency than methylation of quercetin, which may be related to 
the bulkiness of the diglucuronide. Other conversions were estimated to differ only slightly 
compared with the kinetic constants for the formation of mono-conjugates. 
Both exposure to quercetin as aglycone and to its 4′-O-glucoside was predicted to 
result in circulating metabolites of quercetin that are di- and tri-conjugates of 
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monoglucuronides, especially QdiG and QGSM (Figure 2.6). Already at 0.5 h upon dosing 
with 0.4 mg/kg bw quercetin, their AUC in plasma makes up 64% of the total quercetin and 
its metabolites in plasma. This prediction is in agreement with data reported in rats [21-23] as 
well as in humans [24, 25]. In rats, various di- and tri-conjugates of quercetin were detected at 
0.5 h upon dosing with 7.6 mg/kg bw [2-14C]quercetin-4′-O-glucuronide, in which QdiG was 
the major circulating metabolites at 0.5 h as time passed QGSM became the major 
metabolites at 1 h [21]. The same results are also observed in humans, also various di- and tri-
conjugates of quercetin were detected in plasma at 0.5 h upon dosing with onion [24, 25]. The 
biological activity of quercetin or flavonoids in vivo could be due to these circulating 
metabolites as conjugation of flavonoid does not always result in a reduced biological activity 
of flavonoids [8]. In addition, it is increasingly postulated that deconjugation of the 
conjugates may be responsible for the biological activity by releasing the active aglycone in a 
tissue [49, 50]. However, so far no in vitro experiments have been performed to identify 
whether deconjugating enzymes can actually deconjugate di- and tri-conjugates. The results 
obtained with the PBK model allow to identify which metabolites will be relevant to study for 
their biological activity or to use in incubation to determine deconjugation, which are 
predominantly QdiG and QGSM metabolites. 
Overall, the newly developed PBK model adequately predicted plasma concentrations 
of quercetin and its metabolites including mono-, di-, and tri-conjugates and provides an 
indication of the nature of the circulating metabolites of quercetin in plasma of rat. As we still 
lack in vivo kinetic data for many flavonoids, the developed model has a great potential to be 
used as a platform to build PBK models for other flavonoids as well as to predict the kinetics 
of flavonoids in humans. 
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CHAPTER 3 
 
Use of physiologically based kinetic (PBK) modeling to 
study interindividual human variation and species differences 
in plasma concentrations of quercetin and its metabolites 
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Abstract  
Biological activities of flavonoids in vivo ultimately depend on the systemic 
bioavailability of the aglycones and their metabolites. We aimed to develop physiologically 
based kinetic (PBK) models to predict plasma concentrations of the flavonoid quercetin and 
its metabolites in individual human subjects and to define species differences compared with 
male rat. The human models were developed based on in vitro metabolic parameters derived 
from incubations with pooled and 20 individual human tissue fractions and by fitting kinetic 
parameters to available in vivo data. The outcomes obtained were compared to a previously 
developed model for quercetin and its metabolites formation in male rat. Quercetin-3´-O-
glucuronide was predicted to be the major circulating metabolite in 19 out of 20 individuals, 
while in male rat di- and tri-conjugates of quercetin containing a glucuronic acid, sulfate 
and/or methyl moiety are the major metabolites. Significant species differences occur in 
major circulating metabolites of quercetin suggesting that rat is not an adequate model to 
study effects of quercetin in man. The defined PBK models can be used to guide the 
experimental design of in vitro experiments with flavonoids, especially to better take into 
account the relevance of metabolism and the contribution of metabolites to the biological 
activity in humans.  
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3.1 Introduction  
Flavonoids are polyphenolic compounds widely distributed in fruits and vegetables. 
These compounds have received a lot of attention for their possible beneficial health effects 
against various degenerative disorders such as cancer [1], cardiovascular diseases [2, 3], and 
obesity and diabetes [4]. A vast amount of in vitro studies have been conducted to elucidate 
modes of actions underlying these health effects. However, where most of these in vitro 
studies are performed with the aglycone, this form is hardly available in vivo due to extensive 
metabolism of the flavonoid aglycone in the intestine and liver. As a result, mainly flavonoid 
conjugates occur in the systemic circulation. Little is known about the nature and 
physiologically relevant concentrations of these circulating conjugates, nor about species 
differences and interindividual human variation herein. However, interpretation as well as 
design of both in vitro and in vivo animal and human experiments would benefit from insight 
in the nature and physiologically relevant concentrations of circulating conjugates. The aim of 
the present study was to use physiologically based kinetic (PBK) modeling to predict the 
nature and regiospecificity of the major circulating metabolites using quercetin as a model 
compound.  
Quercetin is one of the most prevalent flavonoids in the human diet (e.g. onions) and 
also one of the most widely studied flavonoids [5]. Upon absorption, quercetin aglycone can 
be directly taken up in the small intestine by passive diffusion, but its glucoside needs to be 
deglycosylated to the aglycone by brush-border lactase phlorizin hydrolase or by intestinal 
microflora prior to absorption [6, 7]. In the small intestine and liver, quercetin is metabolized 
via glucuronidation, sulfation and methylation (Figure 3.1). Numerous mono-, di- and tri-
conjugates of quercetin containing glucuronic acid, sulfate and/or methyl moieties have been 
detected in plasma of rat as well as in human [8-10]. Various metabolites have been reported 
as major circulating metabolites of quercetin in humans. Mullen et al. reported quercetin-3´-
O-sulfate and quercetin-3-O-glucuronide to be among the major circulating metabolites 0.5 h 
after consumption of 270 g fried onions [10]. Lee et al. found that quercetin 
monoglucuronides are major circulating metabolites 0.5 h after consumption of 47.5 g onion 
powder [9]. Another study by Day et al. reported that the major circulating metabolites of 
quercetin in plasma 1.5 h after consumption of 200 g fried onions, are quercetin-3-O-
glucuronide, 3´-O-methylquercetin-3-O-glucuronide, and quercetin-3´-O-sulfate [11]. In 
comparison, in rats the major circulating metabolite detected 1 h after dosing of 7.6 mg/kg bw 
quercetin-4´-O-glucoside (Q4´Gly) was a tri-conjugate containing glucuronic acid, sulfate and 
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methyl moieties [8]. Based on our previous PBK model studies, this tri-conjugate in rat was 
tentatively identified as 7-O-glucuronide,-3´-O-sulfate,-4´-O-methylquercetin [12].  
 
Figure 3.1 Conversion of quercetin to different possible mono-conjugates [12]. 
 
To obtain better insights in the nature and concentration of circulating metabolites of 
quercetin and interindividual human variation, PBK models for quercetin in (individual) 
humans were defined based on kinetic parameters for the formation of different metabolites 
obtained from in vitro incubations with relevant individual and pooled human tissue fractions 
and by fitting kinetic parameters to the available in vivo data [9-11]. A subsequent 
comparison was made with the previous defined PBK model for quercetin in male rats [12] to 
elucidate possible species differences in the major circulating metabolites.  
 
3.2 Material and methods 
3.2.1 Materials 
Pooled, mixed-gender human small intestine and liver S9 fractions, individual human 
liver S9 fractions from 20 different individual, and pooled human liver cytosol were 
purchased from Xenotech (Lenexa, USA). Quercetin, L-ascorbic acid, uridine 5′-
diphosphoglucuronic acid (purity 98%), S-(5′-adenosyl)-L-methionine (purity 80%), 3′-
phosphoadenosine-5′-phosphosulfate (purity 65%,), tris (hydroxymethyl)aminomethane, 
alamethicin (from Trichoderma viride), and β-glucuronidase/sulfatase (from Helix pomatia) 
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were purchased from Sigma-Aldrich (Steinheim, Germany). Potassium dihydrogen 
phosphate, dipotassium hydrogen phosphate trihydrate, acetic acid (glacial), hydrochloric acid 
(fuming 37%), ammonium acetate, magnesium chloride, sodium acetate trihydrate, and 
trifluoroacetic acid (for spectroscopy) were purchased from VWR International (Darmstadt, 
Germany). Dimethyl sulfoxide (DMSO) was purchased from Acros Organic (New Jersey, 
USA). Acetonitrile (ULC/MS) and methanol (ULC/MS) were purchased from Biosolve 
(Valkenswaard, The Netherlands). Quercetin-3-O-glucuronide, isorhamnetin (3′-O-
methylquercetin), and tamarixetin (4′-O-methylquercetin) were purchased from Extrasynthese 
(Genay Cedex, France).  
 
3.2.2 Glucuronidation of quercetin by pooled and individual human tissue fractions 
To obtain kinetic parameters for glucuronidation of quercetin, incubation mixtures 
(final volume of 100 µl) were prepared containing (final concentrations) 0.1 M Tris-HCl (pH 
7.4), 10 mM MgCl2, 1 mM ascorbic acid, 0.04 mg/ml pooled human small intestine or 0.03 
mg/ml pooled liver S9 fractions, and 4 mM uridine 5′-diphosphoglucuronic acid as cofactor. 
The incubation mixtures were pre-treated on ice with 0.025 mg/ml alamethicin added from a 
200 times concentrated stock solution in methanol for 15 min to obtain optimal 
glucuronidation activity [13]. The reactions were initiated by adding quercetin (final 
concentrations ranging from 0.15 µM to 20 µM) added from 200 times concentrated stock 
solutions in DMSO after preincubating at 37ºC for 1 min. The reactions were terminated by 
adding 25 µl ice-cold acetonitrile:acetic acid (94:6) (v/v) after 6 min or 7 min for incubations 
with small intestine S9 or liver S9. To evaluate interindividual human variation in 
glucuronidation, incubations with individual human liver S9 fractions were performed as 
described for pooled liver S9. These reactions were carried out for 5 to 20 min at 37ºC and at 
an S9 protein content ranging from 0.01 to 0.03 mg/ml, depending on the human subject. 
Under the specified conditions, the formation of quercetin monoglucuronides was linear in 
time and with protein concentration (data not shown). The nature of the glucuronide 
metabolites was confirmed by treating samples with β-glucuronidase (β-
glucuronidase/sulfatase). For these reactions, 50 µl of the non-terminated mixtures were 
added to 50 µl of 0.1 M sodium acetate (pH 5.0) containing 1 mM ascorbic acid and 0.8 
units/ml β-glucuronidase. These incubations were carried for 1 h at 37ºC and terminated by 
addition of 25 µl ice-cold acetonitrile:acetic acid (94:6) (v/v).  
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3.2.3 Sulfation of quercetin by pooled and individual human tissue fractions 
To obtain kinetic parameters for sulfation of quercetin, incubation mixtures (final 
volume of 100 µl) were prepared containing (final concentrations) 0.1 M potassium phosphate 
(pH 7.4), 1 mM ascorbic acid, 0.2 mg/ml pooled human small intestine or 1 mg/ml pooled 
liver S9 fractions, and 0.1 mM 3′-phosphoadenosine-5′-phosphosulfate as cofactor. Samples 
were preincubated at 37ºC for 1 min prior to the addition of quercetin (final concentration 
ranging from 0.15 µM to 4 µM) added from 200 times concentrated stock solutions in DMSO 
to initiate the reactions. The reactions were terminated after 12 min by the addition of 25 µl 
ice-cold acetonitrile:acetic acid (94:6) (v/v). To evaluate interindividual human variation in 
sulfation, incubations with individual human liver S9 fractions were performed as described 
for pooled liver S9. These reactions were carried out at an S9 protein content ranging from 0.2 
to 0.8 mg/ml for 6 to 40 min, depending on the human subject. Under the specified 
conditions, the formation of quercetin sulfate conjugates was linear in time and with protein 
concentration (data not shown). Formation of the quercetin sulfate conjugates was confirmed 
by adding 50 µl of a non-terminated mixture to 50 µl of 0.2 M potassium phosphate (pH 6.2) 
containing 1 mM ascorbic acid and 100 units/ml sulfatase (β-glucuronidase/sulfatase). These 
samples were incubated for 1 h at 37ºC and the reactions were terminated by addition of 25 µl 
ice-cold acetonitrile:acetic acid (94:6) (v/v). To determine whether the microsomal protein in 
S9, which can serve as a potential source of sulfatase enzymes could influence the rate of 
formation of the different sulfate conjugates, incubations were performed with cytosol [14, 
15]. These reactions revealed proportionally the same kinetic constants as with S9 indicating 
no influence of microsomes on the reaction (data not shown). 
 
3.2.4 Methylation of quercetin by pooled and individual human tissue fractions 
To obtain kinetic parameters for methylation of quercetin, incubation mixtures (final 
volume 100 µl) were prepared containing (final concentrations) 0.1 M potassium phosphate 
(pH 7.4), 1 mM ascorbic acid, 1 mg/ml pooled human small intestine or 1 mg/ml pooled liver 
S9 fractions, and 2 mM S-(5′-adenosyl)-L-methionine as cofactor. The reactions were 
initiated by the addition of quercetin (final concentrations ranging from 0.25 µM to 40 µM) 
added from a 200 times concentrated stock solution in DMSO after 1 min preincubation at 
37ºC. Upon incubating for 22 min, 25 µl ice-cold acetonitrile:acetic acid (94:6) (v/v) were 
added to terminate the reactions. To evaluate interindividual human variation in quercetin 
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methylation, incubations with individual human liver S9 fractions were performed as 
described for pooled liver S9. These reactions were carried out at an S9 protein content 
ranging from 0.3 to 1 mg/ml for 15 to 122 min at 37ºC, depending on the human subject. 
Under the specified conditions, methylation of quercetin was linear in time and with protein 
concentration (data not shown).  
 
3.2.5 UPLC analysis 
Kinetic constants were obtained from triplicate incubations for pooled tissue fractions 
and duplicate incubations for individual human liver fractions. Blank incubations were carried 
out without the cofactor. The amount of glucuronide, sulfate and methyl conjugates formed, 
was analyzed on a UPLC-DAD system consisting of a Waters (Milford, MA) Acquity binary 
solvent manager, sample manager, and photodiode array detector, equipped with a Waters 
Acquity UPLC BEH RP 18 column (1.7 μm, 2.1 x 50 mm). Before analysis, all samples were 
centrifuged at 18,600 x g for 5 min at 5ºC to precipitate proteins and 10 µl of the supernatant 
was immediately analyzed. For glucuronide conjugates, a gradient of 2.5 mM ammonium 
acetate in nanopure water (eluent A) and acetonitrile (eluent B), was used with a flow rate of 
0.6 ml/min with the following profile: 10-25% B (0-1.8 min); 25-90% B (1.8-2.5 min); 90% B 
(2.5-3.8 min); 90-10% B (3.8-4 min) and 10% B (4-5 min). For sulfate and methyl 
conjugates, a gradient of nanopure water containing 0.1% (v/v) trifluoroacetic acid (eluent A) 
and acetonitrile (eluent B) was used with a flow rate of 0.6 ml/min with the following profile: 
20-25% B (0-1.8 min); 25-35% B (1.8-2.3 min); 35% B (2.3-2.8 min); 35-100% B (2.8-3 
min); 100% B (3-4.1 min); 100-0% B (4.1-4.3 min); 0% B (4.3-5.5 min); 0-20% B (5.5-5.6 
min) and 20% B (5.6-5.8 min).  
The metabolites obtained from glucuronidation and sulfation were identified by 
comparing the UV-spectra and the elution order of each metabolite with those reported in the 
studies of Boersma et al. [16] and van der Woude et al. [17] as described previously for 
incubations with rat tissue fractions [12]. The metabolites obtained from incubations 
measuring methylation were identified by comparing the UV-spectra and the retention time 
with commercially available standards of 3´-O-methylquercetin and 4´-O-methylquercetin. 
All quercetin metabolites were quantified by integrating the peak areas at 370 nm and by 
using the calibration curves of quercetin-3-O-glucuronide (for glucuronide conjugates), 
quercetin (for sulfate conjugates), and 3′-O-methylquercetin and 4´-O-methylquercetin (for 
methyl conjugates). 
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3.2.6 LC-MS analysis 
 The nature of the formed metabolites from glucuronidation, sulfation and methylation 
of quercetin was identified using LC-MS on a Perkin Elmer 200 series HPLC system (Perkin 
Elmer, Waltham, MA) coupled to an API 3000 system (Applied Biosystem, Foster city, CA). 
Aliquots of 10 µl were injected on an Agilent Zorbax Extend-C18 column, 2.1 x 50 mm, 3.5 
Micron 80 Å with a Zorbax guard column (Basel, Switzerland). The same gradient 
compositions as described in Section 3.2.5 were used, except that eluent A was nanopure 
water containing 0.1% (v/v) acetic acid and a flow rate of 0.2 ml/min was used with the 
following profile: 20% B (0-1 min), 20-35% B (1-4 min), 35% B (4-6 min), 35-80% B (6-10 
min), 80% B (10-15 min), 80-20% B (15-16 min), and 20% B (16-20 min). The mass 
spectrometric analysis was performed in the negative ion mode using a spray voltage of 4.5 
kV and a capillary temperature of 180ºC. The nebulizer gas (air), curtain (nitrogen), 
declustering potential, focusing potential, and entrance potential were set to 10, 8, -51, -200, 
and -13.7, respectively. Analysis was carried out using product ion (MS2) scanning from m/z 
200-600. 
 
3.2.7 Kinetic analysis 
Kinetic parameters (i.e. apparent maximum velocity (Vmax(app)) and apparent 
Michaelis-Menten constant (Km(app))) for glucuronidation, sulfation, and methylation of 
quercetin were determined by fitting the data to the standard Michaelis-Menten equation:  
v = Vmax x [S]/(Km+[S])        (1) 
where [S] represents the substrate concentration. The data were fitted to the Michaelis-
Menten equation with GraphPad Prism, version 5.04 (GraphPad Software, San Diego, 
California, USA).  
 
3.2.8 Definition of the PBK model for (individual) human subjects 
The PBK models that describe the absorption, distribution, metabolism and excretion 
(ADME) of quercetin in (individual) humans were defined in a similar manner as used for 
developing the previously defined PBK model for quercetin in male rats [12]. The structure of 
the models is displayed in Figure 3.2. The kinetic data describing metabolic conversion of 
quercetin to its primary metabolites were obtained in the present study based on the in vitro 
experiments (see section 3.3.1-3.3.3). Even though quercetin is one of the most studied 
flavonoids, there are only few studies identifying and quantifying the plasma profiles of 
quercetin in humans [9-11]. Therefore, we only used these studies for the development of the 
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models. The parameters describing excretion via urine, bile and intestinal enterocyte efflux 
back to lumen were fitted to the available experimental human data [9-11]. These data are 
primary available for onion intake, containing mainly Q4´Gly and quercetin-3,4´-O-
diglucoside (Q34´diGly) [9, 10] and are hydrolyzed to the aglycone by luminal lactase 
phlorizin hydrolase [18, 19]. Thus disappearance of the glucosides to the aglycone in the 
intestinal lumen was included and fitted to the experimental data, assuming each glucoside 
has its own deglycosylation rate with values ranging from 0.51 – 1 l/h and 0.01 – 0.1 l/h for 
Q4´Gly and Q34´diGly, respectively. The uptake rate constant of quercetin aglycone to the 
small intestine in humans was assumed to be similar to rats with a value of 5.32 h-1 [20]. For 
the PBK model describing the ADME in an average human, the kinetic constants obtained 
from incubations with pooled human tissue fractions were used. Whereas for the PBK models 
in individual human subjects, the kinetic constants obtained with the individual human liver 
fractions were used. No interindividual human variation in metabolism by the small intestine 
was taken into account in the individual human models as the plasma concentrations of 
quercetin metabolites is mainly influenced by the kinetic constants for formation of primary 
metabolites in liver (see section 3.3.4). 
 
Figure 3.2 Schematic diagram of the PBK models for prediction of the formation of mono-conjugates 
(A), di-conjugates (B), and tri-conjugates (C).  
 
For description of further conjugation of the primary metabolites to di- and tri-
conjugates, only further conjugation of different monoglucuronides was simulated since the 
glucuronide metabolites were estimated to account for ~96% of the dose (see section 3.3.4). 
Lower catalytic efficiencies for further glucuronidation, sulfation, and methylation of the 
monoglucuronides to di- and tri-conjugates were assumed in comparison to the catalytic 
efficiencies for formation of the respective mono-conjugates, due to both an increase in Km 
and a decrease in Vmax [12]. The correction factors for further conjugation were obtained by 
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fitting the predicted plasma AUC or concentrations to the available experimental data  [9-11]. 
Taking the regiospecificity of possible conjugations into account, a total of 34 different 
mono-, di- and tri-conjugates could in theory be expected and were thus included in the 
model.  
 
Table 3.1 Physiological parameters used in the PBK model for quercetin in human and male rat [21] 
Parameters  Symbol Human Male rat 
Body weight (kg)  BW 70 0.25 
Tissue volumes (% body weight)     
     lumen VLu 1.4 5 
     small intestine VI 0.9 1.4 
     liver VL 2.6 3.4 
     kidney  VK 0.4 0.7 
     rapidly perfused tissues VR 4 3.2 
     slowly perfused tissues  VS 75.7 74.6 
   blood VB 7.9 7.4 
Cardiac output (l/h)  QC 310.4 5.4 
Blood flow to tissue (% cardiac output)      
     small intestine QI 18.1 15.1 
     liver (exclude portal vein) QL 4.6 9.9 
     kidney  QK 17.5 14.1 
     rapidly perfused tissues QR 29.8 36.9 
     slowly perfused tissues  QS 30 24 
 
The physiological parameters were obtained from the literature [21] and the 
tissue:blood partition coefficients were calculated based on the methods described by 
DeJongh et al. [22]. The physiological parameters and the tissue:blood partition coefficients, 
thus obtained and used in the models are summarised in Table 3.1 and 3.2. Mass balance 
equations were numerically integrated in Berkeley Madonna 8.3.18 (Macey and Oster, UC 
Berkeley, CA) using the Rosenbrock’s algorithm for stiff system. Mass balance equations for 
quercetin and its metabolites in tissues and blood were similar to those previously described 
in the PBK model for quercetin in male rats [12]. Model performance was assessed by 
comparing the predicted excretions via urine, bile and intestinal enterocyte efflux back to 
lumen against available in vivo data [10, 23, 24]. With the obtained model, the systemic 
bioavailability of quercetin aglycone and the nature and regiospecificity of the major 
circulating quercetin metabolites in plasma were predicted. Conversion of the blood 
concentrations of the different metabolites to plasma concentrations was done by dividing the 
blood concentrations by a blood/plasma ratio (R). For quercetin and its metabolites a R value 
of 0.66 was applied and calculated using Simcyp prediction tools [25, 26]. The systemic 
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bioavailability of quercetin aglycone and the sensitivity analysis for the plasma AUC0-24h  of 
quercetin metabolites were determined follow the methods previously described by 
Boonpawa et al. [12].   
 
Table 3.2 Physico-chemical parameters of quercetin and its metabolites in humans 
Compound LogP1 pKa2 fu3 R4 Tissue:blood partition coefficients5 
     Small 
intestine 
Liver Kidney 
Rapidly 
perfused 
tissue 
Slowly 
perfused 
tissue 
quercetin 1.99 6.31 0.071 0.69 2.46 2.46 1.42 1.83 1.81 
quercetin-7-O-glucuronide -0.47 2.73 0.362 0.61 0.62 0.62 0.79 0.72 0.76 
quercetin-3-O-glucuronide 0.62 2.76 0.186 0.64 0.77 0.77 0.88 0.91 0.85 
quercetin_3'-O-glucuronide 0.00 2.78 0.619 0.62 0.65 0.65 0.81 0.78 0.78 
quercetin-4'-O-glucuronide -0.12 2.78 0.615 0.62 0.64 0.64 0.80 0.76 0.77 
quercetin-7-O-sulfate 1.20 -4.92 0.123 0.66 1.11 1.11 1.01 1.16 1.04 
quercetin-3'-O-sulfate 1.18 -4.37 0.125 0.66 1.09 1.09 1.00 1.14 1.03 
3'-O-methylquercetin 2.79 6.31 0.038 0.72 5.27 5.27 2.39 3.30 3.41 
4'-O-methylquercetin 2.67 6.31 0.041 0.72 4.82 4.82 2.20 3.02 3.15 
quercetin diglucuronides -2.74 
 
  0.59 0.59 0.76 0.65 0.75 
quercetin glucuronide sulfate 
conjugates -2.20  
  0.59 0.59 0.76 0.65 0.75 
quercetin glucuronide methyl 
conjugates 
-0.16 
 
  0.64 0.64 0.80 0.76 0.77 
quercetin diglucuronide 
methyl conjugates 
-2.29 
 
  0.59 0.59 0.76 0.65 0.75 
quercetin glucuronide sulfate 
methyl conjugates -1.81  
  0.59 0.59 0.76 0.66 0.75 
1 LogP values for quercetin and its mono-conjugates were obtained from Scifinder (American Chemical Society, USA), while 
CLogP values for di- and tri-conjugates were calculated using ChemBio3D Ultra 2010 (Cambridgesoft, USA). 
2 pKa values were obtained from Scifinder (American Chemical Society, USA). 
3 Fraction unbound (fu) was calculated using Simcyp prediction tools – fu [25]. 
4 Blood/plasma ratio (R) was calculated using Simcyp prediction tools - blood to plasma partition ratio [26]. 
5Tissue:blood partition coefficients were calculated based on method described by DeJongh et al. [22]. 
 
3.3 Results 
3.3.1 Glucuronidation of quercetin by pooled and individual human tissue samples 
Analysis of the incubations with pooled human liver and intestine S9 revealed that 
both fractions were able to metabolize quercetin towards different types of glucuronide 
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conjugates. In incubations with human small intestine S9, quercetin-7-O-glucuronide, 
quercetin-3-O-glucuronide, quercetin-3´-O-glucuronide, and quercetin-4´-O-glucuronide were 
formed. The same metabolites, except for quercetin-4´-O-glucuronide, were formed in 
incubations with human liver S9. The LC-MS results confirmed that the formed metabolites 
were quercetin monoglucuronide as all formed metabolites had an M- at m/z 477, which 
fragmented to produce m/z 301 (quercetin). The quercetin concentration dependent rate of 
formation of the monoglucuronides in these incubations with pooled liver or small intestine 
S9 is shown in Figure 3.3A and 3.3B. For both tissues, quercetin-3´-O-glucuronide was 
formed with the highest catalytic efficiency, which was 5- to 18-fold higher than the catalytic 
efficiency for formation of the other glucuronide conjugates in these tissues (Table 3.3). 
 
Figure 3.3 Quercetin concentration-dependent formation of mono-conjugates by pooled mixed-gender 
human liver S9 (A, C, and E) or small intestine S9 (B and D); quercetin (Q), glucuronide (G), sulfate 
(S) and methyl conjugate (M). 
 
Analysis of interindividual human variation in formation of monoglucuronides 
revealed 39-fold variation in the catalytic efficiencies for formation of these metabolites 
between the 20 individual human liver S9 samples that were analyzed (Table 3.4). Quercetin-
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7-O-glucuronide and quercetin-3´-O-glucuronide were formed with the highest catalytic 
efficiency by individual H0420 (male, Caucasian, 42 years) and quercetin-3-O-glucuronide by 
individual H0270 (male, Caucasian, 5 months). All three conjugates were formed with the 
lowest catalytic efficiency by individual H0291 (female, Caucasian, 18 years). The latter 
differences were due to both a ± 3-fold lower Vmax and a ± 20-fold higher Km for 
glucuronidation by individual H0291. The incubations with individual human liver S9 
fractions also revealed that quercetin-3´-O-glucuronide is the predominant glucuronide 
formed by 18 out of 20 individual human liver S9. 
 
Table 3.3 Kinetic constants for mono-conjugates of quercetin with pooled mixed-gender human 
tissues S9 fractions 
Metabolite Organ 
Km(app) 
(µM) 
Vmax(app) 
(nmol/min/mg S9) 
In vitro catalytic 
efficiency 
(min /mg S9)1 
quercetin-7-O-glucuronide small intestine 0.84 ± 0.23 0.14 ± 0.01 0.17 
quercetin-3-O-glucuronide small intestine 0.56 ± 0.15 0.34 ± 0.02 0.61 
quercetin-3'-O-glucuronide small intestine 0.20 ± 0.05 0.61 ± 0.03 3.05 
quercetin-4'-O-glucuronide small intestine 0.46 ± 0.12 0.37 ± 0.02 0.80 
quercetin-7-O-sulfate small intestine 0.41 ± 0.14 0.02 ± 0.001 0.05 
quercetin-3'-O-sulfate small intestine 1.17 ± 0.35 0.11 ± 0.01 0.09 
quercetin-7-O-glucuronide liver 1.37 ± 0.04 0.66 ± 0.04 0.48 
quercetin-3-O-glucuronide liver 0.87 ± 0.14 0.39 ± 0.02 0.45 
quercetin-3'-O-glucuronide liver 0.21 ± 0.08 0.40 ± 0.02 2.67 
quercetin-4'-O-glucuronide liver nd nd nd 
quercetin-7-O-sulfate liver nd nd nd 
quercetin-3'-O-sulfate liver 0.35±0.07 0.01±0.0004 0.03 
3'-O-methylquercetin liver 0.93 ± 0.21 0.02 ± 0.001 0.02 
4'-O-methylquercetin liver 1.14 ± 0.27 0.01 ± 0.0004 0.01 
1 Vmax(app)/ Km(app) 
 
3.3.2 Sulfation of quercetin by pooled and individual human tissue samples 
Analysis of the incubations with pooled human liver and intestine S9 revealed that 
both fractions were able to metabolize quercetin to sulfate conjugates. Quercetin-3´-O-sulfate 
was the predominant sulfate metabolite formed in incubations with human intestine S9 and 
quercetin-7-O-sulfate was a minor metabolite. In incubations with human liver S9 only 
quercetin-3´-O-sulfate was formed. The LC-MS results confirmed that the formed metabolites 
were quercetin sulfate as all formed metabolites had an M- at m/z 381, which fragmented to 
produce m/z 301 (quercetin). The quercetin concentration dependent rate of formation of the 
sulfate conjugates in these incubations with pooled human liver or small intestine S9 is shown 
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in Figure 3.3C and 3.3D and the kinetic constants derived from these curves are displayed in 
Table 3.3.  
 In incubations with individual human liver S9 also only quercetin-3´-O-sulfate was 
formed, showing an 833-fold variation in formation of this metabolite between the different 
human samples (Table 3.5). The highest catalytic efficiency was observed for individual 
H0251 (female, Caucasian, 42 years), and the lowest for individual H0420 (male, Caucasian, 
42 years). The differences between these individuals were due to 13- and 76-fold variation in 
the Vmax and the Km for sulfation respectively (Table 3.5).  
 
Table 3.5 Kinetic constants for formation of quercetin monosulfates obtained from in vitro 
incubations with 20 individual human liver S9 fractions 
Individual 
liver S9 
 
Description (sex, age, race) 
 
Quercetin-3'-O-sulfate 
Km(app) (µM) 
Vmax(app) (nmol 
min/mg S9) 
In vitro catalytic 
efficiency1 
H0120 female, 57, Caucasian 0.13 ± 0.06 0.010 ± 0.001 0.08 
H0164 male, 30, Caucasian 0.11 ± 0.04 0.011 ± 0.001 0.10 
H0177 female, 45, Caucasian 0.13 ± 0.06 0.003 ± 0.0003 0.02 
H0205 female, 48, Caucasian 0.22 ± 0.03 0.010 ± 0.0003 0.05 
H0208 female, 78, Caucasian 0.02 ± 0.02 0.015 ± 0.001 0.75 
H0217  female, 66, Caucasian 0.11 ± 0.03 0.008 ± 0.0003 0.07 
H0220 female, 33, Caucasian 0.04 ± 0.01 0.013 ± 0.0004 0.33 
H0236 male, 17, Asian 0.02 ± 0.01 0.005 ± 0.0001 0.25 
H0238 male, 3 m, African American 0.15 ± 0.07 0.010 ± 0.001 0.07 
H0251 female, 42, Caucasian 0.01 ± 0.02 0.025 ± 0.002 2.50 
H0270 male, 5 m, Caucasian 0.04 ± 0.03 0.019 ± 0.002 0.48 
H0291 female, 18, Caucasian 0.57 ± 0.24 0.009 ± 0.001 0.02 
H0311 male, 21, Hispanic 0.09 ± 0.03 0.016 ± 0.001 0.18 
H0420 male, 42, Caucasian 0.76 ± 0.16 0.002 ± 0.0002 0.003 
H0422 male, 69, Caucasian 0.06 ± 0.01 0.010 ± 0.0002 0.17 
H0428 female, 57, Caucasian 0.02 ± 0.02 0.021 ± 0.001 1.19 
H0432 male, 60, African American 0.12 ± 0.06 0.007 ± 0.001 0.06 
H0438 male, 56, Caucasian 0.06 ± 0.04 0.012 ± 0.001 0.20 
H0441 male, 63, Caucasian 0.09 ± 0.05 0.005 ± 0.0005 0.06 
H0442 male, 49, Caucasian 0.03 ± 0.01 0.014 ± 0.001 0.47 
1 Vmax(app)/ Km(app), ml/min/mg S9. 
 
3.3.3 Methylation of quercetin by pooled and individual human tissue samples 
Analysis of the incubations with pooled human liver and intestine S9 revealed that 
only liver S9 was able to metabolize quercetin to methyl conjugates. In incubations with liver 
S9, both 3´-O-methylquercetin and 4´-O-methylquercetin were formed. The LC-MS results 
confirmed that the formed metabolites were quercetin methyl conjugates as all formed 
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metabolites had an M- at m/z 315, which fragmented to produce m/z 301 (quercetin). Figure 
3.3E shows the quercetin concentration dependent rate of formation of methyl conjugates of 
quercetin in incubations with human liver S9 fractions and the kinetic constants derived from 
these curves are displayed in Table 3.3. The highest catalytic efficiency was observed in 
individual H0420 (male, Caucasian, 42 years) and the lowest in individual H0238 (male, 
African American, 3 months) (Table 3.6). These differences were mainly due to a ±80-fold 
higher Km for methylation by individual H0238. 
 
Table 3.6 Kinetic constants for formation of quercetin methyl conjugates obtained from in vitro 
incubations with 20 individual human liver S9 fractions 
Individual 
liver S9 
  
Description 
(sex, age, 
race) 
  
3'-O-methylquercetin 
 
4'-O-methylquercetin 
Km(app) (µM) 
Vmax(app) (nmol 
min/mg S9) 
In vitro 
CE1 
Km(app) 
(µM) 
Vmax(app) (nmol 
min/mg S9) 
In vitro 
CE1 
H0120 female, 57, Caucasian 0.65 ± 0.29 0.003 ± 0.0003 0.005 0.34 ± 0.29 0.001 ± 0.0002 0.003 
H0164 male, 30, Caucasian 0.15 ± 0.13 0.001 ± 0.0001 0.01 4.46 ± 1.64 0.001 ± 0.0001 0.0002 
H0177 female, 45, Caucasian 0.86 ± 0.19 0.010 ± 0.0005 0.01 1.07 ± 0.52 0.003 ± 0.0004 0.003 
H0205 female, 48, Caucasian 0.40 ± 0.18 0.002 ± 0.0002 0.01 1.27 ± 0.85 0.001 ± 0.0002 0.001 
H0208 female, 78, Caucasian 0.50 ± 0.30 0.002 ± 0.0003 0.004 2.63 ± 2.62 0.003 ± 0.001 0.001 
H0217  female, 66, Caucasian 0.22 ± 0.23 0.005 ± 0.001 0.02 0.53 ± 0.24 0.003 ± 0.0002 0.01 
H0220 female, 33, Caucasian 0.15 ± 0.12 0.002 ± 0.0002 0.01 9.01 ± 6.50 0.002 ± 0.001 0.0002 
H0236 male, 17, Asian 0.47 ± 0.30 0.003 ± 0.0004 0.01 2.61 ± 2.37 0.002 ± 0.001 0.001 
H0238 
male, 3 m, 
African 
American 
60.5 ± 61.5 0.010 ± 0.01 0.0002 37.1 ± 27.7 0.003 ± 0.001 0.0001 
H0251 female, 42, Caucasian 0.57 ± 0.52 0.010 ± 0.002 0.02 0.78 ± 0.38 0.006 ±0.001 0.01 
H0270 male, 5 m, Caucasian 0.14 ± 0.13 0.001 ± 0.0001 0.01 0.90 ± 0.60 0.0002 ± 0.0001 0.0002 
H0291 female, 18, Caucasian 0.07 ± 0.08 0.002 ± 0.0002 0.03 2.05 ± 0.56 0.001 ± 0.0001 0.0005 
H0311 male, 21, Hispanic 0.44 ± 0.08 0.010 ± 0.0003 0.02 1.00 ± 0.25 0.004 ± 0.0002 0.004 
H0420 male, 42, Caucasian 0.46 ± 0.18 0.014 ± 0.001 0.03 1.29 ± 0.72 0.008 ± 0.001 0.01 
H0422 male, 69, Caucasian 1.17 ± 0.48 0.020 ± 0.002 0.02 1.92 ± 1.00 0.010 ± 0.001 0.01 
H0428 female, 57, Caucasian 2.44 ± 1.60 0.022 ± 0.004 0.01 4.63 ± 3.21 0.015 ± 0.004 0.003 
H0432 
male, 60, 
African 
American 
1.49 ± 0.64 0.008 ± 0.001 0.01 3.22 ± 0.98 0.005 ± 0.0005 0.002 
H0438 male, 56, Caucasian 0.50 ± 0.19 0.014 ± 0.001 0.03 1.39 ± 0.72 0.008 ± 0.001 0.006 
H0441 male, 63, Caucasian 1.12 ± 0.86 0.007 ± 0.001 0.01 2.36 ± 2.06 0.003 ± 0.001 0.001 
H0442 male, 49, Caucasian 0.56 ± 0.27 0.004 ± 0.0004 0.01 0.81 ± 0.53 0.002 ± 0.0003 0.002 
1 in vitro catalytic efficiency was calculated by Vmax(app)/ Km(app) and expressed in ml/min/mg S9. 
 
Inter- and intraspecies differences in metabolic plasma profiles of quercetin 
 67 
3.3.4 Development of the (individual) human PBK models and evaluation of their 
performance 
The kinetic constants obtained from in vitro incubations with pooled and individual 
human tissue fractions were combined into PBK models to predict the bioavailability of 
quercetin aglycone. The average predicted bioavailability of quercetin aglycone was 0.005% 
of the dose and ranged between 0.001 and 0.04% of the dose for the individual human models 
at an average dietary intake of 0.4 mg/kg bw quercetin. Quercetin was completely 
metabolized within 1.5 h for all individuals and ~96% of the dose was converted to 
monoglucuronides. Among the mono-conjugates, quercetin-3´-O-glucuronide was predicted 
to be formed to the highest extent accounting for 53 to 57% of the dose. 
 
Figure 3.4 Prediction on plasma profiles of quercetin metabolites in (individual) human subjects 
compared to the reported levels in vivo at a dose of 0.64 mg/kg bw Q4′Gly and 0.70 mg/kg bw 
Q34′diGly as detected with positive (A) and negative detection mode (B) [9], at a dose of 0.95 mg/kg 
bw Q4′Gly and 0.96 mg/kg bw Q34′diGly (C) [10], at a dose of 0.56 mg/kg bw Q4′Gly and 0.53 
mg/kg bw Q34′diGly [11] (D); quercetin (Q), glucuronide (G), sulfate (S) and methyl conjugate (M). 
 
Further conjugation of different monoglucuronides to di- and tri-conjugates was 
simulated. Because in vivo also quercetin-3´-O-sulfate has been detected in the plasma, the 
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formation of this metabolite was included in the comparison between the model predictions 
and in vivo data, but given the low overall percentage of its formation (i.e < 3% of the dose),  
this metabolite was not simulated to be subject to further conjugation. In general, the fitted 
models showed comparable plasma levels of metabolites to the levels reported in literatures 
(i.e. within 1- to 4-fold) (Figure 3.4). Only for quercetin-3´-O-sulfate predictions were 4- to 
44-fold lower than the reported values in the three studies [9-11]. For further development of 
the model for prediction of di- and tri-conjugates, parameters obtained with the data from the 
study of Lee et al. [9] with positive detection mode were used since these provided the best 
fit, with a 4-fold deviation between predicted and observed values for quercetin-3´-O-sulfate 
(Figure 3.4A). The fitted parameters obtained are displayed in the Table 3.7. 
Figure 3.5 Prediction on urinary profiles of quercetin metabolites as compared with the reported 
levels in vivo at a dose of 0.46 mg/kg bw Q4′Gly and 0.49 mg/kg bw Q34′diGly (A) [23] and 0.95 
mg/kg bw Q4′Gly and 0.96 mg/kg bw Q34′diGly (B) [10]; quercetin (Q), glucuronide (G), sulfate (S) 
and methyl conjugate (M). 
 
With the adequate predictions of the plasma levels of the different metabolites 
obtained by the (individual) human PBK models, the performance of models was further 
assessed by comparing the predicted excretion of quercetin metabolites via urine, bile and 
intestinal enterocyte efflux back to lumen to the reported levels in vivo [10, 23, 24]. Figure 3.5 
shows that the models adequately predicted urinary profiles with 1- to 4-fold and 1- to 7-fold 
accuracy 4 h and 24 h after consumption of onions corresponding to dose levels of 0.46 
mg/kg bw Q4´Gly and 0.49 mg/kg bw Q34´diGly [23] and 0.95 Q4´Gly and 0.96 mg/kg bw 
Q34´diGly [10]. After 72 h following consumption of 1.4 mg/kg bw 14C-quercetin, 3.5 to 
5.7% of the dose was recovered in the urine which is 1- to 2-fold lower than the model 
prediction of 7.5% of the dose at the same dose [24]. In the same study 52.1 ± 6.4% of the 
dose was recovered as 14CO2 in the expired air. This value can be used to evaluate the biliary 
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excretion and intestinal efflux back to lumen, because 14CO2 is likely a product of 
microorganisms present in the intestinal lumen [27]. The predicted biliary excretion (74% of 
the dose) together with intestinal enterocyte efflux back to lumen (16% of the dose) is 2-fold 
higher than the reported CO2 level in vivo at the same dose.  
The key parameters that influence the predicted plasma AUC0-24h of all quercetin 
metabolites in human at a dose of 0.4 mg/kg bw quercetin were assessed and are shown in 
Figure 3.6. The plasma AUC0-24h of quercetin metabolites are mainly influenced by 
parameters determining concentration in the liver, namely liver volume, biliary excretion rate 
constant and S9 protein content in liver. The blood/plasma ratio is also found to have a great 
influence on the prediction as it determines the concentration of metabolites in plasma. The 
kinetic parameters for formation of mono-conjugates especially in the liver as well as the 
correction factors for the Vmax and the Km for formation of di- and tri-conjugates, have an 
influence on the plasma AUC0-24h of quercetin metabolites. Other parameters including 
partition coefficients and blood flow rates to tissue do not have an effect on the predicted 
plasma AUC0-24h of quercetin metabolites.  
 
3.3.5 Model simulations 
Figure 3.7 shows the predicted regiospecificity of the six metabolites with the highest 
plasma AUC0–24h at a dose of 0.4 mg/kg bw quercetin (average dietary intake) and a dose of 
12 mg/kg bw quercetin (average supplementary intake), including interindividual human 
variation and species differences. At a dose of 0.4 mg/kg bw, quercetin-3´-O-glucuronide was 
predicted to be the major metabolite for 19 out of 20 individual human subjects accounting 
for 19 to 42% of the total plasma AUC0-24h (Figure 3.7A). However, individual H0270 (male, 
Caucasian, 5 months) that expressed a high level of glucuronidation at the 3-OH, was 
predicted to have mainly quercetin-3,3´-O-diglucuronide in the plasma accounting for 43% of 
the total plasma AUC0-24h. At a dose of 12 mg/kg bw quercetin, quercetin-3´-O-glucuronide 
becomes the major metabolite for all individuals (Figure 3.7B) due to saturation of other 
reactions at higher dose levels. 
Comparison of the predicted levels of the major circulating metabolites of quercetin in 
humans to those previously predicted for male rats revealed major species differences in 
circulating metabolites [12]. In male rats a di- and tri-conjugate of quercetin containing a 
glucuronic acid, sulfate and/or methyl moiety were predicted to be the major circulating 
metabolites of quercetin at both average dietary and supplementary intake. The differences 
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between male rats and human in regiospecificity of circulating metabolites were especially a 
result of the catalytic efficiency and regioselectivity, which the primary metabolites are 
formed (Table 3.7).  
 
Table 3.7 Kinetic parameters used in the PBK model for quercetin in human and male rat 
Parameter                      Human 
 
 
                                     Male rat1 
    
Uptake rate of quercetin (h-1) [20] 5.32 5.32 
Biliary excretion (h-1) 27 16 
Urinary excretion (h-1) 15 6.5 
Intestinal enterocyte efflux (l/h)   5 0.17 
Kinetics for mono-conjugates      
 
      
Small intestine Km2 Vmax3 
catalytic 
efficiency4 Km2 Vmax3 
catalytic 
efficiency4 
     quercetin-7-O-glucuronide 0.84 ± 0.23 0.14 ± 0.01 0.11 0.28 ± 0.07 1.89 ± 0.1 4.62 
     quercetin-3-O-glucuronide 0.56 ± 0.15 0.34 ± 0.02 0.42 0.28 ± 0.07 0.47 ± 0.02 1.15 
     quercetin-3´-O-glucuronide 0.20 ± 0.05 0.61 ± 0.03 2.09 1.14 ± 0.24 0.92 ± 0.06 0.55 
     quercetin-4´-O-glucuronide 0.46 ± 0.12 0.37 ± 0.02 0.55 nd5 nd 
      quercetin-7-O-sulfate 0.41 ± 0.14 0.02 ± 0.001 0.03 nd nd 
      quercetin-3´-O-sulfate 1.17 ± 0.35 0.11 ± 0.01 0.44 0.11 ± 0.03 0.01 ± 0.001 0.07 
Liver 
  
 
        quercetin-7-O-glucuronide 1.37 ± 0.04 0.66 ± 0.04 4.13 8.08 ± 2.6 6.11 ± 0.83 6.49 
     quercetin-3-O-glucuronide 0.87 ± 0.14 0.39 ± 0.02 3.85 nd nd 
      quercetin-3´-O-glucuronide 0.21 ± 0.08 0.40 ± 0.02 20 1.13 ± 0.29 1.46 ± 0.09 11 
     quercetin-4´-O-glucuronide nd nd 
 
0.12 ± 0.04 0.66 ± 0.02 47 
     quercetin-7-O-sulfate nd nd 0.25 0.47 ± 0.2 0.04 ± 0.004 0.73 
     quercetin-3´-O-sulfate 0.35±0.07 0.01±0.0004 0.18 0.27 ± 0.07 0.14 ± 0.01 4.45 
     3´-O-methylquercetin 0.75±3.12 0.03±0.002 0.08 24 ± 3.39 0.46 ± 0.02 0.16 
     4´-O-methylquercetin 0.75±3.12 0.02±0.001 0.11 24 ± 3.39 0.23 ± 0.01 0.08 
Correction factor for Km 
           sulfation of QG or QGM 5 
  
2.2 
       methylation of QG or QGS 1.6 
  
1 
       glucuronidation of QG or QGM 41 
  
13 
       methylation of  QdiG 2 
  
87 
  Correction factor for Vmax 
           sulfation of QG or QGM 
 
1.7 
  
1.5 
      methylation of QG or QGS 
 
3 
  
1 
      glucuronidation of QG or QGM 
 
20 
  
12 
      methylation of  QdiG 
 
2.9 
  
31 
 1 Kinetic parameters for male rat were obtained from Boonpawa et al. [12]. 
2 Km(app) expressed as µM. 
3 Vmax(app) expressed as nmol/min/mg S9 protein. 
4 catalytic efficiency (Scaled Vmax/Km(app)) expressed as l/h/g tissue; scaled Vmax (µmol/h/g tissue) calculated from Vmax 
(app)/(1000 nmol/µmol)*(60 min/h)*(mg S9/g tissue): 11.4 and 143 mg S9 yield in small intestine and in liver. 
5 nd = not detect able. 
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Figure 3.6 Sensitivity analysis of the predicted plasma AUC0-24h of quercetin monoglucuronides 
(QG), quercetin diglucuronides (QdiG), quercetin glucuronide methyl conjugates (QGM), quercetin 
glucuronide sulfate conjugates (QGS), quercetin diglucuronide methyl conjugates (QdiGM), quercetin 
glucuronide sulfate methyl conjugates (QGSM), and quercetin-3′-O-sulfate (Q3′S) in human exposed 
to 0.4 mg/kg bw quercetin. The parameters are stand for: BW = body weight, VTi = tissue volume (Ti 
= I (small intestine), L (liver), K (kidney)), QC = cardiac output, Ka = uptake rate of quercetin, Kurine = 
urinary excretion rate constant, Kbile = biliary excretion rate constant, R = blood/plasma ratio, S9PI = 
small intestinal S9 protein content, S9PL = liver S9 protein content, Vmax and Km =  the maximum rate 
of formation and the Michaelis-Menten constant for formation of metabolite (G (glucuronide), S 
(sulfate), M (methylate), and correction factors for the reduction of Vmax for sulfate-conjugates of QG 
or QGM (a), methylate-conjugates of QG or QGS (b), methylate-conjugated of QdiG (b3), 
glucuronide-conjugates of QG or QGM (c) and for the induction of Km for sulfate-conjugates of QG or 
QGM (d), methylate-conjugates of QG or QGS (e), methylate-conjugated of QdiG (e3), glucuronide-
conjugates of QG or QGM (f). 
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Figure 3.7 Prediction on regiospecificity of the major circulating metabolites of quercetin in 
(individual) human subjects as compared with male rat [12] at a dose of 0.4 (A) and 12 mg/kg bw 
quercetin (B); quercetin (Q), glucuronide (G), sulfate (S) and methyl conjugate (M). Data were 
expressed as % of total plasma AUC0-24h. The bar and dots present the prediction obtained from the 
average and individual models.   
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3.4 Discussion  
Flavonoid aglycones have been intensively used in vitro to elucidate its mode of 
actions underlying the health beneficial effects of flavonoids. However, in vivo effects of 
flavonoids are ultimately dependent on the bioavailability of flavonoid aglycones and its 
metabolites. In the present study, (individual) human PBK models for quercetin were defined 
by integrating kinetic data obtained from in vitro incubations with (individual) human tissue 
fractions, providing information on the nature and time-dependent formation of quercetin and 
its metabolites in humans and interindividual human variation herein. The outcomes obtained 
allowed to tentatively predict the regiospecificity of the major circulating metabolites in 
human, which were compared to those previously predicted with a PBK model for quercetin 
in male rat to elucidate species differences [12]. The focus was on metabolites that formed by 
intestinal and liver tissue. Potential metabolic conversion by gut microbiota, was indirectly 
accounted for by simulating biliary excretion and intestinal enterocyte efflux back to lumen. 
The bioavailability of quercetin aglycone in (individual) human subjects was predicted 
to be limited ranging from 0.001 to 0.04% of the dose at an average dietary intake of 0.4 
mg/kg bw quercetin. This result is in agreement with results from previous studies of Gugler 
et al. [28] and Graefe et al. reporting that no quercetin aglycone can be detected in human 
plasma after consumption of 50 to 60 mg/kg bw quercetin or 2.2 mg/kg bw Q4´Gly [29]. The 
low bioavailability of quercetin aglycone is due to extensive first pass metabolism of 
quercetin in the body, especially via glucuronidation as ~96% of the dose was predicted in the 
present study to be converted to monoglucuronides within 1.5 h.  
Quercetin-3´-O-glucuronide was predicted to be the major circulating metabolite of 
quercetin in most individual humans both at a dose relevant to average dietary and 
supplementary intake of 0.4 and 12 mg/kg bw, respectively. In one individual, however, a 
glucuronide at the 3-position of quercetin-3´-O-glucuronide was the major circulating 
metabolite, indicating a swift further conversion of quercetin-3´-O-glucuronide in this 
individual. The importance of quercetin-3´-O-glucuronide and its further conjugates as major 
metabolites of quercetin is supported by a study of Mullen et al. in which quercetin-3´-O-
glucuronide and di- and tri-conjugates containing a glucuronide moiety were the major 
metabolites in the urine after consumption of onions [10]. However, these metabolites were 
not observed to be the major metabolites in the plasma, which was observed to mainly contain 
quercetin-3´-O-sulfate [10]. A more recent study by Lee et al., revealed that quercetin 
conjugates containing glucuronide moiety are the most important metabolites present in 
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human plasma, when quantified with LC-MS in positive ion mode [9]. In the study of Lee et 
al. the regiospecificity of these metabolites was not determined, and the importance of 
especially quercetin-3´-O-glucuronide as a major circulating can therefore not be confirmed 
based on this study.  
Interindividual human variation was observed in the kinetic constants for 
glucuronidation, sulfation and methylation as determined with the incubations performed with 
the 20 individual human liver fractions of the present study (Table 3.4-3.6). These differences 
lead to a variation in the plasma concentrations of quercetin metabolites including a 4-fold 
variation in the predicted level of the major circulating metabolite, quercetin-3´-O-
glucuronide. This variation was mainly a result of differences in glucuronidation efficiency at 
positions besides the 3´-position, rather than interindividual human variation for further 
conjugation of this metabolite to sulfate or methyl conjugates or formation of 3´-O-
glucuronide itself. For example, the lowest plasma concentration of quercetin-3´-O-
glucuronide was observed for individual H0270, who displayed the highest catalytic 
efficiency for further conjugation of quercetin-3´-O-glucuronide at the 3-position, resulting in 
quercetin-3,3´-O-diglucuronide as the major circulating metabolite for this individual. These 
results may suggest that especially the genetic- and lifestyle factors influencing the expression 
and/or activity of UGT enzymes involved in quercetin glucuronidation, including UGT1A1, 
UGT1A3, UGT1A8, UGT1A9, and UGT2B7 may influence the regiospecificity of circulating 
metabolites [16].  
With the developed PBK models for quercetin in (individual) human subjects and the 
previously defined model for rats, also species differences in metabolism of quercetin could 
be evaluated. Whereas the major predicted circulating metabolites of quercetin in humans are 
monoglucuronides and predominantly quercetin-3´-O-glucuronide, the major circulating 
metabolites in rats were di- and tri-conjugates containing glucuronic acid, sulfate and/or 
methyl moiety (Figure 3.7). These differences are partly due to a 2.3–fold higher metabolic 
conversion in rats as compared with humans, resulting in a faster further conversion of the 
monoglucuronides. A higher rate of glucuronidation in rats compared with human is more 
commonly observed. For example, Furukawa et al., reported that glucuronidation of quercetin 
in rat is 2.2-fold more efficient than in human based on the catalytic efficiencies obtained 
from in vitro incubations with rat and human intestinal microsomes [30]. Glucuronidation of 
related flavonoids, including hesperetin, kaempferol, genistein, daidzein, and glycitein has 
been reported to be more efficient in rat than in human as observed in in vitro incubations 
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with tissue fractions [31-34]. Studies on the glucuronidation of other compounds including 
buprenorphine, entacapone, ezetimibe, mycophenolic acid, and tolcapone further support that 
rat has higher glucuronidating activities than human based on the catalytic efficiencies 
obtained from in vitro incubations with rat and human intestinal microsomes [30]. Also 
species differences in the tentatively identified regiospecificity of circulating metabolites were 
observed, as rats mainly show primary glucuronidation at the 4´-OH and humans at the 3´-OH 
and di- and tri-conjugates building further on these different mono-conjugates in both species. 
This differences in conversion of flavonoids may be a result of differences in the size and 
shape of the binding pocket of different enzymes involved in the reactions [35]. 
Glucuronidation of quercetin in humans has been identified to be catalyzed by UGT1A1, 
UGT1A8 and UGT1A9 based on incubations with recombinant enzymes [16], whereas 
glucuronidation in rats has been linked to UGT1A1 and UGT1A7 activity in an in vitro study 
with rat tissue fractions [36]. Especially UGT1A1 has been reported to preferentially convert 
flavones at the 3´-OH (the primary glucuronide formed in humans in the present study) [35]. 
A difference in contribution of this enzyme to the total glucuronidation activity between the 
two species might therefore explain the observed differences in primary metabolites that are 
formed and consequently the secondary and tertiary metabolites that build upon these primary 
glucuronides.  
Considering that the nature and the position of flavonoid conjugation could be a key 
factor determining biological activity of flavonoids in vivo [37], the observed differences 
between individual human subjects in circulating metabolites could indicate critical 
differences in sensitivity to health beneficial effects. In addition, the differences between rats 
and humans may suggest that the biological effects of flavonoids observed in rats may not 
necessary be relevant for the human situation. At present little is known about the biological 
activity of flavonoid metabolites. Metabolism does not always result in a reduced biological 
activity of flavonoids [37]. In addition, biological activity might be a result of the extent by 
which the flavonoids are deconjugated to the active aglycone in a tissue [38, 39]. The results 
obtained with the PBK model allow to identify which metabolites will be relevant to study for 
their biological activity or to use in incubations to determine deconjugation, which are for 
humans predominantly quercetin-3´-O-glucuronide and conjugates of this metabolite. 
Overall, the newly developed PBK model adequately predicted overall plasma 
concentrations of quercetin and its metabolites including mono-, di-, and tri-conjugates and 
provides an indication of the nature of the circulating metabolites of quercetin in plasma of 
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humans and interindivdiual human variation herein. Significant species differences occur in 
the major circulating metabolites of quercetin in the systemic circulation indicating that rat is 
not an adequate model to study effects of quercetin in man. The developed PBK models can 
also be used to guide experimental design of in vitro experiments with flavonoids, especially 
to take into account the relevance of metabolism and the contribution of metabolites to the 
biological activity of flavonoids in humans.  
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Abstract  
 In vivo estrogenicity of genistein and its glycoside genistin is still under debate. The 
present study aimed to develop a physiologically based kinetic (PBK) model that provides 
insight in dose-dependent plasma concentrations of genistein aglycone and its metabolites and 
enables prediction of in vivo estrogenic effective dose levels of genistein and genistin in 
humans. A PBK model for genistein and genistin in humans was developed based on in vitro 
metabolic parameters. The model obtained was used to translate in vitro estrogenic 
concentration-response curves of genistein to in vivo estrogenic dose-response curves for 
intake of genistein and genistin. The model predicted that genistein-7-O-glucuronide was the 
major circulating metabolite and that levels of the free aglycone were generally low (0.5-17% 
of total plasma genistein at oral doses from 0.01-50 mg/kg bw. The predicted in vivo BMD05 
(benchmark dose for 5% response) values for estrogenicity varied between 0.03 and 4.56 
mg/kg bw genistein. For genistin, these values were 1.3-fold higher. These values are in line 
with reported human data and show that estrogenic responses can be expected at an Asian 
dietary and a supplementary intake, while intake resulting from a Western diet may not be 
effective. The present study shows how plasma concentrations of genistein and its metabolites 
and estrogenic dose levels of genistein in humans can be predicted by combining in vitro 
estrogenicity with PBK model based reverse dosimetry, eliminating the need for human 
intervention studies. 
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4.1 Introduction  
 Isoflavones are a common group of polyphenols and are generally known as 
phytoestrogens as they can exert weak estrogenic potencies due to their basic structural 
similarity to endogenous estrogen [1]. Isoflavones have been reported to reduce the incidence 
of mammary tumors in experimental animal models [2] and in observational epidemiologic 
studies [3]. However, there is also evidence suggesting that isoflavones can stimulate cell 
proliferation of breast cancer cells in vitro [4-8] and in ovariectomized animal models of 
breast cancer [9] in a dose-dependent manner. These findings raised a concern about the 
safety of these isoflavones, especially in patients with existing estrogen-sensitive tumors and 
woman at risk of developing breast cancer. A possible mode of action underlying these 
positive and negative effects of isoflavones might be the modulation of estrogen receptor 
(ER) signaling as agonist or antagonist depending on the endogenous concentration of ERs 
[1]. ERs consist of two major isoforms; ERα that drives proliferation and ERβ that inhibits 
proliferation and stimulates apoptosis [1]. These two receptors moderate each other’s effects 
and therefore their absolute concentration and ratio within a tissue may influence the cellular 
response toward different xenoestrogens [10]. A recent scientific opinion of the European 
Food Safety Authority (EFSA) concluded that “there is no indication for adverse effects on 
the mammary gland, uterus, and thyroid function and no genotoxic concern in post-
menopausal women taking 30-900 mg/day isoflavones supplements for 3-36 months, but that 
there are insufficient data to assess the risk of isoflavone supplements in post-menopausal 
women with a current diagnosis or history of estrogen-dependent cancer” [11].  
Genistein is the major isoflavone in soy occurring in plants mainly in its glycosylated 
form, genistin (genistein-7-O-glucoside) [12], while fermentation increases the aglycone 
content in soy-based products [12, 13]. The metabolic pathways of genistin and genistein are 
shown in Figure 4.1. The glycosylated genistin is hydrolyzed to genistein aglycone prior to 
absorption in the intestine by brush-border lactase phlorizin hydrolase [14] or by gut 
microbiota [15]. Upon absorption, genistein is extensively metabolized via glucuronidation 
and sulfation in both intestinal cells and liver cells. Most of the absorbed genistein is present 
in the systemic circulation in the form of glucuronides, sulfates, and mixed conjugates at the 
4´- and/or 7-position [16-18].  
The genistein conjugates tested so far, including genistein-7-O-glucuronide (G-7G), 
genistein-7-O-sulfate (G-7S), and genistein-4´-O-sulfate (G-4´S), appeared inactive in assays 
Chapter 4 
 84 
for estrogenicity leading to the conclusion that the action of the soy phytoestrogen genistein 
will be mainly related to the plasma and tissue concentration of the free aglycone [13, 19].  
 
Figure 4.1 Proposed metabolic pathways of genistin and genistein in humans [16-18].  
 
Available data on the estrogenic activity of genistein in humans under realistic 
exposure scenario’s are contradicting and inconclusive. In some human studies, genistein and 
other isoflavones have been reported to exert an estrogenic response in especially healthy 
premenopausal women [20-23]. Contradictory, some human studies report no estrogenic 
response of genistein/isoflavones in healthy as well as breast cancer women even at 
supplementary doses [2, 24-26]. Given that the estrogenicity of genistein might strongly 
depend on the plasma levels of its aglycone, it is of importance to better understand the 
absorption, distribution, metabolism, and excretion (ADME) of genistein in humans and the 
actual plasma levels of genistein and its various metabolites in human subjects. The aim of 
the present study was to develop a physiologically based kinetic (PBK) model that provides 
insight in the dose-dependent plasma concentration of genistein aglycone and its metabolites 
and enables prediction of the in vivo dose-response curves for estrogenicity of genistein and 
genistin in humans based on in vitro concentration-response curves. The outcomes obtained 
can be used to determine whether and if so at what oral dose levels genistein or genistin may 
elicit estrogenic effects in vivo. 
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4.2 Materials and Methods 
4.2.1 Materials 
 Pooled mixed-gender human small intestine and liver S9 fractions were purchased 
from Xenotech (Lenexa, USA). Uridine 5′-diphosphoglucuronide acid (UDPGA, purity 98%), 
3′-phosphoadenosine 5′-phosphosulfate (PAPS, purity 65%), Tris, alamethicin (from 
Trichoderma viride), D-saccharic acid 1,4-lactone monohydrate, and β-
glucuronidase/sulfatase (from Helix pomatia) were purchased from Sigma-Aldrich 
(Steinheim, Germany). Hydrochloric acid (fuming 37%), magnesium chloride, trifluoroacetic 
acid (for spectroscopy), and DMSO (99.9%) were purchased from VWR International 
(Darmstadt, Germany). Acetonitrile (chromatography grade) was purchased from Biosolve 
(Valkenswaard, The Netherlands). Genistein (>99%) was purchased from LC Laboratories 
(Woburn, MA, USA). G-7G was purchased from Extrasynthese (Geny, France). G-7S, G-4 ̕G, 
genistein-4 ̕ ,7-O-diglucuronide (G-4´7diG), and genistein-7-O-glucuronide-4 ̕ -O-sulfate (G-
7G-4´S) were purchased from Toronto Research Chemicals (Toronto, Canada).  
 
4.2.2 Enzymatic conjugation of genistein and genistein mono-conjugates with pooled human 
tissue fractions 
 Kinetic constants for sulfation of genistein and  conjugation of the mono-conjugates 
G-7G, G-4 ̕ G, and G-7S to di-conjugates, needed as parameters in the PBK models, were 
obtained from in vitro incubations with pooled mixed-gender human small intestine and liver 
S9 fractions based on methods described by Islam et al. [12] with some modifications. Use of 
mixed-gender human tissue fractions was considered adequate to represent both male and 
female individuals, because no significant gender differences on maximum concentration 
(Cmax), area under the -concentration-time curve (AUC), and time to read Cmax (Tmax) in 
plasma of total genistein (genistein aglycone and its metabolites) between male and female 
human volunteers following consumption of soy foods were observed [27].  
For glucuronidation, 100 µl incubation mixtures (final volume) were prepared 
containing 10 mM MgCl2, 20 mM D-saccharic acid 1,4-lactone (pH 7.4), 10 mM UDPGA, 
and human tissue fractions in 50 mM Tris-HCl (pH 7.4). D-saccharic acid 1,4-lactone was 
added to inhibit β-glucuronidase [28]. A protein content of 0.8, 0.8, and 0.2 mg/ml human 
small intestine S9 and of 1.2, 0.8, and 0.8 mg/ml human liver S9 were applied for the 
incubations of G-7G, G-4 ̕ G, and G-7S, respectively. The incubation mixtures were pre-
treated on ice with 0.025 mg/ml alamethicin added from a 200 times concentrated stock 
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solution in methanol for 15 min. After 1 min pre-incubation at 37ᵒC, the reactions were 
initiated by adding substrate (final concentration ranging from 0.5 to 400 µM) added from a 
200 times concentrated stock solution in DMSO. The incubations of G-7G, G-4 ̕G, and G-7S 
were terminated after 60, 180, and 40 min for incubations with human small intestine S9 and 
after 240, 240, and 240 min for incubations with human liver S9, respectively, by adding 25 
µl ice-cold acetonitrile. Blank incubations were carried out without UDPGA. Under the 
specified conditions, glucuronidation was linear in time and with protein content (data not 
shown). 
For sulfation reactions, 100 µl incubation mixtures (final volume) were prepared 
containing 10 mM MgCl2, 20 mM D-saccharic acid 1,4-lactone (pH 7.4), 0.1 mM PAPS, and 
human tissue fractions in 50 mM Tris-HCl (pH 7.4). A protein content of 0.4, 0.8, and 0.8 
mg/ml human small intestine S9 or human liver S9 were applied for the incubations of 
genistein, G-7G, and G-4 ̕G, respectively. The incubation mixtures were pre-incubated for 1 
min at 37ᵒC prior to an addition of substrate (final concentration ranging from 0.5 to 400 µM) 
added from a 200 times concentrated stock solution in DMSO to initiate the reactions. The 
incubations of genistein, G-7G, and G-4 ̕G were terminated after 20, 240, and 180 min for 
incubations with human small intestine S9 and after 20, 240, and 240 min for incubations 
with human liver S9, respectively, by adding 25 µl ice-cold acetonitrile. Blank incubations 
were carried out without PAPS. Under the specified conditions, sulfation was linear in time 
and with protein content (data not shown). 
 
4.2.3 Identification and quantification of genistein metabolites 
 All samples were analyzed on a UPLC-DAD system consisting of a Waters (Milford, 
MA) Acquity binary solvent manager, sample manager, and photodiode array detector, 
equipped with a Waters Acquity UPLC BEH RP 18 column (1.7 μm, 2.1 x 50 mm). Before 
analysis, the samples were centrifuged at 15000 rpm for 5 min at 5ºC to precipitate proteins 
and 3.5 µl of the supernatant was subsequently analyzed. A gradient was applied consisting of 
nanopure water containing 0.1% trifluoroacetic acid (eluent A) and acetonitrile (eluent B) 
with a flow rate of 0.6 ml/min with the following profile: 0-10% B (0-0.58 min), 10-15% B 
(0.58-2.85 min), 15-50% B (2.85-4.28 min), 50-80% B (4.28-4.40 min), 80% B (4.40-4.52 
min), 80-0% B (4.52-4.63 min) and 0% B (4.63-5.80 min).  
Identification of the formed metabolites obtained from glucuronidation and sulfation 
reactions was carried out by comparing their UV-spectra and retention times with those of 
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commercially available reference compounds including G-7S, G-7G-4´S, and G-4´,7diG. The 
nature of the sulfate metabolite of G-4 ̕ G and the glucuronide metabolite of G-7S was 
confirmed by treating incubation samples with β-glucuronidase/sulfatase as there was no 
commercially reference compound available. To this end, 50 µl of non-terminated mixtures 
(incubation samples) were added to 50 µl of 0.1 M sodium acetate (pH 5.0) containing 189 
units/ml β-glucuronidase and 1 units/ml sulfatase. The reactions were carried out for 2 h at 
37°C and were terminated by adding 25 µl of ice-cold acetonitrile.  
Metabolites were quantified by integrating the peak areas at 260 nm and by using the 
calibration curves of their commercially available reference compounds. G-4 ̕ G-7S was 
quantified by using the calibration curve of G-7G-4´S, which was considered adequate 
because G-4 ̕ G-7S has the same UV-spectrum as G-7G-4´S (data not shown) and was 
assumed to display a similar molar extinction coefficient.  
 
4.2.4 Kinetic analysis 
 Kinetic constants namely the apparent maximum velocity (Vmax(app)) and apparent 
Michaelis-Menten constant (Km(app)) for formation of all metabolites were determined by 
fitting the data to the standard Michaelis-Menten equation. For reactions demonstrating 
substrate inhibition, the Vmax, Km, and inhibition constant (Ki) were determined by fitting the 
data to the substrate inhibition equation. The kinetic constants were determined using 
GraphPad Prism version 5.04 (GraphPad Software, San Diego, California, USA).  
Michaelis-Menten equation:  v = Vmax* [S]/(Km+[S])    (1) 
Substrate inhibition equation:  v = Vmax* [S]/((Km+[S])*(1+[S]/Ki))   (2) 
where [S] represents the substrate concentration. The values of Vmax, Km, and  Ki were 
expressed in nmol/min/mg protein, µM, and µM, respectively.  
  
4.2.5 PBK model 
 A PBK model for genistein and its glycoside, genistin, in humans was developed in a 
similar manner as previously defined for quercetin [29, 30]. The model consists of separate 
compartments for the intestinal lumen, small intestine, liver, kidney, rapidly perfused tissues 
(e.g. heart, lung, brain), and slowly perfused tissues (e.g. skin, muscle, bone) as shown in 
Figure 4.2. Genistin was modeled to be hydrolyzed to its aglycone, genistein, in the intestinal 
lumen by brush-border lactase phlorizin hydrolase with a hydrolysis clearance of 9.6 l/h as 
reported by Islam et al. [12]. The uptake of genistein to the small intestine compartment was 
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described by first-order kinetics with an absorption rate constant of 5.02 h-1 as reported by 
Steensma et al. [31]. The genistein aglycone was not modeled to be excreted since only a 
trace amount of unconjugated genistein is detected in human urine following oral uptake of 
genistein [17, 18]. The kinetic parameters for excretion of genistein conjugates via urine, bile, 
and intestinal efflux back to intestinal lumen were obtained by fitting the predicted dose-
dependent plasma concentration of total genistein (genistein aglycone plus metabolites) with 
available experimental plasma human data [16-18, 32, 33] resulting in an average value of 4 
h-1, 2 h-1, and 0.1 l/h, respectively. Genistein was modeled to undergo metabolic conversion 
via glucuronidation and sulfation reactions forming different mono- and di-conjugates at the 
4´- and/or 7-position. The kinetic constants for glucuronidation of genistein were obtained 
from in vitro incubations by Islam et al. [12]. For other reactions including sulfation of 
genistein, G-7G, and G-4´G as well as glucuronidation of G-7G, G-4´G, and G-7S the kinetic 
constants were obtained in the present study based on in vitro experiments. The apparent Vmax 
values for formation of the different mono- and di-conjugates were scaled to in vivo Vmax 
values using a S9 content of 11.4 and 143 mg/g tissue for small intestine and liver as scaling 
factors [29]. It is of importance to note that the current PBK model does not include the 
formation of the microbiota metabolite equol, a potent estrogenic metabolite [34, 35], because 
equol is a major metabolite of daidzein, not of genistein and only approximately one-third to 
one-half of the population are actually equol producers [36]. Dihydrogenistein is a 
corresponding metabolite formed of genistein by gut microbiota, however only a few studies 
have been reported on its estrogenicity [34, 35]. Morito et al. [34] reported that 
dihydrogenistein showed similar binding affinity and induced similar transcriptional 
activation of human ERα and ERβ as genistein aglycone. Contradictory, Hwang et al. [35] 
found that dihydrogenistein exerted much weaker estrogenic responses in binding and 
inducing transcriptional activation of human ERα and ERβ as well as in stimulating ERα 
mediated cell proliferation than genistein aglycone. Given these contradicting reports on 
estrogenicity formation of the microbiota metabolite dihydrogenistein was not included in the 
PBK model. 
The physiological parameters including organ volumes, cardiac output and blood 
flows were obtained from Brown et al. [37] are shown in Table S4.1 in the Supporting 
information. The physico-chemical parameters for genistein and its metabolites are shown in 
Table 4.1. Tissue:blood partition coefficients of genistein and its metabolites were estimated 
from log Kow according to a method described by DeJongh et al. [38]. Log Kow values were 
In vitro-in silico approach for genistein estrogenicity 
 89 
estimated from Clog P values obtained from Scifinder (American Chemical Society, USA) 
and ChemBioDraw Ultra 14.0 (Cambridge-Soft, USA). Conversion of blood concentrations 
of genistein and its metabolites to plasma concentrations was done by dividing the blood 
concentrations by a blood/plasma ratio (R). The R value of 0.66 was used and calculated using 
Simcyp prediction tools [39, 40]. Mass balance equations were numerically integrated in 
Berkeley Madonna version 8.3.18 (Macey and Oster, UC Berkeley, CA) using Rosenbrock’s 
algorithm for stiff system. Mass balance equations for genistein and its metabolites were 
similar to those previously described by Boonpawa et al. for quercetin [29, 30]. Model 
performance was evaluated by comparing the predicted amounts of genistein metabolites 
excreted in urine to the reported amounts of genistein metabolites in human urine [17, 18]. A 
sensitivity analysis was performed to assess key parameters that contribute substantially to the 
Cmax of genistein aglycone in plasma following intake of genistein and genistin at oral doses 
of 0.5 and 7 mg/kg bw, representing an average Asian dietary [1] and supplementary intake of 
genistein/genistin [11], respectively. Normalized sensitivity coefficients (SCs) were 
calculated for the model parameters according to the method described by Evens and 
Andersen as follows [41]:  
SC = (C′-C)/(P′-P) x (P/C)        (3) 
where C is the initial value of the model output, C′ is the modified value of the model output 
resulting from an increase in parameter value, P is the initial parameter value, and P′ is the 
modified parameter value assuming a 5% increase in its value.  
 
 
Figure 4.2. PBK model structure for mono-conjugates (A) and di-conjugates (B) of genistein: 
genistein-7-O-glucuronide (G-7G), genistein-4´-O-glucuronide (G-4´G), genistein-7-O-sulfate (G-7S), 
genistein-4´-O-sulfate (G-4´S), genistein-4´,7-O-diglucuronide (G-4´7diG), genistein-7-O-
glucuronide-4´-O-sulfate (G-7G-4´S), and genistein-4´-O-glucuronide-7-O-sulfate (G-4´G-7S). 
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Table 4.1 Physico-chemical parameters of genistein and its metabolites in human 
Compound CLogP1 pKa2 fu3 R4 
Tissue:blood partition coefficients5 
Small 
intestine 
Liver Kidney 
Rapidly 
perfused tissue 
Slowly 
perfused tissue 
Genistein 3.11 6.51 0.03 0.73 6.44 6.44 3.01 3.01 4.08 
G-7G 0.84 2.73 0.16 0.64 0.86 0.86 0.92 0.92 0.90 
G-4'G 0.36 2.78 0.22 0.63 0.71 0.71 0.84 0.84 0.81 
G-7S 2.51 -4.92 0.05 0.70 4.18 4.18 1.97 1.97 2.79 
G-4'S 2.03 -4.24 0.07 0.68 2.56 2.56 1.46 1.46 1.87 
G-7G-4'S -1.69 - - - 0.59 0.59 0.76 0.76 0.75 
G-4'G-7S -1.69 - - - 0.59 0.59 0.76 0.76 0.75 
G-4'7diG -1.91 2.73 0.66 0.57 0.59 0.59 0.76 0.76 0.75 
1 CLogP values for genistein and its metabolites were estimated using Scifinder (American Chemical Society, USA) and 
ChemBioDraw Ultra 14.0 (Cambridgesoft, USA). 
2 pKa values were obtained from Scifinder (American Chemical Society, USA). 
3 Fraction unbound (fu) was calculated using Simcyp prediction tools-fu [39]. 
4 Blood/plasma ratio (R) was calculated using Simcyp prediction tools-blood to plasma partition ratio [40]. 
5 Tissue:blood partition coefficients of genistein and its metabolites were calculated according to the method described by 
DeJongh et al. [38]. 
 
4.2.6 Translation of in vitro estrogenic activity to in vivo estrogenicity  
 PBK model based reverse dosimetry was carried out to predict in vivo estrogenic 
responses upon exposure to genistein and genistin by relating the in vitro effect to plasma 
concentrations of genistein aglycone based on the methods described by Louisse et al. [42] 
and Strikwold et al. [43]. We considered the plasma Cmax as relevant parameter for these 
conversions to predict dose dependent in vivo estrogenic responses to genistein or genistin, 
because interaction of phytoestrogens with ERs is a short term effect. Furthermore, in vivo 
estrogenicity of genistein and genistin will especially depend on plasma concentrations of the 
free aglycone since its phase II metabolites have been shown to exert no estrogenic response 
in ERD-positive MCF-7 and T47D breast cancer cells [13, 19]. Even though genistein 
monoglucuronides were reported to moderately bind to recombinant human ERα and ERβ, 
this binding appears not to result in efficient transcriptional activation of both ERs as shown 
in yeast cells carrying human ERs [6]. For translation, available concentration-response 
curves for in vitro estrogenic activities of genistein available in literature were used, including 
concentration-response curves for 1) binding of genistein to human ERα and ERβ [4-8], 2) 
genistein induced ERα and ERβ mediated gene expression in U2OS reporter gene assays [10, 
19, 44, 45], and 3) genistein stimulated cell proliferation in ERα-positive MCF-7 and T47D 
breast cancer cells [5-10, 13, 19, 46-50]. Before making the in vitro to in vivo translation, it is 
of importance to realize that only the free fraction of the chemical will exert the effects which 
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implies a correction is required for the binding of genistein to protein and lipid. This 
correction was made to take into account differences in albumin and lipid concentrations 
between in vitro and in vivo conditions. The binding of genistein to human ERα and ERβ 
were obtained from in vitro assays containing no protein and lipid, thus assumed 100% 
availability in vitro. In this case each nominal in vitro effect concentration (ECin vitro) of 
genistein aglycone for the binding activity was extrapolated to an in vivo effect concentration 
(ECin vivo) by dividing the ECin vitro with free fraction (fu) of genistein in vivo. The fuin vivo of 
genistein in human plasma was estimated to be 0.03 (see Table 4.1). For other estrogenic 
responses, including genistein induced ERα and ERβ mediated gene expression and 
stimulated cell proliferation, each ECin vitro of genistein aglycone was extrapolated to an ECin 
vivo according to the extrapolation rule of Gülden and Seibert as follows [51].  
EC𝑖𝑛 𝑣𝑖𝑣𝑜 =  EC𝑖𝑛 𝑣𝑖𝑡𝑟𝑜x [(1 − fb𝑖𝑛 𝑣𝑖𝑡𝑟𝑜)x
1+KOW x V′L,serume
1+KOW x V′L,𝑖𝑛 𝑣𝑖𝑡𝑟𝑜
+ fb𝑖𝑛 𝑣𝑖𝑡𝑟𝑜x 
Pserum
P𝑖𝑛 𝑣𝑖𝑡𝑟𝑜
] (4) 
where fbin vitro is the fraction of chemical bound to protein and lipid in culture medium, which 
is calculated from 1 - fuin vitro. V´L is the lipid fraction in serum and in vitro. P is the protein 
content in plasma serum and culture medium.  
 For the extrapolation, in vivo plasma albumin and lipid concentrations of 600 µM and 
6 g/l, were used [51]. The albumin and lipid concentrations in culture medium of the reported 
in vitro bioassays were estimated from the reported data by Gülden et al. [52] indicating that 
5% FBS contains 18 µM BSA and 0.1 g/l lipid. The fuin vitro of genistein in in vitro medium 
was estimated using the reported binding constant of genistein to BSA of 1.3 x 104 M-1 and a 
binding site number of 0.9 [53]. The ECin vivo obtained was set equal to the plasma Cmax of 
genistein aglycone in the PBK model. The PBK model was subsequently used to calculate the 
corresponding oral dose levels in humans. This provided a dose-response curve that was 
subsequently used to derive the benchmark dose at 5% response (BMD05) based on the 
default benchmark response for continuous data [54]. The BMD05 values were estimated by 
fitting to the Hill model, using Benchmark Dose Software version 2.6 (The Environmental 
Protection Agency’s, USA). The BMD05 values obtained for estrogenic responses of genistein 
were evaluated against reported active [20-23] and inactive [2, 24-26] dose levels of genistein 
on estrogenicity in humans as taken from the literature and summarized in Table 4.2. 
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4.3 Results 
4.3.1 Enzymatic conjugation of genistein and genistein mono-conjugates in incubations with 
pooled human tissue fractions 
 Analysis of the glucuronidation of G-7G, G-4 ̕G, and G-7S in incubations with pooled 
human tissue fractions revealed that all three substrates were metabolized by pooled human 
small intestine S9, while pooled human liver S9 only metabolized G-4 ̕ G. The metabolite 
formed in incubations with G-7G and G-4 ̕ G coeluted with and showed similar spectral 
characteristics as commercially available G-4´7diG and was thus identified as G-4´7diG. The 
metabolite formed in glucuronidation incubations with G-7S with a retention time of 2 min 
was identified by treating the unterminated samples with β-glucuronidase/sulfatase resulting 
in a complete disappearance of the respective peak and a concomitant equivalent increase in 
the peak area of genistein aglycone (data not shown), confirming it to be a glucuronidated 
conjugate of G-7S. This metabolite was most likely G-7S-4 ̕ G because conjugation of 
flavonoids likely occurs at free OH positions [55]. 
 Analysis of the sulfation incubations, revealed that human small intestine and liver S9 
could metabolize genistein and G-7G, whereas sulfation of G-4 ̕ G was only observed in 
incubations with human liver S9. At the specified conditions in the present study, only one 
sulfated metabolite was formed in the incubations with genistein. The formed metabolite 
coeluted with and showed similar spectral characteristics as commercially available G-7S and 
was thus identified as G-7S. One metabolite was formed in the sulfation incubations with G-
7G. The formed metabolite coeluted with and showed similar spectral characteristics as 
commercially available G-7G-4 ̕ S and was thus identified as G-7G-4 ̕ S. The metabolite 
formed in sulfation incubations with G-4 ̕G with a retention time of 2 min was identified by 
treating the unterminated samples with β-glucuronidase/sulfatase resulting in a complete 
disappearance of the respective peak and a concomitant equivalent increase in the peak area 
of genistein aglycone (data not shown), confirming it to be a sulfated conjugate of G-4 ̕ G. 
This metabolite was most likely G-4 ̕G-7S because conjugation of flavonoid likely occurs at 
free OH positions [55]. 
 
4.3.2 Kinetic constants for formation of genistein mono- and di-conjugates 
 The concentration-dependent rates of glucuronidation and sulfation of genistein, G-
7G, G-4 ̕ G, and G-7S by human small intestine and liver S9 fractions are shown in the 
Supporting information (Figure S4.1). The kinetic constants for formation of all metabolites 
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derived from these results are summarized in Table 4.3. The results showed that the total 
catalytic efficiency for metabolic conversion of genistein amounted to 2.34 l/h/g tissue in liver 
which was 7.5-fold higher than the total catalytic efficiency of 0.31 l/h/g tissue for small 
intestine. Genistein mono-conjugates especially G-7G and G-7S were the major metabolites 
formed in incubations with both small intestine and liver S9. Formation of G-7S by human 
liver S9 showed a strong substrate inhibition at concentration above 1 µM with a Ki value of 
25 µM. Formation of genistein di-conjugates was more than 10-fold less efficient than 
formation of its respective mono-conjugates due to a decrease in the Vmax and an increase in 
Km values.  
 
Table 4.3 Kinetic constants for formation of mono- and di-conjugates of genistein obtained from in 
vitro incubations with human tissue fractions. For full concentration dependent activity curves from 
which these kinetic constants are derived (see Figure S4.1 in the Supporting information). 
 
Substrate Metabolites Small intestine S9 Liver S9 
Km1 Vmax2 Scaled 
Vmax3 
CE4 Km1 Vmax2 Scaled 
Vmax3 
CE4 
Genistein G-7G5 5.8 0.7 0.48 0.08 22 1.50 12.87 0.59 
 G-4'G5 19 0.2 0.14 0.01 32 0.10 0.86 0.03 
 G7S6  0.11 0.03 0.02 0.19 0.11 0.02 0.17 1.56 
 G4'S nd7 nd -  nd nd - - 
G-7G G-4',7diG  229 0.04 0.03 0.0001 nd nd - - 
 G-7G-4'S  134 0.003 0.002 0.00002 35 0.002 0.02 0.0005 
G-4'G G-4',7diG  665 0.51 0.35 0.001 196 0.01 0.09 0.0004 
 G-4'G-7S  nd nd - - 152 0.02 0.17 0.001 
G-7S G-7S-4'G  18 0.65 0.44 0.02 nd nd - - 
1 µM. 
2 nmol/min/mg S9. 
3 Expressed as µmol/h/g tissue and calculated from Vmax(app)/(1000 nmol/µmol) x (60 min/h) x (mg S9/g tissue): 
S9 protein content yield 11.4 and 143 mg/g tissue for small intestine and liver, respectively. 
4 Catalytic efficiency expressed as l/h/g tissue. 
5 Kinetic constants for formation of genistein monoglucuronides were obtained from Islam et al. [12]. 
6 Human liver S9 showed G-7S substrate inhibition at concentration >1 uM; Ki = 25 µM. 
7 nd = no detection at specified conditions. 
 
4.3.3 PBK model development and evaluation 
 To define the PBK model for genistein and its glycoside genistin, kinetic parameters 
for metabolic conversion of genistein to mono- and di-conjugates were obtained from in vitro 
incubations. Kinetic parameters for excretion via bile, urine, and intestinal efflux back to 
intestinal lumen were obtained by fitting the predicted total genistein in plasma with reported 
data in humans [16-18, 32, 33], resulting in an average value of 4 h-1, 2 h-1, and 0.1 l/h, 
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respectively. Subsequently, the model thus defined was used to predict the plasma kinetics of 
genistein aglycone and its metabolites. The model predicted plasma Cmax and AUC of 
genistein aglycone within 2- to 4-fold deviation from the reported human plasma data (Figure 
4.3A-4.3B). Furthermore, the model also adequately predicted metabolic plasma profiles of 
genistein metabolites within 1- to 3-fold deviation from the reported metabolic plasma 
profiles in humans (Figure 4.3C).  
 
Figure 4.3 Comparison of the PBK model based predicted and experimentally reported data on (A) 
plasma Cmax, and (B) plasma AUC of genistein aglycone, and of (C) the metabolic profile of genistein 
in humans [16-18, 32, 33]. The in vivo data come from Setchell et al. at a dose of 0.71 mg/kg bw 
genistein or 0.71 mg/kg bw genistin [33], Hosoda et al. at a dose of 0.92 mg/kg bw genistein and 0.86 
mg/kg bw genistin [32], Hosoda et al. at a dose of 0.92 mg/kg bw genistein and 0.76 mg/kg bw 
genistin [16], Hosoda et al. at a dose of 0.18 mg/kg bw genistein and 0.15 mg/kg bw genistin [17], and 
Yuan et al. at a dose of 0.13 mg/kg bw genistein or 0.21 mg/kg bw genistin [18]: Gen = genistein, Gin 
= genistin, glucuronides  = sum of genistein mono- and diglucuronides, sulfates = sum of genistein 
monosulfates, and mixed conjugates = sum of genistein metabolites containing glucuronide and sulfate 
moieties. 
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The performance of the newly defined PBK model was evaluated by comparing the 
predicted amounts of genistein metabolites excreted in urine against reported data in humans 
for excretion of genistein metabolites in urine [17, 18]. The results revealed that the model 
adequately predicted the amount of genistein metabolites excreted in urine within 2- to7-fold 
deviation from the reported urinary profiles of genistein metabolites in humans [17, 18] 
(Figure 4.4). These results also indicate that the model adequately predicted the kinetics of 
genistein in humans.  
 
Figure 4.4 Model evaluation by comparison of the predicted urinary profiles of genistein metabolites 
against urinary profiles of genistein metabolites in humans as reported by Hosoda et al. at a dose of 
0.18 mg/kg bw genistein and 0.15 mg/kg bw genistin [17], and by Yuan et al. at a dose of 0.13 mg/kg 
bw genistein or 0.21 mg/kg bw genistin [18]: Gen = genistein, Gin = genistin, glucuronides = sum of 
genistein mono- and diglucuronides, sulfates = sum of genistein monosulfates, and mixed conjugates 
= sum of genistein metabolites containing glucuronide and sulfate moieties.  
 
To further evaluate the performance of the newly defined model, a sensitivity analysis 
was performed to assess key parameters that influence the predicted plasma Cmax of genistein 
aglycone at oral doses of 0.5 and 7 mg/kg bw genistein/genistin (expressed in genistein 
equivalents), representing an average Asian dietary [1] and a supplementary intake of 
genistein/genistin [11]. Only parameters that had a normalized sensitivity coefficient higher 
than 0.1 (in absolute value) are displayed in Figure S4.2 in the Supporting information. When 
consumed as aglycone, the most influential physiological and physico-chemical parameters 
for the predicted plasma Cmax of genistein aglycone are the body weight, the volumes of the 
small intestine and liver, the cardiac output, the reginal blood flow through the small intestine 
and rapidly perfused tissues, the small intestine tissue:blood partition coefficient of genistein, 
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the uptake rate constant, and the blood/plasma ratio (expressing normalized sensitivity 
coefficients between 0.3 to 1.0 in absolute value). The predicted plasma Cmax of genistein 
aglycone is also largely affected by the parameters that influence the formation of G-7G and 
G-7S including the S9 protein yield in the small intestine and liver, and the kinetic constants 
for formation of G-7G and G-7S in the small intestine and liver (expressing normalized 
sensitivity coefficients between 0.2 to 1.20 in absolute value). As the dose increases, the 
kinetic parameters for formation of G-7G and G-7S in the small intestine become less 
influential and the kinetics for formation of G-7G in the liver become the most influential 
kinetic parameters at high dose. When consumed as its glycoside genistin, the predicted 
plasma Cmax of genistein aglycone are influenced by similar parameters and in a similar 
manner with as additional influential parameters including the volume of the intestinal lumen 
and the hydrolytic clearance of genistin (expressing normalized sensitivity coefficients of 
approximately 0.4 in absolute value). 
 
4.3.4 PBK model predictions of metabolic plasma profiles of genistein 
 The PBK model was used to simulate the dose-dependent plasma concentration of 
genistein and its metabolites at different oral dose levels. The results obtained revealed that 
G-7G was predicted to be the major circulating metabolite of genistein with a plasma Cmax of 
0.03-343 µM at oral doses ranging from 0.01-50 mg/kg bw genistein, contributing to 40-82% 
of the total plasma genistein concentrations (genistein plus metabolites) (Figure 4.5A). G-7S 
and G-4´G-7S were predicted to be the second and the third most prevalent circulating 
metabolites of genistein with a plasma Cmax of 3.2-0.03 and 8.9-0.01 µM accounting for 35-
0.7 and 18-1.8% of the total plasma genistein concentrations at an oral dose up to 8 mg/kg bw 
genistein, respectively. At the higher doses, the relative contribution of these metabolites 
decreases, accompanied by a relative increase in the concentration of genistein aglycone, due 
to the saturation of sulfation reactions at high doses, resulting in a relative higher genistein 
aglycone concentrations in the systemic circulation. The plasma concentrations of genistein 
aglycone were predicted to be 0.0003-77 µM amounting to 0.5-17% of total plasma genistein 
concentrations at oral doses ranging from 0.01-50 mg/kg bw genistein. When consumed as 
the glycoside genistin, similar metabolic profiles of genistein in plasma were predicted, 
requiring approximately 1.3-fold higher oral dose levels (expressed in genistein equipvalents) 
to achieve similar plasma concentrations. This is due to the slow release of genistein aglycone 
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from its glycoside genistin that limits the amount of genistein being taken up resulting in 
lower genistein concentrations in plasma and tissues at equimolar dose levels. 
 
Figure 4.5 PBK model based prediction of dose-dependent plasma Cmax of genistein and its circulating 
metabolites at oral doses ranging from 0.01-50 mg/kg bw (A) genistein and (B) genistin (expressed in 
genistein equivalents). 
 
4.3.5 Translation of in vitro concentration-response data for genistein estrogenicity to in vivo 
dose-response curves 
 Using PBK model based reverse dosimetry, the in vitro concentration-response curves 
for estrogenic responses of genistein were translated to in vivo dose-response curves for the 
binding of genistein to human ERα and ERβ, genistein induced ERα and ERβ mediated gene 
expression, and genistein stimulated cell proliferation in ERα-positive breast cancer cells. 
Figure 4.6 depicts the translation of the in vitro concentration-response curves to in vivo dose-
response curves upon oral intake of genistein (for the curves obtained from these in vitro data 
for in vivo dose-response curves for oral intake of genistin see Figure S4.3 in the Supporting 
information). The steps to be taken in this in vitro to in vivo translation can be described as 
follows, using the binding activity of genistein to ERα as an example. In the first step all 
available in vitro data for the binding activity of genistein to human ERα were collected from 
literature [4-7]. This provides the curves presented in the left half of Figure 4.6, so Figure 
4.6A for in vitro ERD binding of genistein. Secondly, each ECin vitro was extrapolated to an 
ECin vivo in plasma taking into account the differences in protein and lipid concentration 
between the in vitro bioassays and the in vivo situations (see Section 4.2.6). The in vivo 
plasma concentrations thus obtained were then used as input in the PBK model that was used 
to predict the corresponding in vivo dose level. These predicted dose levels could then be used 
to define the in vivo dose-response curve plotting the respective dose levels against the 
responses detected in the in vitro bioassay. This provides the curves presented in the right half 
of Figure 4.6. This was followed by fitting the obtained in vivo dose-response curves to derive 
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the 95% lower and upper confidence limits of the in vivo dose-response curves. The obtained 
in vivo dose-response curve were subsequently used to estimate the BMD05 values for 
estrogenicity of genistein in humans.  
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Figure 4.6 Translation of in vitro estrogenic concentration-response curves for genistein dependent 
(A) binding to ERα [4-7], (B) binding to ERβ [4-6, 8], (C) ERα mediated gene expression in U2OS 
reporter gene assays [10, 19, 44, 45], (D) ERβ mediated gene expression in U2OS reporter gene assays 
[10, 19, 44, 45], and (E) ERD dependent proliferation of MCF-7 and T47D breast cancer cells [5-10, 
13, 19, 46-50], to in vivo human genistein dose-response curves using PBK model based reverse 
dosimetry based on plasma Cmax values of genistein aglycone. The dashed lines represent the 95% 
lower and upper confidence limits. 
 
In a similar way, the BMD05 values for in vivo estrogenicity were predicted using PBK model 
based reverse dosimetry to translate in vitro estrogenic response for ERE binding (Figure 
4.6B), induction of ERD and ERE mediated gene expression (Figure 4.6C and 4.6D), and ERa 
mediated cell proliferation (Figure 4.6E). 
From the results thus obtained it could be concluded that when consumed as genistein 
aglycone, the in vivo BMD05 values for ERα binding and induction of ERα mediated gene 
expression based on in vitro data were predicted to occur at an oral dose ranging from 0.06-
4.56 mg/kg bw genistein. The in vivo BMD05 values for ERβ binding and induction of ERβ 
mediated gene expression based on in vitro data were predicted to occur at an oral dose 
ranging from 0.06-0.33 mg/kg bw genistein. The in vivo BMD05 values for estrogenic 
response of genistein on ERα dependent cell proliferation based on in vitro data were 
predicted to occur at an oral dose ranging from 0.03-0.72 mg/kg bw genistein. When 
consumed as the glycoside genistin, the predicted in vivo BMD05 values for estrogenicity 
based on in vitro data are approximately 1.3-fold higher for all in vitro estrogenic endpoints 
as compared with the predicted in vivo BMD05 values for consumption as genistein aglycone. 
This is due to the slow release of genistein aglycone from its glycoside genistin that limits the 
amount of genistein being taken up and overall lower genistein concentrations in the plasma. 
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 The predicted in vivo BMD05 values for estrogenic responses based on the in vitro 
PBK approach were evaluated by comparing the predicted in vivo BMD05 values with the 
reported active [20-23] and inactive [2, 24-26] dose levels of genistein in studies on 
estrogenic responses in humans (Figure 4.7). The results indicate that the predicted BMD05 
values for genistein induced ER mediated gene expression are in line with reported active 
dose levels of genistein (0.23-8 mg/kg bw) in in vivo studies reporting induction of ER 
mediated gene expression in humans in different tissues [21-23]. Furthermore, an oral dose 
level of 0.54 mg/kg bw genistein reported to induce a weak estrogenic response of genistein 
in humans [20] also falls in the range of the predicted dose levels for estrogenicity of 
genistein. The overview presented in Figure 4.7 also reflects that studies reporting the absence 
of effects of genistein in human in vivo studies fall in the same range as the dose levels 
predicted and observed to have estrogenic responses. For example, Van der Velpen et al. [26] 
reported no significantly change in the expression ER target genes and gene sets related to ER 
signaling in peripheral blood mononuclear cells in human at an oral dose of 0.17 mg/kg bw 
genistein, which is not in line with the predicted dose levels for this estrogenic response in the 
present study. This result was also opposite to the result reported by the same authors at a 
comparable dose regimen in a similar study population of healthy postmenopausal women 
when analyzing expression of estrogen responsive genes in adipose tissue representing a more 
likely target tissue than peripheral blood mononuclear cells [23]. Genistein at dose levels 
between 0.08 and 1.43 mg/kg bw appeared also to not affect breast tissue density, normal 
breast epithelial cell proliferation, and breast cancer or epithelial cell proliferation in breast 
cancer patients [2, 24, 25], although these values all fall within the range of in vivo BMD05 
values predicted to be active based on ERD mediated in vitro cell proliferation (0.03-0.72 
mg/kg bw genistein). The reasons underlying these discrepancies remain to be elucidated, but 
may be related to the endpoint or target tissue studied or the study population (i.e. healthy 
women versus breast cancer patients). 
The PBK model-based predicted dose-response curves and in vivo BMD05 values 
derived from them also revealed that at a Western dietary intake of genistein amounting to 
0.003-0.01 mg/kg bw [11] the plasma Cmax of genistein aglycone would generally not be high 
enough to induce ER mediated gene expression or activities (Figure 4.7). At an Asian dietary 
and a supplementary intakes of genistein amounting to 0.21-0.71 [1] and 0.43-13 [11] mg/kg 
bw, the plasma Cmax of genistein aglycone would be high enough to exert estrogenic 
responses induced by both ERα and ERβ mediated pathways (Figure 4.7). 
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4.4 Discussion  
 The aim of the present study was to develop a PBK model that provides insight in the 
dose-dependent plasma concentration of genistein aglycone and its metabolites and enables 
prediction of the in vivo dose-response curves for estrogenicity of genistein and genistin in 
humans based on in vitro concentration-response curves. Evaluation of the PBK model 
obtained against reported data on plasma and urinary metabolic profiles of genistein revealed 
that the model could make adequate predictions with deviations that were limited from 1- to 
7-fold. The model predicted that G-7G. was the major plasma metabolite of genistein and that 
plasma concentrations of free genistein were predicted to be 0.0003-77 µM at oral doses 
ranging from 0.01-50 mg/kg bw genistein, amounting to 0.5-17 % of total plasma genistein. 
PBK model based predictions for genistin were overall quite similar with a major difference 
being 1.3-fold lower plasma concentration of free genistein at similar dose levels expressed in 
genistein equivalents. These differences were mainly due to the slow release of genistein 
aglycone from its glycoside genistin that limits the amount of genistein being taken up 
resulting in lower genistein concentrations in the plasma.  
Upon evaluation, the PBK model was used to convert available in vitro concentration-
response curves in bioassays detecting estrogenicity of genistein to in vivo dose-response 
curves by reverse dosimetry, in order to better understand in vivo estrogenic responses upon 
intake of genistein and genistin. The in vivo dose-response curves obtained were subsequently 
used to derive in vivo BMD05 dose levels of genistein and genistin, at which the plasma 
concentration of the genistein aglycone would be high enough to induce 5% estrogenic 
response. When consumed as genistein, the in vivo BMD05 values for binding and induction 
of ERα mediated gene expression based on in vitro data were predicted to be at oral doses 
ranging from 0.06-4.56 mg/kg bw genistein. For estrogen responses on ERβ, the predicted in 
vivo BMD05 values based on in vitro data were at oral dose ranging from 0.06-0.33 mg/kg bw 
genistein. The in vivo BMD05 values for ERα mediated cell proliferation were predicted to be 
at oral doses ranging from 0.03-0.72 mg/kg bw genistein. When consumed as genistin, the 
predicted in vivo BMD05 values were approximately 1.3-fold higher as compared to the 
predicted in vivo BMD05 values when consumed as genistein. This is due to the slow release 
of genistein aglycone from its glycoside genistin that limits the amount of genistein being 
taken up resulting in lower genistein concentrations in the plasma. The available in vitro data 
for ERα mediated cell proliferation show large variation (Figure 4.6E), which might be due to 
differences between the laboratories where the cells were cultivated as highlighted by 
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Osborne et al. [56] who reported that even though MFC-7 cell lines obtained from different 
laboratories have similar karyotype, they may have unique biological properties.  
Evaluation of the predicted in vivo BMD05 values obtaining from the PBK model 
based reverse dosimetry against the reported estrogenic responses of genistein in humans 
available in literature indicated that the prediction of in vivo BMD05 values based on in vitro 
genistein induced ER mediated estrogenicity are in line with the reported active dose levels 
for these estrogenic responses in humans in different tissues [21-23] (Figure 4.7). 
Furthermore, a dose level of 0.54 mg/kg bw genistein reported to induce weak estrogenic 
activity in humans also falls in the range of the predicted dose levels that exert estrogenic 
responses. Contradictory, some human intervention studies reported the absence of genistein 
induced ER mediated gene expression in peripheral blood mononuclear cells in healthy 
women [26] and no effect on breast tissue density, normal breast epithelial cell proliferation, 
and breast cancer or epithelial cell proliferation in breast cancer patients [2, 24, 25] at the 
predicted oral dose levels for estrogenic responses of genistein. The reasons underlying these 
discrepancies remain to be elucidated, but may be related to the endpoint or target tissue 
studied (adipose tissue or peripheral blood mononuclear cells) or the study population 
(healthy woman versus breast cancer patients). The difference in the expression of ERα and 
ERβ between in vitro bioassays and the target tissues studied in the breast cancer patients 
might result in a difference in the cellular response toward different xenoestrogens as the 
absolute concentration and ratio of ERα to ERβ within a tissue influence the cellular response 
toward different xenoestrogens [10]. Breast cancer cell lines like MCF-7 and T47D, present 
high expression of ERα and very low expression of ERβ [10, 57], reflecting what is likely for 
the tumors but not for healthy breast tissue [58]. Given these considerations, it would be of 
use that human intervention studies on the estrogenic activity of xenoestrogens should 
analyze and report the concentration and ratio of ERα and ERβ in the target tissue studied, 
and select a relevant surrogate tissue for the endpoint of interest in order to obtain a better 
accuracy of the interpretation of the estrogenic activity of the xenoestrogens in in vivo. 
Based on the predicted in vivo BMD05 values for estrogenic responses of genistein 
derived from in vitro data, the plasma Cmax of genistein aglycone at an Asian dietary and a 
supplementary intake of genistein amounting to 0.21-0.71 [1] and 0.43-13 [11] mg/kg bw 
genistein, would be high enough to induce estrogenic responses in vivo. A Western dietary 
intake of genistein amounting to 0.003-0.01 mg/kg bw genistein [11] would generally not be 
high enough to induce an estrogenic response.  
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Considering that the plasma concentration of genistein aglycone could be a key 
parameter determining estrogenic responses in vivo, any factors that influence this parameter 
may influence sensitivity to estrogenic responses between individual human subjects. Based 
on the sensitivity analysis, the plasma concentration of genistein aglycone is highly influent 
by the kinetic constants for formation of G-7G in the small intestine and liver and the kinetic 
constants for formation of G-7S in the liver at low oral dose (at dietary intake levels). As the 
dose increases (at supplementary intake levels), the kinetic constants for formation of G-7G in 
the liver become the most influential parameters that limit the plasma concentration of 
genistein aglycone. This indicates a saturation of metabolism in the small intestine and a 
saturation of the sulfation reactions at high oral dose. This analysis suggests that especially 
genetic and lifestyle factors influencing the expression and/or activity of conjugating enzymes 
may influence the plasma concentration of genistein aglycone between individual human 
subjects [59]. Aside from the interindividual human variation in conjugating metabolism in 
the small intestine and liver, metabolism of genistein at the site of action may also play a 
crucial role in the bioavailability of the free aglycone at the target tissues. In the case of breast 
tissue, expression of β-glucuronidases (enzymes that deconjugate glucuronidated metabolites 
to aglycone) [19] as well as of UDP-glucuronosyl transferases [60] may influence the local 
concentrations of the free aglycone. The relative conjugation and deconjugation activity in 
breast tissue is not well studied. In the present study, the defined PBK model does not yet 
include such tissue specific metabolism of genistein and its metabolites in possible target 
tissues such as breast tissue, because there is a lack of human data to perform and evaluate 
this simulation. For further refinement of the predictions by the PBK model based reverse 
dosimetry approach for estrogenic activity of genistein, interindividual human variation in 
conjugating enzymes and the possible role of intracellular metabolism at the site of action 
could be studied to a further extent. 
Overall, the present study shows that it is possible to predict dose dependent plasma 
concentrations of genistein and its metabolites and also at what dose levels estrogenic 
responses of genistein in humans can be expected, the latter by combining in vitro 
concentration-response curves with PBK model based reverse dosimetry, providing an in 
vitro-in silico approach to obtain insights in human dose-response curves without the need 
for human intervention studies.  
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Supporting information 
Table S4.1. Physiological parameters in human1 
Parameters Symbol Human 
Body weight (kg)  BW 70 
Tissue volumes (% body weight)    
     Lumen VLu 1.4 
     Small intestine VI 0.9 
     Liver VL 2.6 
     Kidney  VK 0.4 
     Rapidly perfused tissues VR 4.0 
     Slowly perfused tissues  VS 75.7 
     Blood VB 7.9 
Cardiac output (l/h) QC 310.4 
Blood flow to tissue (% cardiac output)    
     Small intestine QI 18.1 
     Liver (exclude portal vein) QL 4.6 
     Kidney  QK 17.5 
     Rapidly perfused tissues QR 29.8 
     Slowly perfused tissues  QS 30 
1Physiological parameters were obtained from Brown et al. [37].   
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Figure S4.1 Concentration-dependent formation of genistein mono-conjugates and genistein di-
conjugates with pooled mixed-gender human small intestine S9 (A – E) or liver S9 (F – I): genistein-
7-O-glucuronide (G-7G), genistein-4´-O-glucuronide (G-4´G), genistein-7-O-sulfate (G-7S), 
genistein-4´,7-O-diglucuronide (G-4´7diG), genistein-7-O-glucuronide-4´-O-sulfate (G-7G-4´S), and 
genistein-4´-O-glucuronide-7-O-sulfate (G-4´G-7S). 
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Figure S4.2 Sensitivity analysis of the predicted plasma Cmax of genistein aglycone at an oral dose of 
0.5 and 7 mg/kg bw (A) genistein and (B) genistin. The parameters stand for: BW = body weight, VTi 
= tissue volumn (Ti = I (small intestine), L (liver), BR (breast), R (rapidly perfused tissues), and S 
(slowly perfused tissues), QC = cardiac output, QTi= reginal blood flow through tissue, PTiG = 
partition coefficient of genistein in tissue, Ka = uptake rate constant of genistein, R =  blood to plasma 
ratio, S9PI = small intestinal S9 protein content, S9PL = liver S9 protein content, Vmax and Km = the 
maximum rate of formation and the Michaelis-Menten constant for formation of genistein-7-O-
glucuronide (G7G) and genistein-7-O-sulfate (G7S). 
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Figure S4.3 Translation of in vitro estrogenic concentration-response curves for genistein dependent 
(A) binding to ERα [4-7], (B) binding to ERβ [4-6, 8], (C) ERα mediated gene expression in U2OS 
reporter gene assays [10, 19, 44, 45], (D) ERβ mediated gene expression in U2OS reporter gene assays 
[10, 19, 44, 45], and (E) ERD dependent proliferation of MCF-7 and T47D breast cancer cells [5-10, 
13, 19, 46-50], to in vivo human genistin dose-response curves using PBK model based reverse 
dosimetry based on plasma Cmax values of genistein aglycone. The dashed lines represent the 95% 
lower and upper confidence limits. 
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Abstract 
 The present study aimed to develop a physiologically based kinetic (PBK) model that 
describes the absorption, distribution, metabolism, and excretion (ADME) of hesperidin in 
humans, enabling the translation of in vitro concentration-response curves to in vivo dose-
response curves. Hesperidin was predicted to mainly occur in the systemic circulation as 
different monoglucuronides. The plasma concentration of hesperidin aglycone (hesperetin) 
was predicted to be < 0.02 mg/l at an oral dose of 50 mg/kg bw. The developed PBK model 
allowed conversion of in vitro concentration-response curves for different effects to predict in 
vivo dose-response curves from which BMD05 (benchmark dose for 5% response) values 
could be derived. The BMD05 values for PKA inhibition ranged between 135-529 mg/kg bw 
hesperidin, and for inhibition of endothelial cell migration and PGE2 and NO production 
ranged between 2.19-44 mg/kg bw hesperidin. These values are in line with reported human 
oral dose levels showing in vivo effects by hesperidin and show that these effects may occur 
at a Western dietary and a supplementary intake of hesperidin. It is concluded that the 
developed PBK model adequately predicts ADME of hesperidin in humans, and allows to 
evaluate the human in vivo situation without the need for human intervention studies. 
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5.1 Introduction 
 Hesperidin (hesperetin-7-O-rutinoside) is the β-glycoside form of the flavanone 
hesperetin, and is almost exclusively present in citrus fruits, especially in orange [1]. Sweet 
orange juice contains 487-584 mg hesperidin/l [2]. Hesperetin aglycone has been suggested to 
exert various beneficial health effects against cancer and cardiovascular diseases [3]. 
Available in vitro data reported that not only hesperetin aglycone, but also its metabolites 
could interact with various key proteins such as protein kinases [4-7] and induce or reduce 
specific genes related to cellular functions [8-10]. During uptake following oral ingestion, 
hesperidin as well as its aglycone hesperetin are extensively metabolized in intestinal and 
liver tissue and as a result hesperetin is mostly present in the systemic circulation in 
conjugated forms [11-14]. This raises the question of whether any in vivo biological effect of 
hesperidin or hesperetin is due to the free aglycone hesperetin or perhaps, at least in part, to 
these metabolites. Little is known about physiologically relevant concentrations of hesperetin 
aglycone and its circulating metabolites in vivo. For a better translation of in vitro results to in 
vivo effects, it is of importance to gain more insight in absorption, distribution, metabolism, 
and excretion (ADME) of hesperidin upon ingestion, especially to obtain an indication of the 
physiologically relevant plasma concentrations of hesperetin aglycone and its circulating 
metabolites.  
Dietary intake of hesperidin in Western countries is estimated to be 193-562 mg 
hesperidin corresponding to 2.8-8 mg/kg bw for a 70 kg person [15]. Hesperidin is also 
available as a food supplement with daily doses of 500-2000 mg hesperidin corresponding to 
7-29 mg/kg bw for a 70 kg person [16]. Figure 5.1 illustrates possible metabolic pathways of 
dietary hesperidin in humans. Upon oral ingestion, hesperidin cannot be hydrolyzed by β-
glucosidases in the small intestine, but passes to the colon, where it can be hydrolyzed to 
hesperetin aglycone by colonic microbiota prior to its absorption into the colonic enterocyte 
[12]. The release of hesperetin is the rate-limited step for absorption [14]. In contrast to 
hesperidin, hesperetin aglycone can be directly taken up in the small intestinal enterocyte by 
passive diffusion [12]. The absorbed hesperetin is metabolized by UDP-glucuronosyl 
transferases and sulfotransferases in the colon, small intestine and liver at the 3´- and 7-
position [17]. Several metabolites of hesperetin including mono- and di-conjugates have been 
identified in human urine, indicating further conjugation of mono-conjugates [11, 13, 18].  
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Figure 5.1 Proposed metabolic pathways of dietary hesperidin and hesperetin in humans: glucuronide 
(G) and sulfate (S) [11, 13, 18].  
 
To better understand in vivo effects of dietary hesperidin, the present study aimed to 
develop a physiologically based kinetic (PBK) model for hesperidin to gain insight in dose-
dependent plasma concentrations of hesperetin aglycone and its metabolites. The developed 
PBK model was subsequently combined with in vitro effect data using a so-called reverse 
dosimetry approach, to determine whether in vitro effects of hesperetin and its metabolites 
can also be expected to occur in vivo, and if so, at what hesperidin oral dose levels.  
 
5.2 Materials and methods 
5.2.1 Materials 
 Pooled mixed-gender human tissue fractions including small intestine microsomes, 
small intestine cytosol, liver microsomes, liver cytosol, and individual male colon S9 were 
purchased from Xenotech (Lenexa, USA). Uridine 5′-diphosphoglucuronide acid (UDPGA, 
purity 98%), 3′-phosphoadenosine-5′-phosphosulfate (PAPS, purity 65%), Tris, alamethicin 
(from Trichoderma viride), D-saccharic acid 1,4-lactone monohydrate, and DL-dithiothreitol 
(DTT) were purchased from Sigma-Aldrich (Steinheim, Germany). Hydrochloric acid 
(fuming 37%), magnesium chloride, trifluoroacetic acid (for spectroscopy), potassium 
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dihydrogen phosphate, dipotassium hydrogen phosphate trihydrate, and DMSO were 
purchased from VWR International (Darmstadt, Germany). Acetonitrile (chromatography 
grade) was purchased from Biosolve (Valkenswaard, The Netherlands). Hesperetin (>99%) 
was purchased from Extrasynthese (Genay Cedex, France). Hesperetin-7-O-glucuronide (H-
7G) was purchased from Toronto Research Chemicals (Toronto, Canada). Hesperetin-3´-O-
glucuronide (H-3´G) and hesperetin-3´,7-O-diglucuronide (H-3´7diG) were purchased from 
Apollo Scientific (Cheshire, UK). Recombinant human cAMP-dependent protein kinase, 
catalytic subunit Cα (PKA-Cα), kemptide (LRRASLG), ATP, and staurosporine were 
purchased from Biaffin (Kassel, Germany). ADP was purchased from DiscoveRx 
(Birmingham, UK). 
 
5.2.2 Enzymatic conjugation of H-7G and H-3´G with pooled human tissue fractions 
 To obtain kinetic parameters for glucuronidation and sulfation of the mono-
conjugates, H-7G and H-3´G, to di-conjugates, required for the development of the PBK 
model, in vitro incubations with human tissue fractions were performed according to the 
methods described by Brand et al. [17] with some modifications. For glucuronidation, 100 µl 
incubation mixtures were prepared containing (final concentrations) 10 mM MgCl2, 10 mM 
UDPGA, 0.025 mg/ml alamethicin (added from a 200 times concentrated stock solution in 
methanol), and human tissue fractions in 50 mM Tris-HCl (pH 7.4). For incubations with H-
7G, a protein content of 0.6 mg/ml small intestine microsomes, 0.6 mg/ml liver microsomes, 
or 0.8 mg/ml colon S9 and incubation times of respectively 4, 2, or 6 h were applied. For 
incubations with H-3´G, a protein content of 0.3 mg/ml small intestine microsomes, 1.0 
mg/ml liver microsomes, or 0.8 mg/ml colon S9 and incubation times of respectively 4, 3, or 
6 h were applied. The reactions were initiated by adding H-7G or H-3´G from 200 times stock 
solutions in DMSO (final concentration of the substrate ranging from 5 to 400 µM) and were 
terminated by adding 25 µl of ice-cold acetonitrile. Blank incubations were carried out 
without UDPGA. Under the specified conditions, glucuronidation was linear with time and 
protein content (data not shown). 
 For sulfation, 100 µl incubation mixtures were prepared containing (final 
concentrations) 5 mM MgCl2, 0.1 mM PAPS, 20 mM saccharic acid-1,4-lactone (pH 7.4) as 
β-glucuronidase inhibitor [19], and human tissue fractions in 50 mM potassium phosphate 
(pH 7.4). For incubations with H-7G, a protein content of 0.8 mg/ml small intestine cytosol, 
liver cytosol, or colon S9 and incubation times of respectively 3, 4, or 6 h were applied. For 
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incubations with H-3´G, a protein content of 0.8 mg/ml small intestine cytosol, liver cytosol, 
or colon S9 and incubation times of 5, 4, or 6 h were applied. The reactions were initiated by 
adding H-7G or H-3´G from 200 times stock solutions in DMSO (final concentration of the 
substrate ranging from 5 to 400 µM) and were terminated by adding 25 µl of ice-cold 
acetonitrile. Blank incubations were carried out without PAPS. Under the specified 
conditions, sulfation was linear with time and protein content (data not shown). 
 
5.2.3 Identification and quantification of hesperetin metabolites 
 All incubation samples were analyzed on a UPLC-DAD system consisting of a Waters 
(Milford, MA) Acquity binary solvent manager, sample manager, and photodiode array 
detector, equipped with a Waters Acquity UPLC BEH C18 column (1.7 μm, 2.1 x 50 mm) at 
40°C column temperature. All samples were centrifuged at 15000 rpm for 5 min at 5ºC to 
precipitate proteins and 3.5 µl of the supernatant was subsequently analyzed using the UPLC-
DAD system. A gradient was applied consisting of nanopure water containing 0.1% 
trifluoroacetic acid (eluent A) and acetonitrile (eluent B) with a flow rate of 0.6 ml/min with 
the following profile: 0-25% B (0-1.0 min), 25% B (1.0-3.0 min), 25-50% B (3.0-4.0 min), 
50-80% B (4.0-4.5 min), 80% B (4.5-5.5 min), 80-0% B (5.5-6.0 min) and 0% B (6.0-7.0 
min).  
 The diglucuronide, H-3´7diG, formed by glucuronidation of either H-7G orH-3´G was 
identified by comparing its UV spectrum and retention time with those of commercially 
available H-3´7diG. The nature of the sulfate metabolite of H-7G and H-3´G was confirmed 
by treating the unterminated incubation samples with β-glucuronidase/sulfatase as there was 
no commercially reference compound available. To this end, 50 µl of unterminated incubation 
samples were added to 50 µl of 0.1 M sodium acetate (pH 5.0) containing 189 units/ml β-
glucuronidase and 1 unit/ml sulfatase. The reactions were carried out for 3 h at 37°C and were 
terminated by adding 25 µl of ice-cold acetonitrile.  
All formed metabolites were quantified by integrating the peak area at 280 nm and by 
using a calibration curve of H-3´7diG. The sulfate metabolites of H-7G and H-3´G were 
quantified based on the calibration curve of H-3´7diG, which was considered adequate 
because the sulfate metabolites of H-7G and H-3´G appeared to have the same UV-spectrum 
as H-3´7diG (data not shown) and were assumed to display a similar molar extinction 
coefficient.  
  
A PBK based reverse dosimetry for in vivo effective hesperidin dose levels 
 123 
The kinetic parameters including the apparent maximum velocity (Vmax(app)) and 
apparent Michaelis-Menten constant (Km(app)) for different conjugation reactions were 
determined by fitting the data to the standard Michaelis-Menten equation with GraphPad 
Prism version 5.04 (GraphPad Software, San Diego, California, USA). The Michaelis-Menten 
equation was as follows: 
v = Vmax*[S]/(Km+[S])        (1) 
where [S] represents the substrate concentration. The values of Vmax and Km were expressed in 
nmol/min/mg protein and µM, respectively.  
 
5.2.4 Protein kinase A (PKA) inhibition assay 
 A PKA inhibition assay was carried to measure the potency of hesperetin and its 
monoglucuronides H-7G and H-3´G to inhibit PKA as possible mechanism underlying some 
of its beneficial effects [20, 21]. The PKA inhibition assay was carried out based on the 
method described by Chen et al. [22] with some modifications. The incubation mixtures (final 
volume 50 µl) contained (final concentrations) 5 mM MgCl2, 0.5 mM DTT, 96 ng/ml PKA, 4 
µM kemptide (PKA substrate), hesperetin, H-7G, or H-3´G added from a 100 times 
concentrated stock in DMSO (final concentration ranging from 0 to 500 µM) in 50 mM Tris-
HCl (pH 7.4). The final concentration of DMSO was kept at 1% for all incubations. The 
positive control for PKA inhibition was carried out using 10 µM staurosporine (final 
concentration), a potent PKA inhibitor with a reported IC50 value of 0.015 µM [23]. The 
concentration of the substrate kemptide was selected to be close to the Km value of 4.3 µM at 
5 µM ATP for ADP induction (data not shown). The incubation mixtures were pre-incubated 
for 3 min at 30°C prior to initiation of the reactions by adding 5 µM ATP (final 
concentration). After 30 min, the reactions were terminated by adding 50 µl of ice-cold 
acetonitrile. Under the specified conditions, ADP formation was linear with time and protein 
content (data not shown). 
 All samples were centrifuged at 15000 rpm for 5 min at 5ºC to precipitate proteins and 
5 µl of the supernatants were subsequently analyzed on a UPLC-DAD system consisting of a 
Waters (Milford, MA) Acquity binary solvent manager, sample manager, and photodiode 
array detector, equipped with a Waters Acquity UPLC BEH Amide column (1.7 μm, 2.1 x 
100 mm) at 30°C column temperature. ADP, a byproduct from the phosphorylation reactions, 
was measured at isocratic conditions (70:30―acetonitrile:27 mM KH2PO4 in nanopure water 
pH 4.5) for 8 min and at a flow rate of 0.5 ml/min. With this method, ADP eluted at 2.02 min 
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based on the retention time and UV spectrum of commercially available ADP. Triplicate 
experiments were performed. The inhibitory potency of hesperetin and its monoglucuronides 
was determined based on comparison to the kinase activity in a blank incubation performed 
without added inhibitor containing 1% DMSO. The obtained concentration-response curves 
were translated to in vivo dose-response curve (Section 5.2.6) 
 
5.2.5 PBK model  
 A PBK model for dietary hesperidin was developed in a similar manner as previously 
described for the development of a PBK model for quercetin [24, 25]. The PBK model was 
defined to gain more insight in the ADME characteristics of hesperidin and the various 
metabolites formed in humans and to provide a method for conversion of in vitro effective 
concentrations to in vivo dose levels (Section 5.2.6). The model consisted of separate 
compartments for gastrointestinal (GI)-tract lumen, small intestine, colon, liver, kidney, 
rapidly perfused tissues (e.g. heart, lung, brain), and slowly perfused tissues (e.g. skin, 
muscle, bone) as shown in Figure 5.2A and 5.2B for the mono- and di-conjugates of 
hesperetin. Hesperidin was modeled to be hydrolyzed to its aglycone, hesperetin, by 
microbiota in the colon prior to absorption. The rate constants for hydrolytic clearance of 
hesperidin by the colonic microbiota, for excretion via urine and bile, and for the intestinal 
efflux back to the intestinal lumen were obtained by fitting with available experimental 
human data [11, 13, 14, 26-28], resulting in values of 0.1 l/h, 30 h-1, 30 h-1, and 0.2 l/h, 
respectively. The hesperetin that is released within the lumen was modelled to be absorbed 
into the colonic enterocyte by passive diffusion. The absorption rate constant for intestinal 
uptake of hesperetin is not available. An in situ intestinal perfusion study showed that the rate 
transfer of hesperetin to the intestinal wall was similar to that for genistein [29]. Based on this 
observation the absorption rate constant of hesperetin was assumed to be similar to that for 
genistein with a value of 5 h-1 [30]. To take the transit time of hesperidin from the stomach to 
the colon into account, the GI transit rates were included using the values reported by Kimura 
et al. [31] of 4.63, 2.44, 2.76 h-1 for stomach, jejunum, and ileum, respectively.  
 Hesperetin was modeled to primarily converse via glucuronidation and sulfation 
forming four different mono-conjugates at the 3´- and 7-position in small intestine, colon, and 
liver. Further conjugation of different mono-conjugates to di-conjugates was simulated only 
for the mono-glucuronides, H-7G and H-3´G, since these metabolites were estimated to be the 
major primary metabolites formed accounting for approximately 72% of the hesperidin dose  
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Figure 5.2 PBK model structure for formation of (A) mono- and (B) di-conjugates of hesperetin: 
KTi = transit rate constant for stomach (st), jejunum (je), and ileum (il), hesperetin-7-O-glucuronide 
(H-7G), hesperetin-3´-O-glucuronide (H-3´G), hesperetin-7-O-sulfate (H-7S), hesperetin-3´-O-
sulfate (H-3´S), hesperetin-3´,7-O-diglucuronide (H-diG), and hesperetin-monoglucuronide-O-
monosulfate (H-GS). 
 
based on model stimulation (data not shown). The kinetic constants for formation of mono-
conjugates of hesperetin in small intestine, colon, and liver were taken from the study of 
Brand et al. [17] (Section 5.3.2). The kinetic constants for further conjugations of H-7G and 
H-3´G via glucuronidation and sulfation were obtained in the present study from in vitro 
incubations with relevant human tissue fractions (Section 5.3.1-5.3.2). The Vmax values for 
formation of different mono- and di-conjugates were scaled to in vivo Vmax values using a 
small intestine protein yield of 20.6 mg microsomal protein and 18 mg cytosolic protein [32] 
and a liver protein yield of 40 mg microsomal protein and 80.7 mg cytosolic protein [33]. The 
scaling factors for colonic metabolism were calculated based on the methods described by van 
de Kerkhof et al. [34] using the reported data that the colonic tissue of male F344 rat with 24 
mg wet weight contained 3 mg protein [35]. A microsomal protein yield of 2.4 mg and a 
cytosol protein yield of 16.4 mg were calculated and used as scaling factors for colonic 
metabolism.  
 The physiological parameters for humans were obtained from literature [36] and are 
shown in Table 5.1. The tissue:blood partition coefficients of hesperetin and its metabolites  
Chapter 5 
 126 
Table 5.1 Physiological parameters in human1 
Parameters Symbol Human 
Body weight (kg)  BW 70 
Tissue volumes (% body weight)    
     GI-tract lumen VLu 1.40 
     Small intestine VSI 0.91 
     Colon VLI 0.53 
     Liver VL 2.60 
     Kidney  VK 0.4 
     Rapidly perfused tissues VR 3.46 
     Slowly perfused tissues  VS 7.57 
     Blood VB 7.9 
Cardiac output (l/h) QC 310.4 
Blood flow to tissue (% cardiac output)  
     Small intestine QSI 9.05 
     Colon QLI 9.05 
     Liver (exclude portal vein) QL 4.6 
     Kidney  QK 17.5 
     Rapidly perfused tissues QR 29.8 
     Slowly perfused tissues  QS 30 
1Physiological parameters were obtained from Brown et al. [36]. 
 
were estimated from log Kow according to the method described by DeJongh et al. [37] and 
are shown in Table 5.2. Log Kow values were estimated from Clog P values obtained from 
Scifinder (American Chemical Society, USA) and ChemBioDraw Ultra 14.0 (Cambridge-
Soft, USA). Conversion of blood concentrations of hesperetin and its metabolites to plasma 
concentrations was done by dividing the blood concentrations by a blood/plasma ratio (R). 
This value was calculated using the Simcyp prediction tool [38, 39] and amounted to 0.66. 
Mass balance equations were numerically integrated in Berkeley Madonna version 8.3.18 
(Macey and Oster, UC Berkeley, CA) using Rosenbrock’s algorithm for stiff system. Mass 
balance equations for hesperetin and its metabolites were similar to those previously 
described by Boonpawa et al. [24, 25] for PBK models of quercetin. Model performance was 
evaluated by comparing the predicted concentrations of urinary profiles to the reported data in 
human urine [1, 11, 40]. Further evaluation was done by performing a sensitivity analysis to 
assess key parameters that contribute substantially to the maximum concentration (Cmax) of 
hesperetin aglycone and its metabolites in plasma at an oral dose of 2.8 and 29 mg/kg bw 
hesperidin representing the lowest and the highest hesperidin intake from Western diet and 
food supplements [15, 16]. Normalized sensitivity coefficients (SCs) were calculated for the 
model parameters according to the method described by Evens and Andersen as follows [41]:  
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SC = (C′-C)/(P′-P) x (P/C)        (2) 
where C is the initial value of the model output, C′ is the modified value of the model output 
resulting from an increase in parameter value, P is the initial parameter value, and P′ is the 
modified parameter value, taking a 5% increase in its value.  
 
Table 5.2 Physico-chemical parameters of hesperetin and its metabolites in human 
Compound CLogP1 pKa2 fu3 R4 
 Tissue:blood partition coefficients5 
Small 
intestine Colon Liver Kidney 
Rapidly 
perfused 
tissue 
Slowly  
perfused  
tissue 
Hesperetin 1.94 7.49 0.12 0.72 2.32 2.32 2.32 1.38 1.38 1.73 
H-7G -0.18 2.74 0.31 0.61 0.63 0.63 0.63 0.80 0.80 0.77 
H-3'G 0.232 2.78 0.24 0.63 0.68 0.68 0.68 0.83 0.83 0.80 
H-7S 0.67 - - - 0.79 0.79 0.79 0.88 0.88 0.86 
H-3'S 1.90 -4.14 0.07 0.68 2.22 2.22 2.22 1.35 1.35 1.67 
H-3'7diG -1.83 - - - 0.59 0.59 0.59 0.76 0.76 0.75 
H-7G-3'S -1.01 - - - 0.60 0.60 0.60 0.75 0.75 0.75 
H-3'G-7S -1.25 - - - 0.60 0.60 0.60 0.75 0.75 0.75 
1 CLogP values for hesperetin and its metabolites were estimated using Scifinder (American Chemical Society, USA) and 
ChemBioDraw Ultra 14.0 (Cambridgesoft, USA). 
2 pKa values were obtained from Scifinder (American Chemical Society, USA). 
3 Fraction unbound (fu) was calculated using Simcyp prediction tools-fu [38]. 
4 Blood/plasma ratio (R) was calculated using Simcyp prediction tools-blood to plasma partition ratio [39]. 
5 Tissue:blood partition coefficients of hesperetin and its metabolites were calculated according to the method described by 
DeJongh et al. [37]. 
 
5.2.6 Translation of in vitro effect concentrations to in vivo dose levels 
 PBK based reverse dosimetry was carried out to convert in vitro effect concentrations 
to predicted in vivo dose levels of hesperidin based on the methods described by Louisse et al. 
[42] and Strikwold et al. [43]. To this end, biological effects of hesperetin and its metabolites 
derived from in vitro bioassays were used including inhibition of PKA activity by hesperetin 
and its monoglucuronides (Section 5.3.5) and available in vitro literature data for biological 
effects of hesperetin and its mono-conjugates on inhibition of cell migration induced by TNF-
α in human aortic endothelial cells (HAEC) [44] and inhibition by hesperetin metabolite 
mixtures (mainly mono-conjugates) on prostaglandin E2 (PGE2) and nitric oxide (NO) 
production induced by LPS in RAW 264.7 cells [7]. These in vitro data also showed that not 
only hesperetin aglycone, but also its metabolites could exert similar biological effects with 
comparable potency, indicating that in vivo effects of hesperidin may be due to the mixtures 
of hesperetin aglycone and its metabolites rather than an individual compound. Therefore, the 
in vitro effect concentrations obtained for hesperetin and its metabolites for the respective 
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effects were added up to obtain the in vitro mixture effect concentrations by using the concept 
of concentration addition as follows [45]:  
 EC𝑥𝑚𝑖𝑥 = (∑
𝑝𝑖
EC𝑥𝑖
𝑛
𝑖=1 )
−1
         (3) 
where EC𝑥𝑚𝑖𝑥 is the total concentration of the mixtures (in mg hesperetin equivalents/l) 
required to produce effect x, n is the number of mixture components, 𝑝𝑖 is the relative fraction 
of chemical i in the mixtures, and EC𝑥𝑖 is the concentration of i that produces effect x by 
itself. The 𝑝𝑖 values of hesperetin, H-3´G, H-7G, H-3´S, and H-7S in total plasma 
concentrations of hesperetin (aglycone and metabolites) were predicted to be 0.01, 0.54, 0.32, 
0.08, and 0.05 based on model stimulation (data not shown).  
Before making the in vitro to in vivo translation, it is of importance to realise that only 
the free fraction (fu) of the chemical will exert the effects which implies a correction is 
required for differences between protein and lipid binding in the in vitro bioassays and the in 
vivo situation. For the PKA inhibition activity that was performed using bioassay conditions 
without added protein and lipid, each nominal in vitro effect concentration (ECin vitro) was 
extrapolated to an in vivo effective concentration (ECin vivo) by dividing the ECin vitro with the 
fuin vitro assuming 100% availability in vitro. The average fuin vitro of 0.27 for H-7G and H-3´G 
was used as approximately 70% of the total plasma hesperetin concentration (aglycone and 
metabolites) was predicted to be H-7G and H-3´G (see Table 5.2 in Section 5.2.5 and Section 
5.3.4). For in vitro activities that were obtained from in vitro bioassays performed in the 
presence of culture medium with added protein and lipid, each ECin vitro was extrapolated to an 
ECin vivo according to the extrapolation rule of Gülden and Seibert as follows [46]: 
     EC𝑖𝑛 𝑣𝑖𝑣𝑜 =  EC𝑖𝑛 𝑣𝑖𝑡𝑟𝑜x [(1 − fb𝑖𝑛 𝑣𝑖𝑡𝑟𝑜)x
1+KOW x V′L,serum
1+KOW x V′L,𝑖𝑛 𝑣𝑖𝑡𝑟𝑜
+ fb𝑖𝑛 𝑣𝑖𝑡𝑟𝑜x 
Pserum
P𝑖𝑛 𝑣𝑖𝑡𝑟𝑜
] (4) 
where fbin vitro is the fraction of chemical bound to protein and lipid in culture medium, which 
is calculated from 1–fuin vitro. V´L is the lipid fraction in serum and in vitro. P is the protein 
content in serum and culture medium.  
For the extrapolation, in vivo albumin and lipid concentrations of 600 µM and 6 g/l 
were used [46]. The albumin and lipid concentrations in culture medium of the reported in 
vitro bioassays were estimated from the reported data by Gülden et al. [47] indicating that 5% 
foetal bovine serum contains 18 µM bovine serum albumin and 0.1 g/l lipid. The fuin vitro 
values of hesperetin and its metabolites in in vitro medium were estimated using the reported 
binding constant of hesperetin, H-7G, and H-3´G to human serum albumin of 8, 4, and 6 x 104 
M-1 [48] and a binding site number of 1.05 [49], assuming a similar binding constant for 
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human and bovine serum albumin. This assumption is based on the fact that genistein has 
been reported to have a similar binding constant for bovine and human serum albumin [50]. 
The in vivo effect concentration of the mixtures obtained was set equal to plasma Cmax of the 
mixtures in the PBK model to predict the corresponding oral dose level in humans. 
Subsequently, a dose-response curve was derived and used to estimate the benchmark dose 
for 5 % response (BMD05) based on the default benchmark response for continuous data [51]. 
The BMD05 values were estimated by fitting to the Hill model using Benchmark Dose 
Software version 2.6 (The Environment Protection Agency’s, USA). The BMD05 values 
obtained were evaluated against reported active human data on anti-atherogenic and anti-
inflammatory activity upon oral intake of hesperidin [52-54].  
 
5.3 Results 
5.3.1 Enzymatic conjugation of H-7G and H-3´G in incubations with human tissue fractions 
 Analysis of glucuronidation incubations of H-7G and H-3´G containing pooled human 
tissue fractions indicated that H-7G was further glucuronidated by human small intestine and 
liver microsomes, revealing one metabolite that is formed. Whereas H-3´G was only further 
glucuronidated by human liver microsomes, resulting in the same metabolite as observed 
from the incubations with H-7G. This metabolite co-eluted with and showed similar spectral 
characteristics as commercially available H-3´7diG and could thus be identified as H-3´7diG. 
Under the conditions of the present study no glucuronidated metabolites of H-7G or H-3´G 
were formed in incubations containing human colon S9.  
Analysis of sulfation incubations of H-7G and H-3´G containing pooled human tissue 
fractions revealed that H-7G was further sulfated by human small intestine and liver cytosol, 
while H-3´G was only further sulfated by human small intestine cytosol. The metabolites 
formed in the sulfation incubations with H-7G and H-3´G with a retention time of 1.3 and 1.4 
min were identified by treating the unterminated samples with β-glucuronidase/sulfatase 
resulting in a disappearance of the respect peak and a concomitant equivalent increase in the 
peak area of hesperetin aglycone (data not shown). These results confirm that the metabolites 
were most likely H-7G-3´S and H-3´G-7S because conjugation of the flavonoid likely occurs 
at available free OH moieties [55] and the 5-position is not available for conjugation due to 
intramolecular hydrogen bonding with the carbonyl group at the C-4 position [56]. Under the 
conditions of the present study no sulfated metabolites of H-7G and H-3´G formed in 
incubations with human colon S9 were detected.  
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5.3.2 Kinetic constants for formation of mono- and di-conjugates of hesperetin 
 The concentration-dependent rates of glucuronidation and sulfation of H-7G and H-
3´G by human tissue fractions are shown in Figure S5.1 in the Supporting information. The 
kinetic constants derived from these results and the kinetic constants for formation of 
different hesperetin mono-conjugates obtained from Brand et al. [17] are summarized in 
Table 5.3. The results indicate that small intestine and liver had similar catalytic efficiency for 
metabolism of hesperetin with the total catalytic efficiency amounting to approximately 2.5 
l/h/g tissue for both tissues, followed by colon with a total catalytic efficiency of 0.17 l/h/g 
tissue. Small intestine and liver tissues showed a difference in the type of conjugation of 
hesperetin as small intestine appeared to be especially effective in formation of H-3´S, 
whereas liver was more effective in converting hesperetin into H-3´G. The formation of di-
conjugates was more than 100-fold less efficient than the formation of the respective mono-
conjugates due to a decrease in Vmax and an increase in Km values. Colon could only covert 
hesperetin to mono-conjugates as there was no formation of di-conjugates detected in 
incubations with this tissue fraction. 
 
5.3.3 PBK model development and evaluation 
 To define the PBK model for hesperidin, kinetic parameters for formation of different 
hesperetin mono- and di-conjugates were obtained from in vitro incubations. While the 
hydrolytic clearance of hesperidin by gut microbiota and the kinetic parameters for excretion 
via urine, bile, and intestinal efflux back to intestinal lumen were obtained by fitting the 
predicted dose-dependent plasma concentrations of total hesperetin concentrations with 
available experimental human data in plasma [11, 13, 14, 26-28], resulting in values of 0.1 
l/h, 30 h-1, 30 h-1, and 0.2 l/h, respectively. Subsequently the model thus defined was used to 
predict the total hesperetin plasma kinetics as shown in Figure 5.3. The model predicted 
plasma Cmax, AUC and Tmax of total hesperetin within 1- to 6-fold deviation from the reported 
human data.  
The performance of the defined PBK model was evaluated to a further extent by 
comparing the predicted concentrations of hesperetin metabolites excreted in urine to the 
reported literature data for hesperetin metabolites in human urine [1, 11, 40]. Figure 5.4 
shows the results of this comparison revealing that the model adequately predicted the urinary 
profiles of different mono- and di-conjugates of hesperetin within 1- to 7-fold deviation from 
the reported urinary profiles in humans [1, 11, 40].  
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Figure 5.3 Observed and PBK model-predicted (A) plasma Cmax, (B) plasma AUC, and (C) plasma 
Tmax of total hesperetin (aglycone and metabolites) in humans at different dose levels as indicated by 
the x-axis labels [11, 13, 14, 26-28].
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Figure 5.4 Model evaluation by comparing the PBK model-predicted urinary profiles with those 
reported by (A) Mullen et al. at 0.73 mg/kg bw hesperidin [11], (B) Bredsdorff et al. at 0.93 mg/kg bw 
hesperidin [40], (C) Bredsdorff et al. at 2.92 mg/kg bw hesperidin [40], and (D) Pereira-Caro et al. at 
2.87 mg/kg bw hesperidin [1]. 
 
To further evaluate the performance of the defined model, a sensitivity analysis was 
performed to assess key parameters that influence the predicted plasma Cmax of hesperetin 
aglycone and its metabolites at an oral dose of 2.8 and 29 mg/kg bw hesperidin representing 
the lowest and the highest hesperidin intake originating from the Western diet and from food 
supplements, respectively [15, 16]. Only parameters that had a normalized sensitivity 
coefficient higher than 0.1 (in absolute value), are shown in Figure S5.2 in the Supporting 
information. The results reveal that the normalized sensitivity coefficients of most of the PBK 
model parameters were not dose-dependent. The predicted plasma Cmax of hesperetin aglycone 
and its metabolites are mainly influenced by the body weight, the volume of the GI-tract 
lumen and liver, the reginal blood flow through the small intestine and colon, the blood to 
plasma ratio, and the biliary excretion (expressing normalized sensitivity coefficients between 
0.5 to 2.6 in absolute value). The parameters that influenced the formation of hesperetin 
mono-conjugates in the colon and liver, including the microsomal and cytosol protein 
contents in the colon and liver and the kinetic constants for formation of mono-conjugates, are 
also influential parameters for the predicted plasma Cmax of hesperetin aglycone and its 
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metabolites (expressing normalized sensitivity coefficients between 0.2 to 0.9 in absolute 
value). In addition, the kinetic constants for formation of H-3´7diG and H-7G-3´S in the liver 
and the kinetic constants for formation of H-3´G-7S and the cytosol protein content in the 
small intestine are also influential parameters for the predicted plasma Cmax of its respective 
di-conjugates (expressing normalized sensitivity coefficients between 0.3 to 2.0 in absolute 
value).  
 
5.3.4 PBK model predictions of metabolic plasma profiles of hesperidin 
 The PBK model was used to predict metabolic plasma profiles of hesperidin at 
different dose levels. Figure 5.5 shows the predicted dose-dependent plasma concentrations of 
hesperetin aglycone and its metabolites (expressed in mg hesperetin equivalents/l) at oral 
doses ranging from 0.01-50 mg/kg bw hesperidin, revealing that the conjugation pattern of the 
circulating metabolites does not change with the dose. At all oral doses, H-3´G and H-7G 
were predicted to be the major circulating metabolites together accounting for approximately 
70% of the total plasma hesperetin concentration (aglycone and metabolites), followed by H-
7G-3´S, H-3´S, and H-3´7diG accounting for approximately 15, 6, and 4% of the total plasma 
hesperetin concentration, respectively. Hesperetin aglycone was present at a low 
concentration below 0.02 mg/l at a dose of 50 mg/kg bw and accounted for approximately 
0.5% of the total plasma hesperetin concentration at all oral doses.  
 
 
Figure 5.5 PBK model-based prediction of the dose-dependent plasma Cmax of hesperetin aglycone 
and its metabolites at oral doses ranging from 0.01-50 mg/kg bw hesperidin: hesperetin (H), 
glucuronide (G), and sulfate (S). 
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5.3.5 Translation of in vitro effect concentrations to in vivo effective dose levels in human 
 In the next step the PBK model was used for reverse dosimetry converting in vitro 
effective concentrations to in vivo effective dose levels of hesperidin for selected endpoints. 
To this end, in vitro concentration-response curves were defined in first instance for PKA 
inhibition by hesperetin, H-3´G, and H-7G in the present study. The results obtained reveal 
that hesperetin and also its major circulating metabolites, H-3´G, and H-7G, all inhibit PKA 
activity in vitro in a concentration-dependent manner as shown in the left panel of Figure 
5.6A. This figure, reflecting the in vitro concentration-response curves for PKA inhibition by 
hesperetin, H-3´G, and H-7G (left panel of Figure 5.6A), also depicts as a first approximation 
the concentration-response curves for PKA inhibition by combined exposure to the mixtures 
of hesperetin, H-3´G, and H-7G, assuming the three compounds to be present at the ratios 
predicted to be present in plasma, and using the concentration-response curves for the 
individual compounds, expressing the concentration of the mixture in mg hesperetin 
equivalents/l. Figure 5.6B to 5.6D (left panels) presents similar in vitro data for the effect of 
hesperetin and its conjugates on other endpoints including effects on inhibition of cell 
migration induced by TNF-α (Figure 5.6B left panel), inhibition of PGE2 production induced 
by LPS (Figure 5.6C left panel), and inhibition of NO production induced by LPS (Figure 
5.6D left panel). The latter two Figures (5.6C and 5.6D left panel) only present the in vitro 
concentration-response curves for the mixtures (mainly mono-conjugates) as in vitro studies 
for these endpoints were carried out with mixtures of hesperetin metabolites obtained from rat 
plasma exposed to 50 mg/kg bw hesperetin [7]. The major circulating metabolites of 
hesperetin in rat exposed to 50 mg/kg bw hesperidin were reported to be monoglucuronides 
followed by mixed conjugates containing glucuronic acid and sulfate moieties [57], which is 
comparable to the predicted metabolic plasma profiles in humans (Section 5.3.4). In a 
subsequent step, these in vitro concentration-response curves were translated into in vivo 
dose-response curves using a PBK model based reverse dosimetry. To this end, each in vitro 
mixture concentration was extrapolated to an in vivo mixtures concentration in plasma by 
taking into account the differences in protein and lipid concentration between the in vitro 
bioassays and the in vivo situations (see Section 5.2.6). The plasma in vivo concentrations of 
the mixtures of hesperetin and its metabolites thus obtained were used as input in the PBK 
model to predict the in vivo dose levels of hesperidin required to achieve these plasma 
concentrations, deriving the in vivo dose-response curve. Figure 5.6 (right panels) depicts the 
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in vivo dose-response curves obtained. The figures also present the 95% lower and upper 
confidence limits of the predicted in vivo dose-response curves. Subsequently, the obtained in 
vivo dose-response curves were used to estimate the BMD05 values for the respective 
biological effect of hesperidin in humans. In this way the BMD05 values for several biological 
effects including inhibition of PKA, inhibition of cell migration induced by TNF-α, inhibition 
of PGE2 production induced by LPS, and inhibition of NO production induced by LPS, were 
predicted using a PBK model based reverse dosimetry. 
  The in vivo BMD05 values for PKA inhibition were predicted to occur at oral doses 
ranging from 135-539 mg/kg bw hesperidin. The in vivo BMD05 values for inhibition of 
endothelial cell migration were predicted to occur at oral doses ranging from 4.54-24 mg/kg 
bw hesperidin. The in vivo BMD05 values for inhibition of PGE2 production were predicted to 
occur at oral doses ranging from 2.19-4.10 mg/kg bw hesperidin. And the in vivo BMD05 
values for inhibition of NO production were predicted to occur at oral doses ranging from 17-
44 mg/kg bw hesperidin. 
 The predicted in vivo BMD05 values for effects of hesperetin and its metabolites on 
PKA activity, endothelial cell migration, PGE2 production, and NO production based on the 
in vitro PBK approach were evaluated by comparing the predicted in vivo BMD05 values with 
the reported active dose levels of hesperidin on anti-atherogenic and anti-inflammatory effects 
in healthy humans [52-54] as PKA regulates several cellular functions [21], endothelial cell 
migration is an initiated bioprocess for atherosclerosis [44], and PGE2 and NO are 
inflammatory biomarkers [7]. The results as shown in Figure 5.7 reveal that the predicted in 
vivo BMD05 values for inhibition of endothelial cell migration and PGE2 production are in line 
with the active dose levels of hesperidin (4.2 mg/kg bw) in human intervention studies 
reported to result in improved endothelial function and decreased levels of inflammatory 
biomarkers (i.e. PGE2 and CRP) [52-54]. The predicted in vivo BMD05 values for inhibition of 
NO production are 4- to 10-fold higher than the reported active dose levels of hesperidin in 
humans [52-54]. In the case of PKA activity, the predicted in vivo BMD05 values are more 
than 32-fold higher than the reported active dose levels of hesperidin on anti-atherogenic and 
anti-inflammatory effects of hesperidin in humans [52-54]. 
 The PBK model-based predicted dose-response curves and in vivo BMD05 values 
derived from them also indicate that at a Western dietary and a supplementary intake of 
hesperidin amounting to 2.8-8 and 7-29 mg/kg bw, respetively [15, 16], the plasma Cmax of 
total hesperetin would be high enough to inhibit endothelial cell migration, PGE2 production, 
and NO production (Figure 5.7).  
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Figure 5.6 Translation of in vitro concentration-response curves for A) inhibition of PKA activity 
(present study), B) inhibition of TNF-D induced endothelial cell migration [44], C) inhibition of LPS 
induced prostaglandin E2 (PGE2) production [7], and D) inhibition of LPS induced nitric oxide (NO) 
production [7] to human hesperidin dose-response curves using PBK model based reverse dosimetry 
based on the plasma Cmax of total hesperetin (aglycone and metabolites). For inhibition of LPS induced 
PGE2 and NO production, in vitro studies for these endpoints were carried out with mixtures of 
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hesperetin metabolites, not individual metabolites, and thus only the mixtures concentration-response 
curves are presented (C and D left panel) [7]. 
 
Figure 5.7 Comparison of the predicted in vivo BMD05 values of hesperidin derived from in vitro 
effects of the mixtures of hesperetin and its metabolites on inhibition of PKA activity (present study), 
endothelial cell migration [44], prostaglandin E2 (PGE2) production [7], and nitric oxide (NO) 
production [7] with the reported active dose levels on anti-atherogenic and anti-inflammatory effects 
of hesperidin in humans [52-54] and with a Western dietary [15] and a supplementary [16] intake of 
hesperidin.  
 
5.4 Discussion 
 The aim of the present study was to develop a physiologically based kinetic (PBK) 
model describing the ADME of hesperidin in humans to obtain insight in dose-dependent 
plasma concentrations of hesperetin aglycone and its circulating metabolites and to 
subsequently combine the developed PBK model with in vitro effect concentrations to 
determine whether and if so at what oral dose levels the in vitro effects of hesperetin and its 
metabolites may actually occur in vivo. Evaluation of the PBK model developed against 
literature reported data on plasma kinetics and urinary profiles of hesperidin reveals that the 
model adequately predicted plasma kinetics of total hesperetin and urinary profiles of 
hesperidin within 1- to 7- fold deviation. The model developed was used to predict the dose-
dependent plasma concentrations of hesperetin aglycone as well as the type of circulating 
metabolites. The results revealed that the metabolic plasma profiles of hesperidin appear 
independent of the dose, because similar circulating metabolite patterns of hesperetin were 
predicted at all dose levels from 0.01 to 50 mg/kg bw hesperidin. The model predicted that H-
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3´G and H-7G were the major circulating metabolites of hesperidin and that the plasma 
concentrations of hesperetin aglycone were limited and predicted to be lower than 0.02 mg/l 
even at an oral dose of 50 mg/kg bw hesperidin. This implies that in vivo effects of 
hesperidin, would probably have to be at least in part ascribed to hesperetin metabolites 
including H-3´G and H-7G.  
Given that hesperidin was predicted to be present in the systemic circulation mainly in 
the form of conjugated metabolites, it is crucial to understand the biological activity of these 
conjugates in order to gain more insight in possible in vivo effects of hesperidin. The in vitro 
data on PKA inhibition of hesperetin and its major circulating metabolites H-3´G and H-7G 
showed that the two metabolites were at least equally active in inhibition of PKA as 
hesperetin aglycone. Yang et al. reported that at the same concentration mixtures of 
hesperetin metabolites (mainly mono-conjugates) exhibited approximately 2-fold higher 
inhibition of PGE2 and NO production as compared with hesperetin aglycone in LPS-
stimulated RAW 264.7 [7]. Hesperetin mono-conjugates were also reported to exert inhibition 
activity on cell migration in TNF-α treated HAEC with approximately 1.5-fold lower potency 
than hesperetin aglycone at the same concentration [44]. Overall, this points out that 
conjugation does not necessary result in loss or reduction of the biological activity and in vivo 
effects of hesperidin are at least in part due to its metabolites. Based on these results, it was 
decided that in a first approximation the concentrations of hesperetin and its metabolites could 
be added up for evaluation of how the in vitro effect concentrations translate into the in vivo 
hesperidin dose levels. 
 The PBK model developed provided a unique tool to gain more insight in how the in 
vitro concentrations translate into the in vivo dose levels of hesperidin by applying a PBK 
model based reverse dosimetry. The in vivo dose-response curves obtained were used to 
derive the BMD05 values at which plasma concentrations of hesperetin together with its 
metabolites would be high enough to exert 5% response for inhibition of PKA activity, 
inhibition of TNF-D induced endothelial cell migration, inhibition of LPS induced PGE2 
production, and inhibition of LPS induced NO production. The predicted in vivo BMD05 
values for PKA inhibition ranged from 135-539 mg/kg bw hesperidin. The predicted in vivo 
BMD05 values for inhibition of TNF-D induced endothelial cell migration ranged from 4.54-
24 mg/kg bw hesperidin. The predicted in vivo BMD05 values for inhibition of LPS induced 
PGE2 production ranged from 2.19-4.10 mg/kg bw hesperidin. And in the case of LPS 
induced NO production, the in vivo BMD05 values for inhibition ranged from 17-44 mg/kg bw 
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hesperidin. These predictions were evaluated against the reported active dose levels of 
hesperidin for anti-atherogenic and anti-inflammatory effect as reported in humans [52-54]. 
The predicted in vivo BMD05 values for inhibition of endothelial cell migration and PGE2 
production are in line with the reported active dose levels of hesperidin in humans for 
improving endothelial function and decreasing levels of inflammatory biomarkers (i.e. PGE2 
and CRP) [52-54]. The predicted in vivo BMD05 values for inhibition of NO production are 4- 
to 10-fold higher than the reported active dose levels of hesperidin in humans [52-54]. The 
predicted in vivo BMD05 values for PKA inhibition are more than 32-fold higher than the 
reported active dose levels for anti-atherogenic and anti-inflammatory effects of hesperidin in 
humans [52-54]. This might imply that inhibition of PKA activity (a regulator of several 
cellular functions [21]) is not a major mechanism for anti-atherogenic and anti-inflammatory 
action of hesperidin in vivo.  
 Based on the predicted in vivo BMD05 values for hesperidin derived from in vitro 
concentration-response curves for hesperidin mediated inhibition of PKA activity, TNF-D 
induced endothelial cell migration, and LPS induced production of PGE2 and NO, it can also 
be concluded that the plasma Cmax of total hesperetin (aglycone and metabolites) at a Western 
dietary and a supplementary intake amounting to 2.8-8 [15] and 7-29 [16] mg/kg bw 
hesperidin, would be high enough to induce these effects on endothelial cell migration and 
pro-inflammatory molecules in vivo. For the inhibition of PKA activity, the plasma Cmax of 
total hesperetin upon these dietary or supplementary intakes would generally not be high 
enough to induce a similar effect on PKA activity in vivo.  
  Overall, the PBK model developed in the present study adequately predicted ADME 
of hesperidin in humans. The model obtained was also shown to be of use to translate in vitro 
results on the biological effects of hesperetin aglycone and its metabolites to the human in 
vivo situation and evaluate the possible occurrence of in vivo effects without the need for 
human intervention studies.  
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6.1 Introduction and main findings  
Flavonoids are polyphenolic compounds abundantly present in fruits and vegetables 
mainly as β-glycosides [1]. Flavonoids have been proposed to exert beneficial health effects 
against various degenerative conditions including cancer [2], cardiovascular diseases [3], 
obesity and diabetes [4, 5], as well as neurodegenerative disorders [6, 7]. Possible modes of 
action of flavonoids underlying these beneficial health effects include their activity as ligands 
for various receptors, kinases, enzymes, and/or transport proteins, and these activities have 
often been studied using in vitro test systems with high concentrations of the flavonoid 
aglycones [8-10]. However, the question has been raised on how relevant these in vitro results 
are for the in vivo situation as bioavailability of flavonoid aglycones in vivo would be limited 
[9]. Upon ingestion, flavonoid glycosides are deconjugated and upon absorption from the 
gastrointestinal tract flavonoid aglycones are extensively metabolized, mainly by UDP-
glucuronosyl transferases (UGTs), sulfotransferases (SULTs), and catechol O-
methyltransferases (COMTs) in both intestine and liver cells [11]. As a result, flavonoids are 
mainly present in their conjugated forms in the systemic circulation [12].  
Conjugation of flavonoids may affect their biological activities depending on the type 
and position of the conjugation [10]. To better understand in vivo effects of flavonoids, it is of 
importance to gain insight in absorption, distribution, metabolism, and excretion (ADME) of 
flavonoids in vivo. Therefore, the aim of the present PhD project was to gain quantitative insight 
in dose-dependent plasma concentrations of flavonoid aglycones and their metabolites using 
physiologically based kinetic (PBK) modeling and to use these PBK models to contribute to 
the better understanding of whether the in vitro effect concentrations are relevant for the in vivo 
situation upon realistic dose levels and thus whether these dose levels would actually result in 
biological effects of flavonoids in vivo. The present PhD project focused on the flavonoids 
quercetin, genistein and hesperetin as model compounds. 
In Chapter 2, a PBK model was built for quercetin and its glycoside quercetin-4´-O-
glucoside to predict dose-dependent plasma concentration of quercetin aglycone and to 
tentatively identify the nature and the conjugation position and concentrations of the circulating 
metabolites in rats. Model development was performed by integrating kinetic parameters 
obtained from in vitro incubations with relevant rat tissue fractions and by fitting kinetic 
parameters to literature available in vivo data. The model adequately predicted plasma 
concentrations of different metabolites of quercetin within 1.9- to 3-fold deviation as compared 
with literature reported plasma concentrations of these metabolites in rats exposed to quercetin-
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4´-O-glucoside. The model predictions revealed that bioavailability of quercetin aglycone is 
very low ranging from 0.004-0.1% of the dose at different oral doses of quercetin or quercetin-
4´-O-glucoside. Glucuronidation appeared to be the major pathway responsible for the limited 
bioavailability of quercetin aglycone, with 95-99% of the dose predicted to be converted to 
monoglucuronides within 1.5-2.5 h. Due to the fast metabolic conversion of monoglucuronides, 
these metabolites were subjected to further conjugation forming di- and tri-conjugates, and 
these were predicted to be the major circulating forms of quercetin in rats. The major circulating 
metabolites of quercetin in rats, at normal dietary estimated daily human intake levels, were 
tentatively identified to be quercetin-7-O-glucuronide-3´-O-sulfate-4´-O-methylate, followed 
by quercetin-7, 4´-O-diglucuronide, and quercetin-7-O-glucuronide-3´-O-sulfate. 
 In Chapter 3, the PBK models for quercetin and quercetin-4´-O-glucoside developed 
in rats were used as a platform to build a PBK model for quercetin in humans in order to define 
species differences in ADME of quercetin between humans and rats. First, a PBK model for an 
average human was developed, which was subsequently extended to 20 different individual 
human PBK models to assess interindividual human variation. The kinetic parameters for 
metabolic conversion of quercetin were obtained from in vitro incubations with pooled (for the 
average human model) and 20 individual human tissue fractions (for individual human models). 
The models adequately predicted metabolic profiles of quercetin in plasma and urine within 1- 
to 7-fold deviation from reported data in humans. The PBK model predicted that quercetin-3´-
O-glucuronide is the major circulating metabolite in 19 out of the 20 individuals, indicating 
limited interindividual human variation. Significant species differences occurred in the major 
circulating metabolites as quercetin was predicted to be mainly present as mono-glucuronides 
in human plasma but as di- and tri-conjugates in rat plasma, suggesting that rat may not be an 
adequate model to study effects of quercetin in humans.  
For many flavonoids other than quercetin, in vivo kinetic data are still lacking, and 
therefore the developed PBK models for quercetin formed a basis for the development of 
similar models for other relevant dietary flavonoids such as genistein (soy-based isoflavone) 
and hesperetin (citrus-based flavanone) in Chapter 4 and Chapter 5, respectively. Chapter 4 
describes the development of a PBK model for genistein and its glycoside genistin to gain 
insight in dose-dependent plasma concentrations of genistein aglycone and its metabolites in 
humans. Given that the in vivo estrogenic responses of the soy isoflavones genistein and 
genistin are still under debate, the PBK model obtained for genistein and genistin was used to 
facilitate the translation of in vitro estrogenic concentration-response curves reported in 
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literature to in vivo dose-response curves by applying PBK model based reverse dosimetry. It 
is of importance to note that especially genistein aglycone, and not its metabolites, is likely 
responsible for estrogenic responses in vivo as genistein conjugates tested so far, including 
genistein-7-O-glucuronide, genistein-7-O-sulfate, and genistein-4´-O-sulfate are inactive in 
assays for estrogenicity [13, 14]. The developed PBK model adequately predicted metabolic 
profiles of genistein in plasma and urine within 1- to 7-fold deviation from the reported data in 
humans. The PBK model predicted that genistein-7-O-glucuronide is the major circulating 
metabolite of genistein in human plasma and that plasma concentrations of genistein aglycone 
are generally low, amounting to 0.5-17% of total plasma genistein (aglycone and metabolites) 
at oral doses ranging from 0.01-50 mg/kg bw genistein. When consumed as the glycoside 
genistin, similar metabolic profiles of genistein in plasma were predicted, requiring 
approximately 1.3-fold higher oral dose levels (expressed in genistein equivalents) to achieve 
similar plasma concentrations. This can be explained by the slow release of genistein aglycone 
from its glycoside genistin that limits the amount of genistein being taken up resulting in lower 
genistein concentrations in plasma and tissues at equimolar dose levels. Using the PBK model 
obtained to convert in vitro concentration-response curves for estrogenic activity of genistein 
to in vivo dose-response curves, in vivo benchmark dose for 5% response (BMD05) values for 
estrogenicity between 0.03-4.56 mg/kg bw genistein were predicted. For genistin, these values 
were 1.3-fold higher due to the slow release of genistein aglycone from its glycoside genistin 
that limits the amount of genistein being taken up resulting in lower genistein concentrations in 
the plasma. These values are in line with the reported in vivo dose levels of genistein that appear 
to induce estrogenic responses in humans. The predicted in vivo BMD05 values for genistein 
estrogenicity also revealed that at an Asian dietary and a supplementary intake of genistein 
amounting to 0.21-0.71 [15] and 0.43-13 [16] mg/kg bw estrogenic responses can be expected, 
while intake resulting from a Western diet amounting to 0.003-0.01 mg/kg bw [16] may not be 
effective. Overall, this study shows how plasma concentrations of genistein and its metabolites 
and estrogenic dose levels of genistein in humans can be predicted by combining in vitro 
concentration-response curves with PBK model based reverse dosimetry, eliminating the need 
for human intervention studies. 
In Chapter 5, the PBK models for quercetin were further used as a platform to build a 
PBK model for hesperidin, a glycoside and natural existing form of the flavanone hesperetin 
known to be present in citrus fruits, to gain more insight in dose-dependent plasma 
concentrations of hesperetin aglycone and its metabolites in humans. Also in this case, the PBK 
model obtained was used to facilitate translation of in vitro concentration-response curves for 
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effects of hesperetin and its metabolites on protein kinase A (PKA) activity and other biological 
activities including effects on TNF-a induced endothelial cell migration, LPS induced 
prostaglandin E2 (PGE2) production, and LPS induced nitric oxide (NO) production available 
in literature, to in vivo dose-response curves of hesperidin in humans by applying PBK-model 
based reverse dosimetry. The PBK model obtained adequately predicted plasma kinetics of total 
hesperetin (aglycone and metabolites) and also the amount and nature of different hesperetin 
metabolites excreted in urine within 1- to 7-fold deviation from the reported data in humans. 
The PBK model predicted that hesperetin-3´-O-glucuronide and hesperetin-7-O-glucuronide 
are the major circulating metabolites of hesperidin in humans accounting for approximately 
70% of the total plasma hesperetin (expressed in mg hesperetin equivalents/l) and that plasma 
concentrations of hesperetin aglycone are lower than 0.02 mg/l even at a high oral dose of 50 
mg/kg bw hesperidin. The PBK model thus obtained was used to convert available in vitro 
concentration-response curves for activity of hesperetin together with its metabolites to in vivo 
dose-response curves from which subsequently BMD05 values were derived. The in vivo 
BMD05 values for PKA inhibition by hesperetin and its monoglucuronides based on the results 
from an in vitro PKA inhibition assay were predicted to amount to 135-539 mg/kg bw 
hesperidin. The in vivo BMD05 values for inhibition of TNF-a induced endothelial cell 
migration derived from in vitro data were predicted to amount to 4.54-24 mg/kg bw hesperidin. 
The in vivo BMD05 values for inhibition of LPS induced PGE2 production derived from in vitro 
data were predicted to range from 2.19-4.10 mg/kg bw hesperidin. The in vivo BMD05 values 
for inhibition of LPS induced NO production derived from in vitro data were predicted to vary 
from 17-44 mg/kg bw hesperidin. These predicted in vivo BMD05 values were compared to the 
reported active dose levels on anti-atherogenic and anti-inflammatory effects of hesperidin in 
humans [17-19]. The results obtained revealed that only the predicted in vivo BMD05 values for 
inhibition of endothelial cell migration and PGE2 production fell within the reported active dose 
levels of hesperidin (4.2 mg/kg bw) in humans resulting in improved endothelial function and 
decreased levels of inflammatory biomarkers (i.e. PGE2 and C-reactive protein) [17-19]. The 
predicted in vivo BMD05 values for inhibition of LPS induced NO production are 4- to 10-fold 
higher than the reported active dose levels of hesperidin in humans [17-19], which could be 
considered acceptable as within one order of magnitude [20]. In the case of PKA activity, the 
predicted in vivo BMD05 values are more than 32-fold higher than the reported active dose levels 
of hesperidin on endothelial function in humans [17, 18]. This might indicate that inhibition of 
PKA activity may not represent a major mechanism involved in endothelial function. The 
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predicted in vivo BMD05 values also revealed that inhibition of endothelial cell migration and 
PGE2 and NO production can be expected at a Western dietary and a supplementary intake of 
hesperidin. In conclusion, the PBK model obtained adequately predicted ADME of hesperidin 
in humans and was shown to be of use to translate in vitro results to the human in vivo situation 
without the need for human intervention studies.  
 
6.2 General discussion and future perspectives 
 The PBK models developed in the present thesis have a great potential to facilitate 
further understanding of in vivo effects for a wider range of flavonoids, for which in vivo data 
are limited. The following sections discuss whether and how the results obtained in the present 
thesis can contribute to future research on flavonoids focusing on: 
- further refinement of the PBK models, 
- in vitro biological studies of flavonoid mediated effects, and 
- use of PBK model based reverse dosimetry. 
 
6.2.1 Further refinement of the PBK models 
 In the next sections selected topics for further future refinement and improvement of 
the PBK models are discussed in some more detail. 
 
Defining excretion parameters for the PBK models  
Excretion parameters are influential parameters that affect plasma concentrations of 
flavonoid metabolites as also reflected by the sensitivity analyses for plasma concentrations of 
quercetin, genistein, and hesperetin metabolites (expressing normalized sensitivity coefficients 
higher than 0.1 in absolute value). In the present thesis, the excretion parameters for flavonoid 
conjugates excreted via bile, urine, and intestinal efflux back to the intestinal lumen were 
derived by fitting the predicted time-dependent plasma concentrations of total flavonoid 
(aglycone and metabolites) with experimental human data. The disadvantage of this method is 
that it can be only applied when there are in vivo data available as the fitted parameters are 
dependent on the in vivo data used for the fitting. For other flavonoids, where there is a lack of 
in vivo data, this method is not applicable. Therefore, to define PBK models for other flavonoids 
and to gain insight in the importance of the major excretion route and forms for the ADME of 
flavonoids, a method that can predict excretion parameters without the need for in vivo data 
would be valuable. Available alternative methods to derive the kinetic parameters for biliary 
and urinary excretion, and for intestinal efflux back to the intestinal lumen are as follow: 
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1. Transfected cells with transporter proteins of interest provide the most simple model 
and have been extensively used to characterize polymorphisms, substrate specificity, and 
structure-activity-relationships for efflux transporter proteins [21-27]. Transfected cells with 
transporter proteins of interest can be prepared from baculovirus infected Sf9 cells as well as 
from mammalian cells (e.g. LLC-PK1, MDCKII, HeLa, HEK293T) [21-28]. Excretion of 
flavonoid metabolites via bile, urine, and intestinal efflux back to the intestinal lumen in 
humans, have been reported to be mediated by ATP binding cassette (ABC) transporters [29]. 
ABC transporters use energy from ATP hydrolysis as their driving force and are found on 
extracellular and intracellular membranes of tissue barriers and excretory organs [29]. P-
glycoprotein, breast cancer resistant protein, and multidrug resistant-associated protein 2 have 
been reported to be the major ABC transporters mediating the excretion of flavonoid 
metabolites via bile, urine, and intestinal efflux back to the intestinal lumen in humans [26, 28, 
30-37]. When using the transfected cells with transporter proteins of interest, it is of importance 
to know the differences in expression levels of active transporters between in vitro models and 
human organs to determine the scaling factors to translate the in vitro determined values to in 
vivo relevant input parameters for PBK models. The expression levels of active transporters in 
human intestine, liver, and kidney are available in literature [38].  
 2. Immobilized human cell line monolayers cultured on a permeable membrane in a 
two-compartment cell culture system (apical and basolateral compartment) have been used in 
a number of studies [31, 39, 40]. A variety of cells can be used for these transporter assays, in 
which the cells must express the efflux transporters of interest and form a functionally polarized 
cell monolayer, complete with tight extracellular junctions [40]. Several human derived cell 
lines have met these requirements including the human liver-derived cell lines Fa2N-4, HepG2, 
Hep3B, PLc/PRFs Huh7, HBG, and HepaRG [41], the human renal cell lines HK-2, Caki-1, 
RPTEC/TERT1 and ciPTEC [39, 42, 43], and the human intestinal Caco-2 cell lines [31, 44] 
available for studying excretion via bile, urine, and intestinal efflux back to the intestinal lumen, 
respectively. The kinetic parameters for excretion derived from the immobilized human cell 
line monolayer need to be corrected for the differences in the expression of active transporters 
between human cell lines and human tissues to determine the scaling factors for translation of 
in vitro excretion parameters to in vivo relevant input parameters for the PBK models. The 
differences in expression of active transporters between human cell lines and human organs are 
available in literature [38, 45, 46].  
 3. Primary human cells are ideal for performing transporter assays, as primary cells are 
isolated from human organs and thus may restrain and display important in vivo anatomical and 
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functional characteristics [47, 48]. Furthermore, each culture is derived from cells isolated from 
a single donor enabling a study on interindividual human variation in transporters in the 
respective organ. So far, primary human cells that are available include human hepatocytes and 
human intestinal epithelial cells [47, 48]. Even though primary human cells are useful tools for 
studying uptake and efflux characteristics of substances as well as the consequences of 
interindividual human variation in active transporters, primary human cells are difficult to 
culture, not readily available and expensive which seems to have so far hampered their use in 
defining rate constants for biliary excretion and intestinal efflux back to the intestinal lumen in 
PBK modeling.  
 
Development of QSAR models to derive kinetic constants for formation of different flavonoid 
conjugates 
The development of PBK models as described in the present thesis is undeniable a 
laborious and time-consuming process as a large number of model parameters are required and 
need to be defined. In the studies described in the present thesis, a lot of time was dedicated to 
the performance of in vitro incubations with human tissue fractions to derive kinetic parameters 
for formation of the different flavonoid conjugates. For the future use of PBK models in 
exploring the ADME characteristics for a wider range of flavonoids, there is a need to shorten 
the time needed to derive the kinetic parameters for metabolic conversions. Alternative methods 
to derive such parameters could be based on the development of in silico based quantitative 
structure activity relationships (QSARs). QSAR models should be developed for 
glucuronidation, sulfation, and methylation of flavonoids as these three pathways are important 
for the formation of the major circulating flavonoid metabolites. Knowledge on structure 
activity relationships on the regioselectivity of different UGT and SULT isoforms on formation 
of different monoglucuronides and monosulfates are available in literature [49-51]. This 
knowledge will be useful for the development of the QSAR models to determine kinetic 
constants for formation of different flavonoid conjugates. The standard approach for 
development of QSAR models is to relate molecular descriptors of chemicals to specific 
endpoints of interest. General guidelines for QSAR development as well as their validation are 
available in literature [52]. Even though the development of QSAR models is laborious and 
time-consuming as well, the QSAR models developed will be effective tools to predict kinetic 
parameters for conversion of large numbers of flavonoids into their respective conjugates and 
ultimately accelerate the development of PBK models for other flavonoids.  
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So far, there are QSAR models available for some human UGT [53-55], SULT [56], 
and COMT [57, 58] isoforms. For glucuronidation reactions, the first generalized QSAR 
models were developed for known human UGT1A1 substrates including flavonoids to predict 
substrate selectivity and binding affinity of inhibitors (i.e. apparent inhibition constant, Ki,app), 
revealing the importance of two hydrophobic domains separated from the glucuronidation site 
by 4 Å and 7 Å, respectively, for the prediction of Ki,app [53]. Ethell et al. [54] developed the 
QSAR models to predict the kinetic parameters (i.e. the maximum velocity (Vmax) and 
Michaelis-Menten constant (Km)) for glucuronidation of 4-substituted phenols by human 
UGT1A6 and UGT1A9. The results suggested that the size of the 4-substituent and the 
bulkiness of substrate are important factors because when the size of the 4-substituent 
decreased, the Vmax and Km  values increased and decreased, respectively, and bulky substrates 
might be accepted into the binding site but might not be glucuronidated, or only weakly 
glucuronidated [54]. Recently, Wu et al. [55] successfully developed QSAR models for 
predicting the kinetic parameters (i.e. Vmax and intrinsic clearance (CLin = Vmax/Km)) for 3-O-
glucuronidation of flavonoids by human UGT1A9. The results obtained from this study 
revealed the key structural features including that the presence of multiple electropositive atoms 
or groups (e.g. -OH) to the B-ring would result in poor 3-O-glucuronidation by human 
UGT1A9, contradictory the presence of a bulky substituent at C6 or electronegative atoms or 
groups (e.g. -Cl, -F, -OCH3) around the B-ring would result in fast glucuronidation of the 3-OH 
[55]. Additionally, this study highlighted the important role of electrostatic potential (i.e. 
electronegative versus electropositive entity) in determining human UGT1A9-mediated 3-OH 
glucuronidation of flavonoids [55]. For sulfation reactions, there is a QSAR model available 
for predicting Km values for formation of phenol sulfation by human SULT1A3 [56]. This study 
indicated that phenols with bulky substituents in the para-position have high Km values 
compared to ortho- and meta-substituted analogues and an electronic interaction near Glu146 
in the human SULT1A3 structure was an important structural feature for determining human 
SULT1A3-mediated phenol sulfation [56]. For methylation reactions, there are two QSAR 
models available for predicting kinetic parameters (i.e. Km, Vmax, and CLin) for methylation of 
catecholic substrates by human soluble, cytosolic COMT (S-COMT) [57, 58]. The results 
obtained from these studies suggested the importance of substrate bulkiness and electronic 
parameters [57, 58]. Altogether, the QSAR models available can be used as a platform for the 
development of QSAR models for other UGT, SULT and COMT isoforms and other 
conjugation positions focusing on the major isoforms involved in metabolism of flavonoids. 
Ultimately, combing the predictions from all QSAR models for individual isoform, will allow 
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the estimation of the kinetic parameters for overall glucuronidation, sulfation, and methylation 
of different flavonoid conjugates. Obviously, it remains to be established whether this approach 
would be more time effective than measurements of the respective kinetic parameters using 
relevant in vitro models 
 
Quality of in vivo data on metabolic patterns in plasma for validation of the PBK models  
Once a PBK model is developed, it is crucial to evaluate the performance of the newly 
defined models by comparing the prediction with experimental in vivo data, supporting validity 
of the model and as a consequence supporting the model predictions. The quality of in vivo data 
used to evaluate the performance of the model is of importance. In the present thesis, the PBK 
models were developed to predict dose-dependent plasma concentrations of flavonoid 
aglycones and their metabolites as well as to tentatively identify the type and conjugation 
position of the circulating metabolites. To facilitate the model validation, there is a need for in 
vivo data on metabolic plasma profiles of flavonoids that identify and quantify individual 
circulating metabolites. Even though flavonoids have been intensively studied for decades [59], 
surprisingly there are only limited number of in vivo studies available that provide these data 
[12]. In most studies, flavonoid conjugates in plasma were identified and quantified from the 
amounts of aglycone liberated from conjugated metabolites by using β-glucuronidase and 
sulfatase to deconjugate the conjugated metabolites to their respective aglycone [60-68]. This 
method has been criticized for running a risk of underestimation and lack of information on the 
absolute structural conformation of flavonoid conjugates especially with respect to the 
conjugation position [60, 61]. The use of advanced analytical methods in chromatography and 
mass spectrometry can also not provide the absolute conformation of the chemical structure of 
individual flavonoid conjugates [69]. Nuclear magnetic resonance (NMR) spectroscopy is a 
powerful tool to identify unknown chemicals [70] and in this case can be used to identify the 
conjugation position of individual flavonoid conjugates. However, 1H-NMR measurements 
require relatively large amounts of the tested compounds [70], which might hamper the use of 
NMR to identify conjugation position of individual flavonoid conjugates. Alternative methods 
would be the use of in silico approaches to predict the 1H-NMR spectra of possible flavonoid 
conjugates together with the Metabolite Identification Database (MetIDB), a publicly 
accessible database of predicted and experimental 1H-NMR spectra of flavonoids, to identify 
flavonoid conjugates [70, 71]. Without NMR data unambiguous identification of flavonoid 
metabolites requires available standard compounds for the respective flavonoid conjugates [72-
76]. However, there is a general lack of commercially available standard compounds for 
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flavonoid conjugates and the commercially available standard compounds are generally 
expensive. Standard compounds for flavonoid conjugates can be chemically synthesized, 
although methods for chemical synthesis are only available for a limited number of flavonoid 
conjugates and are quite complex, expensive, laborious, and require specific knowledge and 
equipment [76-78]. Alternative methods would be the use of biosynthesis together with 1H-
NMR using MetIDB to identify the structure of biosynthesized flavonoid conjugates as recently 
described by Beekmann et al. [71]. Altogether, future in vivo studies on flavonoid metabolism 
will need to identify and quantify individual circulating metabolites of flavonoids as this 
information is of importance for validation of the PBK model performance as well as to gain 
more insight in in vivo effects of flavonoids.   
 
Deconjugation of flavonoid conjugates at the site of action 
 Flavonoids are mainly present as conjugates, which represent most likely the forms that 
reach the target tissues. These conjugates might be deconjugated to their respective aglycones 
at the target tissue by β-glucuronidases, deconjugating enzymes. Lysosomal β-glucuronidase is 
reported to be present in high concentrations in neutrophils and eosinophils [79]. Upon 
stimulation, these inflammatory cells release β-glucuronidase into the extracellular space, 
leading to an increase in local β-glucuronidase activity and blood β-glucuronidase 
concentrations during inflammation [79]. In vitro studies with flavonoid monoglucuronides 
reported an increase in the respective aglycones in human neutrophils stimulated with LPS [80, 
81]. Pre-clinical cancer studies with glucuronidated drugs also found an increase in 
unconjugated drug concentrations in necrotic areas of human pancreatic and lung carcinomas 
[82, 83]. Besides β-glucuronidase activity at the site of inflammation, human breast tissue has 
also been reported to contain β-glucuronidase as Islam et al. demonstrated that genistein-7-O-
glucuronide was deconjugated to genistein aglycone by human breast S9 fractions [14]. The 
PBK models defined in the present thesis do not yet include deconjugation of flavonoid 
glucuronides at the site of action, because of the lack of human data to perform and evaluate 
this simulation. For further refinement of the predictions by the PBK model, insight in 
deconjugation of flavonoid glucuronides at the site of action should be studied to a further 
extent including determining kinetic constants for deconjugation of flavonoid glucuronides at 
the site of action.  
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Matrix effects on the ADME of flavonoids 
 It is of importance to note that flavonoids are normally present in a complex food matrix 
(containing additional ingredients such as proteins, carbohydrates, fiber, fat, alcohol), which 
might influence the ADME of flavonoids in vivo. Dissolving cocoa powder in whole milk has 
been reported to alter the metabolic profiles of (-)-epicatechin excreted in urine of healthy 
human volunteers as there was an increase in the amount of sulfated conjugates accompanied 
by a decrease in glucuronidated conjugates as compared with what was formed when cocoa 
powder was administered dissolved in water [84]. Carbohydrate composition of the food matrix 
has been suggested to be a key factor in determining the cocoa flavanols absorption and 
metabolism in the small intestine as maltitol-containing chocolate decreased in levels of total 
flavanol absorption and peak plasma concentrations of unmethylated epicatechin as compared 
with the sucrose-containing equivalent [85]. The sugar content of the matrix has been reported 
to lower bioavailability of resveratrol in grape juice in comparison with the pure aglycone [86]. 
Consumption of quercetin with a fat-rich diet has been reported to increase the plasma AUC of 
total quercetin (aglycone and metabolites) by approximately 45% as compared with subjects 
who consumed quercetin with a fat-free diet [87]. The matrix effect of dietary fibers has been 
in general found to decrease the absorption of flavonoids [88]. Besides matrix effects of food 
components, the presence of other dietary flavonoids and other phytochemicals has also been 
also suggested to influence the ADME of flavonoids. Brand et al. [89] demonstrated that the 
amount of hesperetin metabolites excreted to the basolateral side of a Caco-2 cell monolayer 
increased when hesperetin was co-administered together with other flavonoids. This implies 
that when hesperetin is consumed together with other flavonoids such as quercetin, the plasma 
concentrations of hesperetin metabolites may be increased. Overall, the food matrix can 
influence the ADME characteristics of flavonoids, which can therefore alter the plasma 
pharmacokinetics of flavonoids in vivo. For the future refinement of the PBK models, food 
matrix effects should be considered for a more realistic description of plasma metabolic patterns 
upon flavonoid consumption in vivo. 
 
Microbial metabolism of flavonoids 
 Aside from the availability of flavonoid conjugates in the systemic circulation, several 
small phenolic molecules have also been detected as metabolites in human plasma and urine in 
some human intervention studies with flavonoids [90]. These small phenolic molecules are 
likely the degradation products of flavonoid aglycones and their metabolites formed by gut 
microbiota [90]. There is a lack of human data on plasma concentrations of microbial 
General discussion and future perspectives 
 161 
metabolites of flavonoids, since most of the studies focused on the conjugated flavonoids. 
Furthermore, the contributions of these microbial metabolites to biological effects of flavonoids 
in humans in vitro and in vivo are not well-characterized [90]. An exception is made for equol, 
a well-known estrogenic microbial metabolite of daidzein [91, 92]. Therefore, future 
development of the PBK models defined in the present thesis should include the microbial 
metabolism of flavonoids. Also, more research should be performed to gain insight in the role 
of microbial metabolites of flavonoids in biological effects of flavonoids in human in vivo.  
 
6.2.2 In vitro biological studies of flavonoid mediated effects 
 In vitro studies are important tools for better understanding the modes of action of 
flavonoids that exert specific health effects. In the past in vitro biological studies of flavonoids 
were often performed using flavonoid aglycones, which are, as also shown by the results of the 
present thesis, hardly bioavailable in vivo [59]. Given that flavonoids are present in the systemic 
circulation as their conjugates, it is now undoubtedly clear that in vitro studies on biological 
activities of flavonoids should also focus on flavonoid conjugates, reflecting physiological 
relevant forms of flavonoids. The PBK models developed can be used as guidelines for the 
experimental design of such in vitro studies by enabling definition of the major available forms 
of a flavonoid in the systemic circulation, providing information on the type and conjugation 
position and thus the type of conjugates to be preferably tested in vitro. Based on the PBK 
model predictions in the present thesis, monoglucuronides can be expected to represent the 
major circulating metabolites in humans, followed by mixed conjugates containing a glucuronic 
acid and/or a sulfate moiety and monosulfates. The recent review by Beekmann et al. [10] 
revealed that dependent on the type and conjugation position and in vitro endpoint studied, 
some conjugates could restrain some activity and in some cases conjugates exerted even higher 
activity than their respective aglycone. These results indicate that in vivo biological activities 
of flavonoids could be partly ascribed to their metabolites. The biological activity of hesperetin 
and its major circulating metabolites (i.e. hesperetin-3´-O-glucuronide and hesperetin-7-O-
glucuronide) on PKA activity obtained from in vitro bioassay in the present thesis (Chapter 5), 
showed that the two metabolites were at least equally active in inhibition of PKA activity as 
hesperetin aglycone. Kay [93] reported that at concentrations identified in plasma in human 
studies, flavonoid aglycones are likely to have only limited activity, whereas their metabolites 
(methyl, glucuronide, sulfate conjugates) were active across varies bioassays. Furthermore, 
when these metabolites were applied together as mixtures, some were often just as active and, 
in a few cases, even more active than when applied individually [93]. Therefore, it is also of 
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importance to investigate in vitro biological activity of mixtures of the major circulating 
metabolites of flavonoids. And to the extent possible, in vitro concentration-response curves 
for specific biological activities of flavonoid aglycone but also of its major circulating 
metabolites should be derived.   
Apart from conjugated metabolites, it is of importance to determine the contribution of 
microbial metabolites of flavonoids to in vivo biological activities of flavonoids, as microbial 
metabolites will also be available in the systemic circulation (see section 6.2.1 on Microbial 
metabolism of flavonoids). Aside from equol a potent estrogenic microbial metabolite of 
daidzein [91, 92], biological activities of other microbial flavonoid metabolites are not well 
established in vitro [90]. Based on the review article by Aura [90], some microbial metabolites 
of flavonoids were found to exert biological activities in in vitro bioassays on estrogenicity, 
inhibition of hepatocellular cholesterol synthesis, and inflammatory activity. Another aspect 
that should be implemented in in vitro methods, is to setup a standard methodology for in vitro 
measurements on each specific endpoint that could help to minimize the inter-laboratory 
differences in the obtained results. For example, in vitro data available for genistein induced 
ERa mediated cell proliferation (Chapter 4 of the thesis) show large variation, which is likely 
due to differences between the laboratories where the cells were cultivated, as highlighted by 
Osborne et al. [94] who reported that even though MFC-7 cell lines obtained from different 
laboratories have similar karyotype, they may have unique biological properties. And before 
concluding on any in vivo biological effects, PBK model based reverse dosimetry as performed 
in Chapter 4 and 5 of the present thesis seems to be an essential step to be included to enable 
analysis of whether in vitro effects can be expected at realistic human dose levels. 
 
6.2.3 Use of PBK model based reverse dosimetry 
 The present thesis demonstrated the use of PBK model based reverse dosimetry to 
predict in vivo effective dose levels of flavonoids (Chapter 4 and 5). The in vitro-in silico 
approach applied in the present thesis provides knowledge on pharmacokinetics and 
pharmacodynamics of flavonoids and would be useful to establish dose levels of flavonoids at 
which certain in vitro biological endpoint can be achieved in humans in vivo. The following 
sections discuss how to translate in vitro data to in vivo dose levels and what are the levels of 
uncertainty in the predicted in vivo BMD05 (benchmark dose for 5% response) values predicted 
based on in vitro endpoints by using PBK model based reverse dosimetry. 
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Translation of in vitro data to in vivo dose levels 
 When performing a PBK-model based reverse dosimetry study, it is important to first 
select the in vitro endpoint that is relevant to the in vivo effects, and that can be derived from 
an available in vitro test system that mimics the in vivo situation as closely as possible, and thus 
allows a construction of a suitable in vitro concentration-response curve. Such an in vitro 
concentration-response curve can be translated to an in vivo dose-response curve by relating 
the in vitro concentration to the maximum plasma concentration (Cmax) as in the present thesis 
(Chapter 4 and 5) or to the area under the plasma concentration-time curve (AUC) of the 
flavonoid aglycone or of a relevant mixture of the aglycone and its metabolites. The choice of 
the dose metric (plasma Cmax or plasma AUC) is dependent on the time-course of the effects; a 
short term and/or reversible effect is more likely to be related to the plasma Cmax and vice versa 
long term and/or irreversible effects might likely be better related to the plasma AUC. When 
relating the in vitro endpoint to the plasma AUC, the in vitro AUC values of the tested chemical 
should be estimated by measuring the change in concentration of the tested chemical in the 
culture medium at multiple time points over the assay time [95] or if the concentration of the 
tested chemical remains constant in the culture medium over the assay time the applied in vitro 
concentration can be multiplied with assay time to estimate the in vitro AUC value [96]. Prior 
to translation of the in vitro concentration-response curve to the in vivo dose-response curve, it 
is essential to consider that only the free fraction of the chemical will likely exert the effects in 
vitro and in vivo, implying a requirement for a correction for the binding of the chemical to 
protein and lipids under the in vitro and the in vivo conditions [97, 98]. The free fraction of the 
chemical can be measured using in vitro methods available in literature [96] or in silico methods 
as illustrated in the present thesis (Chapter 4 and 5) [98, 99]. By correcting for the differences 
in protein and lipid concentrations between in vitro and in vivo, each nominal in vitro 
concentration can be extrapolated to an in vivo effect concentration. The in vivo effect 
concentration (or AUC) obtained is set equal to the plasma Cmax (or plasma AUC) of the 
flavonoid aglycone or mixtures of the aglycone and its metabolites. The PBK model is 
subsequently used to calculate the corresponding oral dose levels in humans, providing the in 
vivo dose-response curve. The in vivo dose-response curve obtained can be used to subsequently 
derive the in vivo BMD05 values for the endpoint of interest. 
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Uncertainty factors for the predicted in vivo BMD05 values 
 In the present thesis, a PBK model based reverse dosimetry approach was applied to 
predict in vivo BMD05 values based on in vitro data to establish dose levels of flavonoids at 
which certain in vitro biological endpoint can be achieved in humans in vivo. There are a 
number of uncertainties that can affect the predicted in vivo BMD05 values and need to be 
considered for a better interpretation of the results and to further increase the accuracy of the 
predictions in the future. The kinetic parameters for metabolic conversions of flavonoids are 
influential parameters that affect the plasma concentrations of flavonoid aglycones and their 
metabolites based on the sensitivity analysis obtained in the present thesis. This indicates that 
individual human variation in conjugating enzymes will influence the predicted plasma 
concentrations of flavonoid aglycones and their metabolites and thus affect the predicted in vivo 
BMD05 values. Besides interindividual human variation in conjugating enzymes, other factors 
such as genetic and lifestyle factors influencing the enzymatic expression and/or activity of the 
conjugating enzymes [100], variation in dietary intake of flavonoids, and matrix effects can 
also influence the predicted in vivo BMD05 values. The predicted in vivo BMD05 values for 
biological effects of flavonoids in humans in the present thesis (Chapter 4 and 5) do not yet 
take these uncertainties into consideration. These uncertainties due to interindividual human 
variations might explain the difference in the predicted metabolic plasma profiles and the 
predicted in vivo BMD05 values with reported human data. Altogether, for a better accuracy on 
the predicted metabolic plasma profiles and in vivo dose levels for biological effects of 
flavonoids in humans in vivo, all above mention uncertainties need to be carefully considered 
and better defined to determine how much these uncertainties related to interindividual human 
variation contribute to variation in the biological effects of flavonoids in the population.  
 
6.3 Conclusions 
 Altogether, the present thesis shows that PBK modeling is a powerful tool to gain insight 
not only in dose-dependent plasma concentrations of flavonoid aglycones and their metabolites, 
but also to tentatively identify the type and conjugation position of the circulating metabolites. 
These insights are of importance to better understand in vivo effects of flavonoids because 
conjugations determine the form of the flavonoids available in the systemic circulation in vivo. 
Thus, in this respect PBK model based predictions of the type and conjugation position and the 
concentration of possible metabolites is expected to provide better insight in key parameter 
determining the in vivo effects of flavonoids [10]. The present thesis also demonstrated the use 
of PBK models to assess inter- and intraspecies differences in ADME of flavonoids taking 
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quercetin as the model compound. Furthermore, the PBK models developed were demonstrated 
to be of use as a platform for the development of PBK models for other flavonoids and to guide 
experimental design of in vitro studies. Last but not least, the PBK models developed were 
shown to facilitate the translation of in vitro concentration-response curves to in vivo dose-
response curves to determine whether and if so at what oral dose levels flavonoids may elicit 
biological activity in vivo, providing an in vitro-in silico approach and eliminating the need of 
human intervention studies. It is concluded that PBK modeling provides a useful additional 
research tool for studies on pharmacokinetics and pharmacodynamics of flavonoids presenting 
opportunities that are not easily provided by other methods. 
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Summary 
 Despite numerous reports on possible mechanisms of action of flavonoids for 
beneficial health effects derived from in vitro bioassays, in vivo biological effects of 
flavonoids are contradictory and inconclusive. This is because most in vitro studies have been 
performed with flavonoid aglycones at high concentrations ignoring extensive metabolism of 
flavonoids in vivo. The aim of the present PhD thesis was to gain quantitative insight in dose-
dependent plasma concentrations of flavonoid aglycones and their metabolites using 
physiologically based kinetic (PBK) modeling, and the flavonoids quercetin, genistein and 
hesperetin as model compounds. To this end, PBK models were developed by integrating in 
vitro kinetic parameters for metabolic conversions of flavonoids to different conjugates and 
by fitting excretion parameters to literature available in vivo data. The PBK models obtained 
were validated against available in vivo data on metabolic plasma and urinary profiles of 
flavonoids of interest. Altogether, the results presented in this thesis show that PBK modeling 
is a powerful tool, not only to gain insight in the dose-dependent plasma concentrations of 
flavonoid aglycones and their metabolites, but also to tentatively identify the type and 
conjugation position of the circulating metabolites. These outcomes can be used to guide 
experimental design of in vitro studies by enabling definition of the major available forms of 
a flavonoid in the systemic circulation, providing information on the type and conjugation 
position and thus the type of conjugates to be preferably tested in vitro. The present thesis 
also illustrated that PBK modeling can be used to identify inter- and intraspecies differences 
in the absorption, distribution, metabolism, and excretion of flavonoids taking quercetin as the 
model compound. Moreover, it was demonstrated that the PBK models can facilitate the 
translation of in vitro concentration-response curves for biological effects to in vivo dose-
response curves, allowing to determine at which dose levels the in vitro biological effects can 
be expected in humans in vivo. Overall, PBK modeling thus provides a useful additional 
research tool for studies on pharmacokinetics and pharmacodynamics of flavonoids 
presenting opportunities that are not easily provided by other methods. To implement the 
PBK model based approach developed in the present thesis for a wider range of flavonoids, 
future studies should focus on further refinement of the PBK models, development of 
adequate in vitro biological models of flavonoid mediated effects, and use of PBK model 
based reverse dosimetry to advance our understanding on in vivo effects of flavonoids.  
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